<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10623648</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>156</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Intraneuronal Abeta42 accumulation in human brain.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>20</EndPage><MedlinePgn>15-20</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by the deposition of senile plaques (SPs) and neurofibrillary tangles (NFTs) in vulnerable brain regions. SPs are composed of aggregated beta-amyloid (Abeta) 40/42(43) peptides. Evidence implicates a central role for Abeta in the pathophysiology of AD. Mutations in betaAPP and presenilin 1 (PS1) lead to elevated secretion of Abeta, especially the more amyloidogenic Abeta42. Immunohistochemical studies have also emphasized the importance of Abeta42 in initiating plaque pathology. Cell biological studies have demonstrated that Abeta is generated intracellularly. Recently, endogenous Abeta42 staining was demonstrated within cultured neurons by confocal immunofluorescence microscopy and within neurons of PS1 mutant transgenic mice. A central question about the role of Abeta in disease concerns whether extracellular Abeta deposition or intracellular Abeta accumulation initiates the disease process. Here we report that human neurons in AD-vulnerable brain regions specifically accumulate gamma-cleaved Abeta42 and suggest that this intraneuronal Abeta42 immunoreactivity appears to precede both NFT and Abeta plaque deposition. This study suggests that intracellular Abeta42 accumulation is an early event in neuronal dysfunction and that preventing intraneuronal Abeta42 aggregation may be an important therapeutic direction for the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>G K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience and Fisher Center for Research on Alzheimer's Disease, The Rockefeller University New York, New York 10021, USA. gkgouras@mail.med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Naslund</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Edgar</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Checler</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Greenfield</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Relkin</LastName><ForeName>N R</ForeName><Initials>NR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS02037</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002102" MajorTopicYN="N">Cadaver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>7</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>7</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10623648</ArticleId><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="doi">10.1016/s0002-9440(10)64700-1</ArticleId><ArticleId IdType="pii">S0002-9440(10)64700-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ: The cell biology of &#x3b2;-amyloid precursor protein and presenilin in Alzheimer&#x2019;s disease. Trends Cell Biol 1998, 8:447-453</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y: Visualization of A &#x3b2; 42(43) and A &#x3b2; 40 in senile plaques with end-specific A &#x3b2; monoclonals: evidence that an initially deposited species is A &#x3b2; 42(43). Neuron 1994, 13:45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ: Sequence of deposition of heterogeneous amyloid &#x3b2;-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996, 3:16-32</Citation><ArticleIdList><ArticleId IdType="pubmed">9173910</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P, Gandy S: Generation of Alzheimer &#x3b2;-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci USA 1997, 94:3748-3752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y, Haass C: Intracellular generation and accumulation of amyloid &#x3b2;-peptide terminating at amino acid 42. J Biol Chem 1997, 272:16085-16088</Citation><ArticleIdList><ArticleId IdType="pubmed">9195901</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Doms RW, Lee VM: Detection of a novel intraneuronal pool of insoluble amyloid &#x3b2; protein that accumulates with time in culture. J Cell Biol 1998, 141:1031-1039</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132781</ArticleId><ArticleId IdType="pubmed">9585420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K: Distinct sites of intracellular production for Alzheimer&#x2019;s disease A &#x3b2;40/42 amyloid peptides. Nat Med 1997, 3:1016-1020</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW: Alzheimer&#x2019;s A &#x3b2;(1&#x2013;42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 1997, 3:1021-1023</Citation><ArticleIdList><ArticleId IdType="pubmed">9288730</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, Sisodia SS, Greengard P, Xu H: Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer &#x3b2;-amyloid peptides. Proc Natl Acad Sci USA 1999, 96:742-747</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15207</ArticleId><ArticleId IdType="pubmed">9892704</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X, Stokin GB, Koo EH: Mutagenesis identifies new signals for &#x3b2;-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem 1999, 274:18851-18856</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, Suzuki H, Araki W, Inoue H, Shirotani K, Takahashi K, Gallyas F, Tabira T: Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 1999, 5:560-564</Citation><ArticleIdList><ArticleId IdType="pubmed">10229234</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RA, Otvos L, Jr, Trojanowski JQ, Lee VM: Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer&#x2019;s disease &#x3b2;-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. Am J Pathol 1989, 134:973-978</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879896</ArticleId><ArticleId IdType="pubmed">2524164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM: Polyclonals to &#x3b2;-amyloid(1&#x2013;42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 1994, 667:138-142</Citation><ArticleIdList><ArticleId IdType="pubmed">7895077</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G: Neuronal cell death in Alzheimer&#x2019;s disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 1997, 100:310-320</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508193</ArticleId><ArticleId IdType="pubmed">9218507</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K: Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer&#x2019;s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985, 4:2757-2763</Citation><ArticleIdList><ArticleId IdType="pmc">PMC554575</ArticleId><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Beyreuther K, Masters CL: A4 amyloid protein immunoreactivity is present in Alzheimer&#x2019;s disease neurofibrillary tangles. Neurosci Lett 1989, 101:352-355</Citation><ArticleIdList><ArticleId IdType="pubmed">2671814</ArticleId></ArticleIdList></Reference><Reference><Citation>Allsop D, Haga S, Bruton C, Ishii T, Roberts GW: Neurofibrillary tangles in some cases of dementia pugilistica share antigens with amyloid &#x3b2;-protein of Alzheimer&#x2019;s disease. Am J Pathol 1990, 136:255-260</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877395</ArticleId><ArticleId IdType="pubmed">2407121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR: Perforant pathway changes and the memory impairment of Alzheimer&#x2019;s disease. Ann Neurol 1986, 20:472-481</Citation><ArticleIdList><ArticleId IdType="pubmed">3789663</ArticleId></ArticleIdList></Reference><Reference><Citation>Barelli H, Lebeau A, Vizzavona J, Delaere P, Chevallier N, Drouot C, Marambaud P, Ancolio K, Buxbaum JD, Khorkova O, Heroux J, Sahasrabudhe S, Martinez J, Warter JM, Mohr M, Checler F: Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid &#x3b2; peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer&#x2019;s disease and cerebral amyloid angiopathy cases. Mol Med 1997, 3:695-707</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230230</ArticleId><ArticleId IdType="pubmed">9392006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Xu H, Jovanovic JN, Buxbaum JD, Wang R, Greengard P, Relkin NR, Gandy S: Generation and regulation of amyloid-&#x3b2; peptide variants in neurons. J Neurochem 1998, 71:1920-1925</Citation><ArticleIdList><ArticleId IdType="pubmed">9798916</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS: Familial Alzheimer&#x2019;s disease-linked presenilin 1 variants elevate Abeta1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S: Dominant and differential deposition of distinct &#x3b2;-amyloid peptide species, A &#x3b2; N3(pE), in senile plaques. Neuron 1995, 14:457-466</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S: Estrogen reduces neuronal generation of Alzheimer &#x3b2;-amyloid peptides. Nat Med 1998, 4:447-451</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Stieber A, Mourelatos Z, Gonatas NK: In Alzheimer&#x2019;s disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am J Pathol 1996, 148:415-426</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861703</ArticleId><ArticleId IdType="pubmed">8579105</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, Bondada V, Rangnekar VM, Mattson MP: Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med 1998, 4:957-962</Citation><ArticleIdList><ArticleId IdType="pubmed">9701251</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci USA 1999, 96:3228-3233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999, 274:6483-6492</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid &#x3b2;-peptide deposition. Nat Genet 1997, 17:263-264</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10631151</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9297</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>The number of trait loci in late-onset Alzheimer disease.</ArticleTitle><Pagination><StartPage>196</StartPage><EndPage>204</EndPage><MedlinePgn>196-204</MedlinePgn></Pagination><Abstract><AbstractText>Although it is clear that apoE plays an important role in the genetics of late-onset Alzheimer disease (AD), evidence exists that additional genes may play a role in AD, and estimates of the total contribution of apoE to the variance in onset of AD vary widely. Unfortunately, little information is available on the number and contribution of additional genes. We estimated the number of additional quantitative-trait loci and their contribution to the variance in age at onset of AD, as well as the contribution of apoE and sex, in an oligogenic segregation analysis of 75 families (742 individuals) ascertained for members with late-onset AD. We found evidence that four additional loci make a contribution to the variance in age at onset of late-onset AD that is similar to or greater in magnitude than that made by apoE, with one locus making a contribution several times greater than that of apoE. Additionally, we confirmed previous findings of a dose effect for the apoE varepsilon4 allele, a protective effect for the varepsilon2 allele, evidence for allelic interactions at the apoE locus, and a small protective effect for males. Furthermore, although we estimate that the apoE genotype can make a difference of &lt;/=17 years in age at onset of AD, our estimate of the contribution of apoE (7%-9%) to total variation in onset of AD is somewhat smaller than that which has previously been reported. Our results suggest that several genes that have not yet been localized may play a larger role than does apoE in late-onset AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daw</LastName><ForeName>E W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Division of Medical Genetics, Department of Medicine and Department of Statistics, University of Washington, Seattle, WA 98195-7720, USA. warwickd@u.washington.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payami</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nemens</LastName><ForeName>E J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Nochlin</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>T D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>G D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Wijsman</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM046255</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM 46255</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM046255</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019655" MajorTopicYN="N">Quantitative Trait, Heritable</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10631151</ArticleId><ArticleId IdType="pmc">PMC1288326</ArticleId><ArticleId IdType="doi">10.1086/302710</ArticleId><ArticleId IdType="pii">S0002-9297(07)62247-2</ArticleId></ArticleIdList><ReferenceList><Title>Electronic-Database Information</Title><Reference><Citation>Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for AD [MIM 104300])</Citation><ArticleIdList><ArticleId IdType="pubmed">17642958</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bennett C, Crawford F, Osborne A, Diaz P, Hoyne J, Lopez R, Roques P, et al (1995) Evidence that the APOE locus influences rate of disease progression in late-onset familial Alzheimer's-disease but is not causative. Am J Med Genet 60:1&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">7485228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergem ALM, Engedal K, Kringlen E (1997) The role of heredity in late-onset Alzheimer disease and vascular dementia: a twin study. Arch Gen Psychiatry 54:264&#x2013;270</Citation><ArticleIdList><ArticleId IdType="pubmed">9075467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergem ALM, Lannfelt L (1997) Apolipoprotein E type &#x25b;4 allele, heritability and age at onset in twins with Alzheimer disease and vascular dementia. Clin Genet 52:408&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pubmed">9520135</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, et al (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180&#x2013;184</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Daw EW, Heath SC, Wijsman EM (1999) Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer disease pedigrees. Am J Hum Genet 64:839&#x2013;851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377802</ArticleId><ArticleId IdType="pubmed">10053019</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:1349&#x2013;1356</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 55:809&#x2013;815</Citation><ArticleIdList><ArticleId IdType="pubmed">9736007</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704&#x2013;706</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath SC (1997) Markov chain Monte Carlo segregation and linkage analysis for oligogenic models. Am J Hum Genet 61:748&#x2013;760</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1715966</ArticleId><ArticleId IdType="pubmed">9326339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545&#x2013;548</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45:1092&#x2013;1096</Citation><ArticleIdList><ArticleId IdType="pubmed">7783869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, et al (1999) A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 8:237&#x2013;245</Citation><ArticleIdList><ArticleId IdType="pubmed">9931331</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Tsuang D, Bird TD (1998) Recent advances in the genetics of Alzheimer's disease. J Geriatr Psychiatry Neurol 11:42&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">9877525</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, et al (1995a) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973&#x2013;977</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, et al (1995b) A familial Alzheimer's disease locus on chromosome 1. Science 269:970&#x2013;973</Citation><ArticleIdList><ArticleId IdType="pubmed">7638621</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, et al (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479&#x2013;486</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H, Montee KR, Kaye JA, Bird TD, Yu CE, Wijsman EM, Schellenberg GD (1994) Alzheimer's disease, apolipoprotein E4, and gender. JAMA 271:1316&#x2013;1317</Citation><ArticleIdList><ArticleId IdType="pubmed">8158809</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, et al (1998) Complete genomic screen in late-onset familial Alzheimer's disease. Neurobiol Aging 19:S39&#x2013;S42</Citation><ArticleIdList><ArticleId IdType="pubmed">9562466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bebout JL, Gaskell PC Jr, Yamaoka LH, Hung W-Y, Alberts MJ, Walker AP, et al (1991) Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. Am J Hum Genet 48:1034&#x2013;1050</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683100</ArticleId><ArticleId IdType="pubmed">2035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, The (1998) Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease." Neurobiol Aging 19:109&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pubmed">9558143</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses A, Devlin B, Conneally PM, Small G, Saunders AM, Pritchard M, Locke PA, et al (1995) Measuring the genetic contribution of APOE in late-onset Alzheimer disease. Am J Hum Genet Suppl 57:A202</Citation></Reference><Reference><Citation>Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE (1994) Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet 343:1564&#x2013;1565</Citation><ArticleIdList><ArticleId IdType="pubmed">7911881</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, et al (1993) Association of apolipoprotein E allele &#x25b;4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467&#x2013;1472</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson LL, Nemens E, White JA, et al (1992) Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258:668&#x2013;671</Citation><ArticleIdList><ArticleId IdType="pubmed">1411576</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754&#x2013;760</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Slooter AJC, Cruts M, Kalmijn S, Hofman A, Breteler MMB, Van Broeckhoven C, van Duijn CM (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 55:964&#x2013;968</Citation><ArticleIdList><ArticleId IdType="pubmed">9678314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10632234</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia.</ArticleTitle><Pagination><StartPage>65</StartPage><EndPage>73</EndPage><MedlinePgn>65-73</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The pathophysiological characteristics of schizophrenia appear to involve altered synaptic connectivity in the dorsolateral prefrontal cortex. Given the central role that layer 3 pyramidal neurons play in corticocortical and thalamocortical connectivity, we hypothesized that the excitatory inputs to these neurons are altered in subjects with schizophrenia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To test this hypothesis, we determined the density of dendritic spines, markers of excitatory inputs, on the basilar dendrites of Golgi-impregnated pyramidal neurons in the superficial and deep portions of layer 3 in the dorsolateral prefrontal cortex (area 46) and in layer 3 of the primary visual cortex (area 17) of 15 schizophrenic subjects, 15 normal control subjects, and 15 nonschizophrenic subjects with a psychiatric illness (referred to as psychiatric subjects).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was a significant effect of diagnosis on spine density only for deep layer 3 pyramidal neurons in area 46 (P = .006). In the schizophrenic subjects, spine density on these neurons was decreased by 23% and 16% compared with the normal control (P = .004) and psychiatric (P = .08) subjects, respectively. In contrast, spine density on neurons in superficial layer 3 in area 46 (P = .09) or in area 17 (P = .08) did not significantly differ across the 3 subject groups. Furthermore, spine density on deep layer 3 neurons in area 46 did not significantly (P = .81) differ between psychiatric subjects treated with antipsychotic agents and normal controls.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This region- and disease-specific decrease in dendritic spine density on dorsolateral prefrontal cortex layer 3 pyramidal cells is consistent with the hypothesis that the number of cortical and/or thalamic excitatory inputs to these neurons is altered in subjects with schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glantz</LastName><ForeName>L A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH00519</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH45156</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 2000 Jan;57(1):74-5. doi: 10.1001/archpsyc.57.1.74.</RefSource><PMID Version="1">10632235</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 2001 Feb;58(2):203. doi: 10.1001/archpsyc.58.2.203.</RefSource><PMID Version="1">11177126</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10632234</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.57.1.65</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10632585</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.</ArticleTitle><Pagination><StartPage>558</StartPage><EndPage>567</EndPage><MedlinePgn>558-67</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by the extracellular deposition of beta-amyloid fibrils within the brain and the subsequent association and phenotypic activation of microglial cells associated with the amyloid plaque. The activated microglia mount a complex local proinflammatory response with the secretion of a diverse range of inflammatory products. Nonsteroidal anti-inflammatory drugs (NSAIDs) are efficacious in reducing the incidence and risk of AD and significantly delaying disease progression. A recently appreciated target of NSAIDs is the ligand-activated nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma). PPARgamma is a DNA-binding transcription factor whose transcriptional regulatory actions are activated after agonist binding. We report that NSAIDs, drugs of the thiazolidinedione class, and the natural ligand prostaglandin J2 act as agonists for PPARgamma and inhibit the beta-amyloid-stimulated secretion of proinflammatory products by microglia and monocytes responsible for neurotoxicity and astrocyte activation. The activation of PPARgamma also arrested the differentiation of monocytes into activated macrophages. PPARgamma agonists were shown to inhibit the beta-amyloid-stimulated expression of the cytokine genes interleukin-6 and tumor necrosis factor alpha. Furthermore, PPARgamma agonists inhibited the expression of cyclooxygenase-2. These data provide direct evidence that PPARgamma plays a critical role in regulating the inflammatory responses of microglia and monocytes to beta-amyloid. We argue that the efficacy of NSAIDs in the treatment of AD may be a consequence of their actions on PPARgamma rather than on their canonical targets the cyclooxygenases. Importantly, the efficacy of these agents in inhibiting a broad range of inflammatory responses suggests PPARgamma agonists may provide a novel therapeutic approach to AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Combs</LastName><ForeName>C K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Alzheimer Research Laboratory, Departments of Neurosciences and Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Karlo</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Cannady</LastName><ForeName>S B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG008012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD0710422</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002839">Chromans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>B7IN85G1HY</RegistryNumber><NameOfSubstance UI="D015237">Dinoprost</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="C496540">PTGS2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D011451">Prostaglandin-Endoperoxide Synthases</NameOfSubstance></Chemical><Chemical><RegistryNumber>I66ZZ0ZN0E</RegistryNumber><NameOfSubstance UI="D000077288">Troglitazone</NameOfSubstance></Chemical><Chemical><RegistryNumber>NI40JAQ945</RegistryNumber><NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002839" MajorTopicYN="N">Chromans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015237" MajorTopicYN="N">Dinoprost</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008830" MajorTopicYN="N">Microbodies</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011451" MajorTopicYN="N">Prostaglandin-Endoperoxide Synthases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045162" MajorTopicYN="Y">Thiazolidinediones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077288" MajorTopicYN="N">Troglitazone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10632585</ArticleId><ArticleId IdType="pmc">PMC6772401</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.20-02-00558.2000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aisen PS. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology. 1997;43:143&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">8996836</ArticleId></ArticleIdList></Reference><Reference><Citation>Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia. 1993;7:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423058</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol. 1993;50:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">8460956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkman DJ. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med. 1998;105:8S&#x2013;12S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9715829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol Suppl. 1998;51:2&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596548</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl. 1998;53:127&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700651</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer's disease related cortical lesions. J Neural Transm Suppl. 1998;54:97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs&#x2014;differences and similarities. N Engl J Med. 1991;324:1716&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">2034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature. 1996;380:345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598929</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Johnson DJ, Cannady SB, Lehman TM, Landreth GE. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of &#x3b2;-amyloid and prion proteins. J Neurosci. 1999;19:928&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782151</ArticleId><ArticleId IdType="pubmed">9920656</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni G. Reciprocal control of inflammatory cytokines, IL-1 and IL-6 and &#x3b2; amyloid production in cultures. Neurosci Lett. 1995;188:70&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783982</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">9737710</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood&#x2013;brain barrier model. Mol Med. 1998;4:480&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230332</ArticleId><ArticleId IdType="pubmed">9713826</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">8521497</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D. Reactive glia as rivals in regulating neuronal survival. Glia. 1993;7:102&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423057</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Li J, Karshin WL, Yu J, Tom D, Li X, Kirkpatrick JB. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int. 1995;27:119&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">7655344</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo Y-M, Roher AE. Specific domains of &#x3b2;-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci. 1996;16:6021&#x2013;6037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579176</ArticleId><ArticleId IdType="pubmed">8815885</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin JL, Uemura E, Cunnick JE. Microglia release of nitric oxide by the synergistic action of &#x3b2;-amyloid and IFN-&#x3b3;. Brain Res. 1995;692:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">8548305</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga S, Ikeda K, Sato M, Ishii T. Synthetic Alzheimer amyloid &#x3b2;/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 1993;601:88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8431789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ii M, Sunamoto M, Ohnishi K, Ichimori Y. &#x3b2;-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res. 1996;720:93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">8782901</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha RJ. Thiazolidinediones&#x2014;the new insulin enhancers. Clin Exp Hypertens. 1999;21:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">10052651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. Microglia and Alzheimer's disease. Curr Opin Hematol. 1999;6:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9915549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins. 1997;54:601&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">9373877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y, Shimohama S, Koike H, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun. 1999;254:582&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">9920782</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, McGeer P. &#x3b2;-Amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J Neurosci Res. 1997;49:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">9272645</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, Walker DG, McGeer PL. Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res. 1997a;747:114&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">9042534</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, Walker DG, McGeer PL. Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J Neuroimmunol. 1997b;78:152&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">9307240</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, Walker DG, McGeer PL. Toxicity of human THP-1 cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs. Neuropharmacology. 1999;38:1017&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83:813&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">8521498</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors shifting endocrinology into reverse. Science. 1999;284:757&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretzschmar HA, Giese A, Brown DR, Herms J, Keller B, Schmidt B, Groschup M. Cell death in prion disease. J Neural Transm. 1997;50:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">9120419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagenaur C, Lemmon V. An L1-like molecule, the 8D9 antigen, is a potent substrate for neurite extension. Proc Natl Acad Sci USA. 1987;84:7753&#x2013;7757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299379</ArticleId><ArticleId IdType="pubmed">3478724</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953&#x2013;12956.</Citation><ArticleIdList><ArticleId IdType="pubmed">7768881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406&#x2013;3410.</Citation><ArticleIdList><ArticleId IdType="pubmed">9013583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996;12:335&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorton D, Kocsis J-M, King L, Madden K, Brunden KR. &#x3b2;-Amyloid induces increased release of interleukin 1&#x3b2; from lipopolysaccharide-activated human monocytes. J Neuroimmunol. 1996;67:21&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">8707927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50:986&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566383</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack K. Roles of COX-1 and COX-2. J Rheumatol. 1998;25:2279&#x2013;2281.</Citation><ArticleIdList><ArticleId IdType="pubmed">9818678</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald D, Bamberger M, Combs C, Landreth G. &#x3b2;-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP-1 monocytes. J Neurosci. 1998;18:4451&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792680</ArticleId><ArticleId IdType="pubmed">9614222</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci. 1997;17:2284&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573513</ArticleId><ArticleId IdType="pubmed">9065490</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. The role of immune system in neurodegenerative disorders. Mov Disord. 1997;12:855&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">9399206</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol. 1998;33:371&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762518</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev. 1995;21:195&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866675</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann NY Acad Sci. 1996;777:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624086</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammation of the brain in Alzheimer's disease: implications for therapy. J Leukoc Biol. 1999;65:409&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10204568</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 1992;42:447&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">1736183</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. Microglia in degenerative neurological disease. Glia. 1993;7:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423066</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757015</ArticleId></ArticleIdList></Reference><Reference><Citation>Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610&#x2013;6614.</Citation><ArticleIdList><ArticleId IdType="pubmed">8454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Cassatella MA, Szendrei GI, Otvos L, Jr, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by &#x3b2;-amyloid protein and interferon-&#x3b3;. Nature. 1995;374:647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Bernasconi S, Bonaiuto C, Sozzani S, Zhou D, Otvos L, Jr, Mantovani A, Rossi F, Cassatella MA. &#x3b2;-Amyloid (25&#x2013;35) peptide and IFN-&#x3b3; synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. J Immunol. 1996;157:1213&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995;306:247&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1136508</ArticleId><ArticleId IdType="pubmed">7864817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairet M, Van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res. 1998;47:S93&#x2013;S101.</Citation><ArticleIdList><ArticleId IdType="pubmed">9831330</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova TV, Akama KT, Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-delta12,14-prostaglandin J2. Proc Natl Acad Sci USA. 1999;96:4668&#x2013;4673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16390</ArticleId><ArticleId IdType="pubmed">10200320</ArticleId></ArticleIdList></Reference><Reference><Citation>Plosker GL, Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 1999;57:409&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995;45:51&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422508</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157&#x2013;33160.</Citation><ArticleIdList><ArticleId IdType="pubmed">8969167</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegelman B. PPARg in monocytes: less pain, any gain? Cell. 1998;93:153&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568708</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065537</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Kincaid-Colton CA. The brain's immune system. Sci Am. 1995;273:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">8966536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam S. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders. Clin Exp Hypertens. 1999;21:121&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">10052648</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, Tada K. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 1982;42:1530&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pubmed">6949641</ArticleId></ArticleIdList></Reference><Reference><Citation>Vane JR, Botting RM. Anti-inflammatory drugs and their mechanisms of action. Inflamm Res. 1998;47:S78&#x2013;S87.</Citation><ArticleIdList><ArticleId IdType="pubmed">9831328</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci. 1998;18:2161&#x2013;2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792921</ArticleId><ArticleId IdType="pubmed">9482801</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Mackman N, Edgington TS, Fan S-T. Lipopolysaccharide induction of the tumor necrosis factor-&#x3b1; promoter in human monocytic cells. J Biol Chem. 1997;272:17795&#x2013;17801.</Citation><ArticleIdList><ArticleId IdType="pubmed">9211933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995;270:23975&#x2013;23983.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10634454</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Donepezil therapy in clinical practice: a randomized crossover study.</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>99</EndPage><MedlinePgn>94-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the efficacy of donepezil hydrochloride for the treatment of Alzheimer disease in patients drawn from clinical practice.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Two-center, randomized, placebo-controlled, double-masked crossover study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory disorders units at Massachusetts General and Brigham and Women's hospitals, Boston.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Sixty individuals (30 men and 30 women; mean +/- SD age, 75.0+/-9.5 years) with probable Alzheimer disease and scores of 20 or less on the information-memory-concentration subscale of the Blessed Dementia Scale.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Placebo wash-in, followed in randomized sequence by (1) donepezil hydrochloride therapy, 5 mg/d, for 6 weeks, followed by placebo washout for 6 weeks and (2) placebo treatment for 6 weeks.</AbstractText><AbstractText Label="PRIMARY OUTCOME MEASURE" NlmCategory="METHODS">Change in Alzheimer's Disease Assessment Scale cognitive subscale scores from the beginning to the end of the two 6-week treatment periods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among patients completing treatment and testing for both periods (n = 48), subscale scores improved (mean +/- SEM) 2.17+/-0.98 points (95% confidence interval, 0.20-4.10 points) during donepezil therapy relative to placebo therapy (P = .04). Scores returned toward baseline within 3 weeks of drug washout. There was no associated change in caregiver-rated global impression (donepezil vs placebo: proportion improved, 0.24 vs 0.22; proportion worsened, 0.27 vs 0.35; P = .34) or on specific tests of explicit memory or verbal fluency. Contrary to studies with tacrine, the presence of the apolipoprotein E epsilon4 allele did not predict donepezil treatment failure. Most common adverse events related to donepezil therapy were nausea (5 patients), diarrhea (3 patients), and agitation (3 patients). Serious events possibly related to drug use were seizure, pancreatitis, and syncope (1 patient each).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This independent confirmation of data from phase 3 trials suggests that donepezil therapy modestly improves cognition in patients with Alzheimer disease who are encountered in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>S M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Partners HealthCare Inc of Massachusetts General Hospital, Boston 02114, USA. greenberg@helix.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tennis</LastName><ForeName>M K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>L B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hayden</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Schoenfeld</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Corwin</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Daffner</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Meadows</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5P50 AG05134-14</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MO1-RR01066</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2000 Sep;57(9):1380.</RefSource><PMID Version="1">10987910</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10634454</ArticleId><ArticleId IdType="doi">10.1001/archneur.57.1.94</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10638761</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>403</Volume><Issue>6765</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta.</ArticleTitle><Pagination><StartPage>98</StartPage><EndPage>103</EndPage><MedlinePgn>98-103</MedlinePgn></Pagination><Abstract><AbstractText>Apoptosis, or cellular suicide, is important for normal development and tissue homeostasis, but too much or too little apoptosis can also cause disease. The family of cysteine proteases, the so- called caspases, are critical mediators of programmed cell death, and thus far 14 family members have been identified. Some of these, such as caspase-8, mediate signal transduction downstream of death receptors located on the plasma membrane. Others, such as caspase-9, mediate apoptotic signals after mitochondrial damage. Stress in the endoplasmic reticulum (ER) can also result in apoptosis. Here we show that caspase-12 is localized to the ER and activated by ER stress, including disruption of ER calcium homeostasis and accumulation of excess proteins in ER, but not by membrane- or mitochondrial-targeted apoptotic signals. Mice that are deficient in caspase-12 are resistant to ER stress-induced apoptosis, but their cells undergo apoptosis in response to other death stimuli. Furthermore, we show that caspase-12-deficient cortical neurons are defective in apoptosis induced by amyloid-beta protein but not by staurosporine or trophic factor deprivation. Thus, caspase-12 mediates an ER-specific apoptosis pathway and may contribute to amyloid-beta neurotoxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Morishima</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>B A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003603">Cytotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>11089-65-9</RegistryNumber><NameOfSubstance UI="D014415">Tunicamycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506444">CASP12 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506440">Casp12 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506443">Casp12 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053454">Caspase 12</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2013 Jul;14(7):404. doi: 10.1038/nrm3606.</RefSource><PMID Version="1">23756618</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053454" MajorTopicYN="N">Caspase 12</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003603" MajorTopicYN="N">Cytotoxins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013950" MajorTopicYN="N">Thymus Gland</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014415" MajorTopicYN="N">Tunicamycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10638761</ArticleId><ArticleId IdType="doi">10.1038/47513</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10644715</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network.</ArticleTitle><Pagination><StartPage>2568</StartPage><EndPage>2575</EndPage><MedlinePgn>2568-75</MedlinePgn></Pagination><Abstract><AbstractText>The release of amyloidogenic amyloid-beta peptide (Abeta) from amyloid-beta precursor protein (APP) requires cleavage by beta- and gamma-secretases. In contrast, alpha-secretase cleaves APP within the Abeta sequence and precludes amyloidogenesis. Regulated and unregulated alpha-secretase activities have been reported, and the fraction of cellular alpha-secretase activity regulated by protein kinase C (PKC) has been attributed to the ADAM (a disintegrin and metalloprotease) family members TACE and ADAM-10. Although unregulated alpha-secretase cleavage of APP has been shown to occur at the cell surface, we sought to identify the intracellular site of PKC-regulated alpha-secretase APP cleavage. To accomplish this, we measured levels of secreted ectodomains and C-terminal fragments of APP generated by alpha-secretase (sAPPalpha) (C83) versus beta-secretase (sAPPbeta) (C99) and secreted Abeta in cultured cells treated with PKC and inhibitors of TACE/ADAM-10. We found that PKC stimulation increased sAPPalpha but decreased sAPPbeta levels by altering the competition between alpha- versus beta-secretase for APP within the same organelle rather than by perturbing APP trafficking. Moreover, data implicating the trans-Golgi network (TGN) as a major site for beta-secretase activity prompted us to hypothesize that PKC-regulated alpha-secretase(s) also reside in this organelle. To test this hypothesis, we performed studies demonstrating proteolytically mature TACE intracellularly, and we also showed that regulated alpha-secretase APP cleavage occurs in the TGN using an APP mutant construct targeted specifically to the TGN. By detecting regulated alpha-secretase APP cleavage in the TGN by TACE/ADAM-10, we reveal ADAM activity in a novel location. Finally, the competition between TACE/ADAM-10 and beta-secretase for intracellular APP cleavage may represent a novel target for the discovery of new therapeutic agents to treat Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia,Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Milla</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Doms</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>V M</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002451" MajorTopicYN="N">Cell Compartmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId><ArticleId IdType="doi">10.1074/jbc.275.4.2568</ArticleId><ArticleId IdType="pii">S0021-9258(18)31010-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10648435</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8950</ISSN><JournalIssue CitedMedium="Print"><Volume>123 ( Pt 2)</Volume><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Semantic dementia with ubiquitin-positive tau-negative inclusion bodies.</ArticleTitle><Pagination><StartPage>267</StartPage><EndPage>276</EndPage><MedlinePgn>267-76</MedlinePgn></Pagination><Abstract><AbstractText>Three cases are reported with dementia and ubiquitin-positive but tau-negative inclusion bodies. All patients had a semantic dementia and the clinical details of two of these have been published as the first description of a selective semantic memory impairment. The original diagnosis had been of Pick's disease based on frontotemporal atrophy, but re-examination has revealed ubiquitin-positive but tau-negative inclusions as well as neurites in the frontotemporal cortices and ubiquitin-positive, intracytoplasmic inclusions in the granule cells of the dentate fascia. These inclusions are identical to those reported in association with amyotrophic lateral sclerosis (motor neuron disease), but none were seen in brainstem or spinal cord motor neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>M N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Dementia Research Group, Institute of Psychiatry, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lantos</LastName><ForeName>P L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Warrington</LastName><ForeName>E K</ForeName><Initials>EK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="N">Pick Disease of the Brain</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014452" MajorTopicYN="Y">Ubiquitins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10648435</ArticleId><ArticleId IdType="doi">10.1093/brain/123.2.267</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10651022</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>99</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains.</ArticleTitle><Pagination><StartPage>14</StartPage><EndPage>20</EndPage><MedlinePgn>14-20</MedlinePgn></Pagination><Abstract><AbstractText>The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP), also called alpha-synuclein, is a major component of Lewy bodies in Parkinson's disease (PD) as well as of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. We previously reported argyrophilic, tau-negative glial inclusions in the midbrains of patients with PD and have now conducted immunocytochemical and ultrastructural examinations. The PD glial inclusions also are immunoreactive for NACP/alpha-synuclein, but not for beta-synuclein, and ultrastructurally are composed of filamentous structures about 25-40 nm in diameter. Double immunolabeling showed that the inclusions were present in both astrocytic and oligodendroglial cells. They were located within the substantia nigra in 13 of 30 patients with PD and outside the nigra in 24. The number of inclusions was correlated with the severity of nigral neuronal loss. These findings indicate that abnormal accumulation of NACP/alpha-synuclein in glial cells is a pathological feature of PD related to its progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wakabayashi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Brain Disease Research Center, Brain Research Institute, Niigata University, Japan. koichi@bri.niigata-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yoshimoto</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497607">SNCB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051846">beta-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051846" MajorTopicYN="N">beta-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10651022</ArticleId><ArticleId IdType="doi">10.1007/pl00007400</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10652302</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation.</ArticleTitle><Pagination><StartPage>3173</StartPage><EndPage>3178</EndPage><MedlinePgn>3173-8</MedlinePgn></Pagination><Abstract><AbstractText>The discovery that a deficiency of presenilin 1 (PS1) decreases the production of amyloid beta-protein (Abeta) identified the presenilins as important mediators of the gamma-secretase cleavage of beta-amyloid precursor protein (APP). Recently, we found that two conserved transmembrane (TM) aspartates in PS1 are critical for Abeta production, providing evidence that PS1 either functions as a required diaspartyl cofactor for gamma-secretase or is itself gamma-secretase. Presenilin 2 (PS2) shares substantial sequence and possibly functional homology with PS1. Here, we show that the two TM aspartates in PS2 are also critical for gamma-secretase activity, providing further evidence that PS2 is functionally homologous to PS1. Cells stably co-expressing TM Asp --&gt; Ala mutations in both PS1 and PS2 show further accumulation of the APP-derived gamma-secretase substrates, C83 and C99. The production of Abeta is reduced to undetectable levels in the conditioned media of these cells. Furthermore, endoproteolysis of the exogenous Asp mutant PS2 is absent, and endogenous PS1 C-terminal fragments are diminished to undetectable levels. Therefore, the co-expression of PS1 and PS2 TM Asp --&gt; Ala mutants suppresses the formation of any detectable PS1 or PS2 heterodimeric fragments and essentially abolishes the production of Abeta. These results explain the residual Abeta production seen in PS1-deficient cells and demonstrate the absolute requirement of functional presenilins for Abeta generation. We conclude that presenilins, and their TM aspartates in particular, are attractive targets for lowering Abeta therapeutically to prevent Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kimberly</LastName><ForeName>W T</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rahmati</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG06173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10652302</ArticleId><ArticleId IdType="doi">10.1074/jbc.275.5.3173</ArticleId><ArticleId IdType="pii">S0021-9258(18)30891-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10655101</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>150</EndPage><MedlinePgn>143-50</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer amyloid beta-peptide (Abeta) is a physiological peptide constantly anabolized and catabolized under normal conditions. We investigated the mechanism of catabolism by tracing multiple-radiolabeled synthetic peptide injected into rat hippocampus. The Abeta1-42 peptide underwent full degradation through limited proteolysis conducted by neutral endopeptidase (NEP) similar or identical to neprilysin as biochemically analyzed. Consistently, NEP inhibitor infusion resulted in both biochemical and pathological deposition of endogenous Abeta42 in brain. This NEP-catalyzed proteolysis therefore limits the rate of Abeta42 catabolism, up-regulation of which could reduce the risk of developing Alzheimer's disease by preventing Abeta accumulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsubuki</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Takaki</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sekiguchi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hosoki</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kawashima-Morishima</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Hama</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sekine-Aizawa</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>T C</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2000 Jul;6(7):718-9. doi: 10.1038/77397.</RefSource><PMID Version="1">10888892</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10655101</ArticleId><ArticleId IdType="doi">10.1038/72237</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10655508</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides.</ArticleTitle><Pagination><StartPage>1202</StartPage><EndPage>1205</EndPage><MedlinePgn>1202-5</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by the age-related deposition of beta-amyloid (Abeta) 40/42 peptide aggregates in vulnerable brain regions. Multiple levels of evidence implicate a central role for Abeta in the pathophysiology of AD. Abeta peptides are generated by the regulated cleavage of an approximately 700-aa Abeta precursor protein (betaAPP). Full-length betaAPP can undergo proteolytic cleavage either within the Abeta domain to generate secreted sbetaAPPalpha or at the N- and C-terminal domain(s) of Abeta to generate amyloidogenic Abeta peptides. Several epidemiological studies have reported that estrogen replacement therapy protects against the development of AD in postmenopausal women. We previously reported that treating cultured neurons with 17beta-estradiol reduced the secretion of Abeta40/42 peptides, suggesting that estrogen replacement therapy may protect women against the development of AD by regulating betaAPP metabolism. Increasing evidence indicates that testosterone, especially bioavailable testosterone, decreases with age in older men and in postmenopausal women. We report here that treatment with testosterone increases the secretion of the nonamyloidogenic APP fragment, sbetaAPPalpha, and decreases the secretion of Abeta peptides from N2a cells and rat primary cerebrocortical neurons. These results raise the possibility that testosterone supplementation in elderly men may be protective in the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>G K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience and Fisher Center for Research on Alzheimer's Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Greenfield</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Hai</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS02037</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>W980KJ009P</RegistryNumber><NameOfSubstance UI="D003345">Corticosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003345" MajorTopicYN="N">Corticosterone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012636" MajorTopicYN="N">Secretory Rate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10655508</ArticleId><ArticleId IdType="pmc">PMC15568</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.3.1202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M X, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R. Lancet. 1996;348:429&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8709781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle D D, Metter E. Neurology. 1997;48:1517&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191758</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras G K, Greenfield J P, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic J N, Seeger M, Relkin N R, et al. Nat Med. 1998;4:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternbach H. Am J Psychiatry. 1998;155:1310&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">9766760</ArticleId></ArticleIdList></Reference><Reference><Citation>Winters S J. Arch Fam Med. 1999;8:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">10333822</ArticleId></ArticleIdList></Reference><Reference><Citation>Rako S. J Women's Health. 1998;7:825&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">9785308</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakasam G, Yeh J K, Chen M M, Castro-Magana M, Liang C T, Aloia J F. Bone. 1999;24:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321909</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirassa P, Thiblin I, Agren G, Vigneti E, Aloe L, Stenfors C. J Neurosci Res. 1997;47:198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008150</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman S N, Walsh B T. Am J Geriatr Psychiatry. 1999;7:8&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9919317</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras G K, Xu H, Jovanovic J N, Buxbaum J D, Wang R, Greengard P, Relkin N R, Gandy S. J Neurochem. 1998;71:1920&#x2013;1925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9798916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodovitz S, Klein W L. J Biol Chem. 1996;271:4436&#x2013;4440.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626795</ArticleId></ArticleIdList></Reference><Reference><Citation>Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R, Govoni S, Trabucchi M, Soma M. Biochem J. 1997;322:893&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218272</ArticleId><ArticleId IdType="pubmed">9148766</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti C G, Simons K. Proc Natl Acad Sci USA. 1998;95:6460&#x2013;6464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland D S, Trusko S P, Savage M J, Reaume A G, Lang D M, Hirsch J D, Maeda N, Siman R, Greenberg B D, Scott R W, et al. J Biol Chem. 1998;273:16576&#x2013;16582.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno T, Haass C, Michikawa M, Yanagisawa K. Biochim Biophys Acta. 1998;1373:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">9733943</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner M F, Vobach S, Olsson K, Svetlik D, Risser R C. Biol Psychiatry. 1997;42:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">9386855</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson L E, Sherwin B B, Chertkow H M. Horm Behav. 1999;35:254&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">10373337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizoguchi K, Kunishita T, Chui D H, Tabira T. Neurosci Lett. 1992;138:157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407656</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10662539</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0888-7543</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Genomics</Title><ISOAbbreviation>Genomics</ISOAbbreviation></Journal><ArticleTitle>Analysis of association at single nucleotide polymorphisms in the APOE region.</ArticleTitle><Pagination><StartPage>7</StartPage><EndPage>12</EndPage><MedlinePgn>7-12</MedlinePgn></Pagination><Abstract><AbstractText>The discussion of the prospects of using a dense map of single nucleotide polymorphisms (SNPs) to identify disease genes with association analysis has been extensive. However, there is little empiric evidence to support this strategy. To begin to examine the practical issues surrounding this methodology, we identified 10 SNPs in the region immediately surrounding the apolipoprotein E locus (APOE), an established susceptibility gene for Alzheimer disease. Our goal was to examine patterns of allelic association to begin to investigate the question of whether APOE could have been identified using SNPs. Our strongest evidence of association was at the 2 SNPs immediately flanking APOE.</AbstractText><CopyrightInformation>Copyright 2000 Academic Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>E R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. emartin@chg.mc.duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rogala</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Slotterbeck</LastName><ForeName>B D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Sipe</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Grubber</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>L L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Conneally</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Schmechel</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Purvis</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Roses</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P41RR03655</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2P01NS26630-11A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01NS31153-07</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genomics</MedlineTA><NlmUniqueID>8800135</NlmUniqueID><ISSNLinking>0888-7543</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10662539</ArticleId><ArticleId IdType="doi">10.1006/geno.1999.6057</ArticleId><ArticleId IdType="pii">S0888-7543(99)96057-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10662688</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1074-5521</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Chemistry &amp; biology</Title><ISOAbbreviation>Chem Biol</ISOAbbreviation></Journal><ArticleTitle>Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent.</ArticleTitle><Pagination><StartPage>51</StartPage><EndPage>63</EndPage><MedlinePgn>51-63</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Over 2000 protein kinases regulate cellular functions. Screening for inhibitors of some of these kinases has already yielded some potent and selective compounds with promising potential for the treatment of human diseases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The marine sponge constituent hymenialdisine is a potent inhibitor of cyclin-dependent kinases, glycogen synthase kinase-3beta and casein kinase 1. Hymenialdisine competes with ATP for binding to these kinases. A CDK2-hymenialdisine complex crystal structure shows that three hydrogen bonds link hymenialdisine to the Glu81 and Leu83 residues of CDK2, as observed with other inhibitors. Hymenialdisine inhibits CDK5/p35 in vivo as demonstrated by the lack of phosphorylation/down-regulation of Pak1 kinase in E18 rat cortical neurons, and also inhibits GSK-3 in vivo as shown by the inhibition of MAP-1B phosphorylation. Hymenialdisine also blocks the in vivo phosphorylation of the microtubule-binding protein tau at sites that are hyperphosphorylated by GSK-3 and CDK5/p35 in Alzheimer's disease (cross-reacting with Alzheimer's-specific AT100 antibodies).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The natural product hymenialdisine is a new kinase inhibitor with promising potential applications for treating neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meijer</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CNRS, Station Biologique, Roscoff cedex, 29682, France. meijer@sb-roscoff.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thunnissen</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>A W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Garnier</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nikolic</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>L H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cleverley</LastName><ForeName>K E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Y Z</ForeName><Initials>YZ</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Pettit</LastName><ForeName>G R</ForeName><Initials>GR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA-44344A1-05-10</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Chem Biol</MedlineTA><NlmUniqueID>9500160</NlmUniqueID><ISSNLinking>1074-5521</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C085284">microtubule-associated protein 1B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>95569-43-0</RegistryNumber><NameOfSubstance UI="C107079">hymenialdisine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.-</RegistryNumber><NameOfSubstance UI="D038341">Glycogen Synthase Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D047388">Casein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D017871">Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017871" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047388" MajorTopicYN="N">Casein Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018844" MajorTopicYN="N">Cyclin-Dependent Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038341" MajorTopicYN="N">Glycogen Synthase Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011161" MajorTopicYN="N">Porifera</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="Y">Protein Kinase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10662688</ArticleId><ArticleId IdType="doi">10.1016/s1074-5521(00)00063-6</ArticleId><ArticleId IdType="pii">S1074-5521(00)00063-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10662826</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0270-6474</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis.</ArticleTitle><Pagination><StartPage>1358</StartPage><EndPage>1364</EndPage><MedlinePgn>1358-64</MedlinePgn></Pagination><Abstract><AbstractText>Many cases of early-onset inherited Alzheimer's disease (AD) are caused by mutations in the presenilin-1 (PS1) gene. Studies of cultured neural cells suggest that PS1 mutations result in perturbed cellular calcium homeostasis and may thereby render neurons vulnerable to apoptosis. In light of evidence that metabolic impairment plays a role in AD, that cerebral ischemia may be a risk factor for AD, and that individuals with AD have increased morbidity and mortality after stroke, we examined the impact of a PS1 mutation on neuronal vulnerability to ischemic injury. We report that the extent of brain injury after focal cerebral ischemia reperfusion is increased, and behavioral outcome is worsened, in PS1 mutant knock-in mice compared to wild-type mice. Cultured cortical neurons from PS1 mutant mice exhibit increased vulnerability to glucose deprivation and chemical hypoxia compared to their wild-type counterparts. Calcium imaging studies demonstrated enhanced elevation of intracellular calcium levels after glucose deprivation and chemical hypoxia in neurons from PS1 mutant mice. Agents that block calcium release from IP(3)- and ryanodine-sensitive stores (xestospongin and dantrolene, respectively) protected against the endangering action of the PS1 mutation. Our data suggest that presenilin mutations may promote neuronal degeneration in AD by increasing the sensitivity of neurons to age-related ischemia-like conditions. The data further suggest that drugs that stabilize endoplasmic reticulum calcium homeostasis may prove effective in suppressing the neurodegenerative process in AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>M P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Sanders-Brown Research Center on Aging, Department of Anatomy, University of Kentucky, Lexington, Kentucky 40536, USA. mattsonm@grc.nia.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kindy</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>142M471B3J</RegistryNumber><NameOfSubstance UI="D002245">Carbon Dioxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>F64QU97QCR</RegistryNumber><NameOfSubstance UI="D003620">Dantrolene</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>O5DDB9Z95G</RegistryNumber><NameOfSubstance UI="D012966">Sodium Cyanide</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002245" MajorTopicYN="N">Carbon Dioxide</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015687" MajorTopicYN="Y">Cell Hypoxia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003620" MajorTopicYN="N">Dantrolene</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002546" MajorTopicYN="N">Ischemic Attack, Transient</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010313" MajorTopicYN="N">Partial Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012966" MajorTopicYN="N">Sodium Cyanide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10662826</ArticleId><ArticleId IdType="pmc">PMC6772370</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.20-04-01358.2000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ancolio K, Marambaud P, Dauch P, Checler F. &#x3b1;-secretase-derived product of &#x3b2;-amyloid precursor protein is decreased by presenilin-1 mutations linked to familial Alzheimer's disease. J Neurochem. 1997;69:2494&#x2013;2499.</Citation><ArticleIdList><ArticleId IdType="pubmed">9375682</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki T, Kato H, Kogure K. Alteration of second messenger systems after transient cerebral ischemia in gerbils: protective effect of pentobarbital and an autoradiographic analysis. Neurosci Lett. 1991;130:57&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">1749517</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley JG, Duan W, Duff K, Mattson MP. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J Neurochem. 1999;72:1030&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037474</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate A&#x3b2;25&#x2013;35/1&#x2013;40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, Holtsberg FW, Mattson MP. Altered neuronal and microglial responses to brain injury in mice lacking TNF receptors. Nat Med. 1996;2:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673925</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng B, Mattson MP. NGF and bFGF protect rat and human central neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron. 1991;7:1031&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">1662517</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol. 1996;6:667&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">8937832</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DG, Sung JC, Golde TE, Felsenstein KM, Wojczyk BS, Tanzi RE, Trojanowski JQ, Lee VM, Doms RW. Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites. Proc Natl Acad Sci USA. 1996;93:9223&#x2013;9228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38623</ArticleId><ArticleId IdType="pubmed">8799182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Chen L, Bendle SM, La Ferla FM. Widespread neuronal expression of the presenilin-1 early-onset Alzheimer's disease in the murine brain. Am J Pathol. 1996;148:1797&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861636</ArticleId><ArticleId IdType="pubmed">8669467</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada C-M, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-&#x3b2;42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Elder GA, Tezapsidis N, Carter J, Shioi J, Bouras C, Li D, Johnston JM, Efthimiopoulos S, Friedrich VL, Robakis NK. Identification and neuron specific expression of the S182/presenilin 1 protein in human and rodent brains. J Neurosci Res. 1996;45:308&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">8841992</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol. 1998;18:429&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932614</ArticleId></ArticleIdList></Reference><Reference><Citation>Endres M, Fink K, Zhu J, Stagliano NE, Bondada V, Geddes JW, Azuma T, Mattson MP, Kwiatkowski DJ, Moskowitz MA. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest. 1999;103:347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC407902</ArticleId><ArticleId IdType="pubmed">9927495</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandsen A, Schousboe A. Dantrolene prevents glutamate cytotoxicity and calcium release from intracellular stores in cultured cerebral cortical neurons. J Neurochem. 1991;56:1075&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671584</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Barger SW, Blalock E, Mattson MP. Activation of K+ channels and suppression of neuronal activity by secreted &#x3b2;-amyloid precursor protein. Nature. 1996;379:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8538744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafni J, Munsch JA, Lam TH, Catlin MC, Costa LG, Molinski TF, Pessah IN. Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron. 1997;19:723&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">9331361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg M, Butso R. Rodent models of cerebral ischemia. Stroke. 1989;20:1627&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pubmed">2688195</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg MP, Choi DW. Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. J Neurosci. 1993;13:3510&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576549</ArticleId><ArticleId IdType="pubmed">8101871</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman Y, Mattson MP. Secreted forms of &#x3b2;-amyloid precursor protein protect hippocampal neurons against amyloid &#x3b2;-peptide-induced oxidative injury. Exp Neurol. 1994;128:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8070512</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Furukawa K, Sopher BL, Pham DG, Xie J, Robinson N, Martin GM, Mattson MP. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid &#x3b2;-peptide. NeuroReport. 1996;8:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051814</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo G, Sopher BL, Pham DG, Furukawa K, Robinson N, Martin GM, Mattson MP. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid &#x3b2;-peptide: involvement of calcium and oxyradicals. J Neurosci. 1997;17:4212&#x2013;4222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573527</ArticleId><ArticleId IdType="pubmed">9151738</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Robinson N, Mattson MP. Secreted APP&#x3b1; counteracts the pro-apoptotic action of mutant presenilin-1 by activation of NF-&#x3ba;B and stabilization of calcium homeostasis. J Biol Chem. 1998;273:12341&#x2013;12351.</Citation><ArticleIdList><ArticleId IdType="pubmed">9575187</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999a;5:101&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, Martin GM, Mattson MP. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a presenilin-1 mutation. Proc Natl Acad Sci USA. 1999b;96:4125&#x2013;4130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22431</ArticleId><ArticleId IdType="pubmed">10097174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997;20:154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106355</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. 1994;265:1883&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522345</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R. Alzheimer's disease. N Engl J Med. 1986;314:964&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">2870433</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen H-C, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB, Mattson MP. Mitochondrial MnSOD prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation and mitochondrial dysfunction. J Neurosci. 1998;18:687&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792529</ArticleId><ArticleId IdType="pubmed">9425011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960&#x2013;1984). Neurology. 1996;46:154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs DM, Fausett HJ, Page KJ, Kim T-W, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996;2:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">8574969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, Levey AI. Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci. 1997;17:1971&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793763</ArticleId><ArticleId IdType="pubmed">9045726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Cellular actions of &#x3b2;-amyloid precursor protein and it's soluble and fibrillogenic derivatives. Physiol Rev. 1997;77:1081&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Mark RJ. Excitotoxicity and excitoprotection in vitro. Adv Neurol. 1996;71:1&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">8790786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. &#x3b2;-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992;12:376&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575616</ArticleId><ArticleId IdType="pubmed">1346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Culwell A, Esch F, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of &#x3b2;-amyloid precursor protein. Neuron. 1993a;10:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Zhang Y, Bose S. Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose. Exp Neurol. 1993b;121:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8495704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol. 1995;46:187&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">7541884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Guo Q, Furukawa K, Pedersen WA. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J Neurochem. 1998;70:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422341</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann NY Acad Sci. 1999;893:154&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM, McDonald B, Joachim C, Litchfield S, Barnetson L, Smith AD. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:165&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">9034370</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Szendrei GI, Lee VM, Mantsch HH. Human and rodent Alzheimer &#x3b2;-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. Eur J Biochem. 1993;211:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8425535</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci. 1984;4:1884&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564878</ArticleId><ArticleId IdType="pubmed">6737044</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. The amyloid &#x3b2; protein deposited in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp AH, McPherson PS, Dawson TM, Aoki C, Campbell KP, Snyder SH. Differential immunohistochemical localization of inositol 1,4,5-trisphosphate- and ryanodine-sensitive Ca2+ release channels in rat brain. J Neurosci. 1993;13:3051&#x2013;3063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576698</ArticleId><ArticleId IdType="pubmed">8392539</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA, Tune LE. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997;278:1363&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343469</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MP. Secreted forms of &#x3b2;-amyloid precursor protein protect against ischemic brain injury. J Neurochem. 1994;63:781&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">8035204</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasker RC, Sahota SK, Cotter FE, Williams SR. Early postischemic dantrolene-induced amelioration of poly(ADP-ribose) polymerase-related bioenergetic failure in neonatal rat brain slices. J Cereb Blood Flow Metab. 1998;18:1346&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850147</ArticleId></ArticleIdList></Reference><Reference><Citation>Usachev Y, Shmigol A, Pronchuk N, Kostyuk P, Verkhratsky A. Caffeine-induced calcium release from internal stores in cultured rat sensory neurons. Neuroscience. 1993;57:845&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">8309540</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Capell A, Grunberg J, Pesold B, Schindzielorz A, Prior R, Podlinsy MB, Fraser P, St George-Hyslop P, Selkoe DJ, Haass C. The Alzheimer's disease-associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Mol Med. 1996;2:673&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230134</ArticleId><ArticleId IdType="pubmed">8972483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei H, Perry DC. Dantrolene is cytoprotective in two models of neuronal cell death. J Neurochem. 1996;67:2390&#x2013;2398.</Citation><ArticleIdList><ArticleId IdType="pubmed">8931471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Andou Y, Masuda S, Mitani A, Kataoka K. Dantrolene protects against ischemic, delayed neuronal death in gerbil brain. Neurosci Lett. 1993;158:105&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8233063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10662829</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0270-6474</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Caspase-2 mediates neuronal cell death induced by beta-amyloid.</ArticleTitle><Pagination><StartPage>1386</StartPage><EndPage>1392</EndPage><MedlinePgn>1386-92</MedlinePgn></Pagination><Abstract><AbstractText>beta-amyloid (Abeta) has been proposed to play a role in the pathogenesis of Alzheimer's disease (AD). Deposits of insoluble Abeta are found in the brains of patients with AD and are one of the pathological hallmarks of the disease. It has been proposed that Abeta induces death by oxidative stress, possibly through the generation of peroxynitrite from superoxide and nitric oxide. In our current study, treatment with nitric oxide generators protected against Abeta-induced death, whereas inhibition of nitric oxide synthase afforded no protection, suggesting that formation of peroxynitrite is not critical for Abeta-mediated death. Previous studies have shown that aggregated Abeta can induce caspase-dependent apoptosis in cultured neurons. In all of the neuronal populations studied here (hippocampal neurons, sympathetic neurons, and PC12 cells), cell death was blocked by the broad spectrum caspase inhibitor N-benzyloxycarbonyl-val-ala-asp-fluoromethyl ketone and more specifically by the downregulation of caspase-2 with antisense oligonucleotides. In contrast, downregulation of caspase-1 or caspase-3 did not block Abeta(1-42)-induced death. Neurons from caspase-2 null mice were totally resistant to Abeta(1-42) toxicity, confirming the importance of this caspase in Abeta-induced death. The results indicate that caspase-2 is necessary for Abeta(1-42)-induced apoptosis in vitro.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Troy</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Taub Institute for the Study of Alzheimer's Disease, New York 10032, USA. cmt2@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabacchi</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Frappier</LastName><ForeName>T F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shelanski</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R29 NS035933</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009566">Nitrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020319">Oligodeoxyribonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>26404-66-0</RegistryNumber><NameOfSubstance UI="C039642">peroxynitric acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505410">Casp3 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053143">Caspase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053143" MajorTopicYN="N">Caspase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009566" MajorTopicYN="N">Nitrates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020319" MajorTopicYN="N">Oligodeoxyribonucleotides, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013564" MajorTopicYN="N">Sympathetic Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10662829</ArticleId><ArticleId IdType="pmc">PMC6772358</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.20-04-01386.2000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmad M, Srinivasula SM, Hegde R, Mukattash R, Fernandes-Alnemri T, Alnemri ES. Identification and characterization of murine caspase-14, a new member of the caspase family. Cancer Res. 1998;58:5201&#x2013;5205.</Citation><ArticleIdList><ArticleId IdType="pubmed">9823333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A, Varmuza S, Latham KE, Flaws JA, Salter JC, Hara H, Moskowitz MA, Li E, Greenberg A, Tilly JL, Yuan J. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev. 1998;12:1304&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316779</ArticleId><ArticleId IdType="pubmed">9573047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Griffin WS, Mattson MP. Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. J Neurosci Res. 1999;57:315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol. 1996;6:493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">8944319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Whittemore ER, Watt JA, Anderson AJ, Loo DT. Possible role of apoptosis in Alzheimer's disease. Ann NY Acad Sci. 1994;747:36&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7847684</ArticleId></ArticleIdList></Reference><Reference><Citation>De Azevedo WF, Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA. 1996;93:2735&#x2013;2740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39700</ArticleId><ArticleId IdType="pubmed">8610110</ArticleId></ArticleIdList></Reference><Reference><Citation>Estus S, Tucker HM, van Rooyen C, Wright S, Brigham EF, Wogulis M, Rydel RE. Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant &#x201c;apoptotic&#x201d; pattern of gene induction. J Neurosci. 1997;17:7736&#x2013;7745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793913</ArticleId><ArticleId IdType="pubmed">9315895</ArticleId></ArticleIdList></Reference><Reference><Citation>Farinelli SE, Park DS, Greene LA. Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J Neurosci. 1996;16:2325&#x2013;2334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578529</ArticleId><ArticleId IdType="pubmed">8601812</ArticleId></ArticleIdList></Reference><Reference><Citation>Farinelli SE, Greene LA, Friedman WJ. Neuroprotective actions of dipyridamole on cultured CNS neurons. J Neurosci. 1998;18:5112&#x2013;5123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793500</ArticleId><ArticleId IdType="pubmed">9651195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci. 1997;9:220&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">9245504</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999;97:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS. Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F.DP, in B-amyloid-induced neuronal death. J Biol Chem. 1999;274:19011&#x2013;19016.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383401</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA. 1976;73:2424&#x2013;2428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC430592</ArticleId><ArticleId IdType="pubmed">1065897</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene LA, Cunningham ME, Farinelli SE, Park DS. Methodologies for the culture and experimental use of the PC12 rat pheochromocytoma line. In: Banker G, Goslin K, editors. Culturing nerve cells. MIT; Cambridge, MA: 1998. pp. 161&#x2013;188.</Citation></Reference><Reference><Citation>Guo Q, Sebastian L, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. J Neurochem. 1999;72:1019&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM. Caspase-14 is a novel developmentally regulated protease. J Biol Chem. 1998;273:29648&#x2013;29653.</Citation><ArticleIdList><ArticleId IdType="pubmed">9792675</ArticleId></ArticleIdList></Reference><Reference><Citation>Humke EW, Ni J, Dixit VM. ERICE, a novel FLICE-activatable caspase. J Biol Chem. 1998;273:15702&#x2013;15707.</Citation><ArticleIdList><ArticleId IdType="pubmed">9624166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ii M, Sunamoto M, Ohnishi K, Ichimori Y. beta-Amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res. 1996;720:93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">8782901</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan J, Galindo MF, Miller RJ. Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. J Neurochem. 1997;68:1612&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">9084433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86&#x2013;8275. J Natl Cancer Inst. 1992;84:1736&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">1279187</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Kindy MS, Holtsberg FW, St. Clair DK, Yen HC, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB, Mattson MP. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci. 1998;18:687&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792529</ArticleId><ArticleId IdType="pubmed">9425011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci. 1997;17:5089&#x2013;5100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573293</ArticleId><ArticleId IdType="pubmed">9185546</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Bushnell AF, Lee CM, Perlmutter LS, Wong SK. Beta-amyloid induces apoptosis in human-derived neurotypic SH-SY5Y cells. Brain Res. 1996;738:196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955513</ArticleId></ArticleIdList></Reference><Reference><Citation>Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86&#x2013;8275. Biochem Biophys Res Commun. 1994;201:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">8002990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, Stamler JS. Fas-induced caspase denitrosylation. Science. 1999;284:651&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213689</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol. 1998;57:1041&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9825941</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4:2757&#x2013;2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC554575</ArticleId><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Partin J, Begley JG. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 1998;807:167&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">9757026</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol. 1991a;207:367&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">1783006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991b;563:311&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">1786545</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Ramezan-Arab N, Cotman CW. Beta-amyloid neurotoxicity in vitro: evidence of oxidative stress but not protection by antioxidants. J Neurochem. 1997;69:1601&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pubmed">9326289</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Deciphering Alzheimer's disease: the amyloid precursor protein yields new clues. Science. 1990;248:1058&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">2111582</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997;275:630&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">9019820</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, Park DS, Yan CY, Farinelli SE, Troy CM, Shelanski ML, Greene LA. Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support. Dissociation from apoptosis. J Biol Chem. 1996;271:30663&#x2013;30671.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940042</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, Troy CM, Qi H, Greene LA. Inhibitors of trypsin-like serine proteases inhibit processing of the caspase Nedd-2 and protect PC12 cells and sympathetic neurons from death evoked by withdrawal of trophic support. J Neurochem. 1997;69:1425&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">9326271</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, Troy CM, Qi H, Shelanski ML, Greene LA. Caspase-2 (Nedd-2) processing and death of trophic factor-deprived PC12 cells and sympathetic neurons occur independently of caspase-3 (CPP32)- like activity. J Neurosci. 1998;18:9204&#x2013;9215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792876</ArticleId><ArticleId IdType="pubmed">9801360</ArticleId></ArticleIdList></Reference><Reference><Citation>Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem. 1997;272:9677&#x2013;9682.</Citation><ArticleIdList><ArticleId IdType="pubmed">9092497</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">9721091</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem. 1997;272:17907&#x2013;17911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218414</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, Shelanski ML. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci USA. 1994;91:6384&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44206</ArticleId><ArticleId IdType="pubmed">8022792</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, Derossi D, Prochiantz A, Greene LA, Shelanski ML. Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J Neurosci. 1996a;16:253&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578729</ArticleId><ArticleId IdType="pubmed">8613791</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, Stefanis L, Prochiantz A, Greene LA, Shelanski ML. The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl Acad Sci USA. 1996b;93:5635&#x2013;5640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39300</ArticleId><ArticleId IdType="pubmed">8643629</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, Stefanis L, Greene LA, Shelanski ML. Nedd2 is required for apoptosis after trophic factor withdrawal, but not superoxide dismutase (SOD1) downregulation, in sympathetic neurons and PC12 cells. J Neurosci. 1997;17:1911&#x2013;1918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793762</ArticleId><ArticleId IdType="pubmed">9045720</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S, Mieijer L. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994;224:771&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">7925396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zelenski NG, Yang J, Sakai J, Brown MS, Goldstein JL. Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J. 1996;15:1012&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC449996</ArticleId><ArticleId IdType="pubmed">8605870</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10666378</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>156</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>489</StartPage><EndPage>499</EndPage><MedlinePgn>489-99</MedlinePgn></Pagination><Abstract><AbstractText>The complement system constitutes a series of enzymatic steps involved in the inflammatory response and is activated in Alzheimer's disease (AD). Using Down's syndrome (DS) brains as a temporal model for the progression of AD, we examined components of the complement cascade and their relationship to other principal events in AD pathology: Abeta42 deposition, neuritic changes, neurofibrillary tangles (NFTs), and gliosis (reactive astrocytes, activated microglia). Adjacent sections of frontal cortex from 24 DS subjects ranging in age from 12 to 73 years were immunohistochemically examined for immunoreactivity (IR) of classical complement proteins (Clq and C3), markers indicating activation of complement (C4d and C5b-9), the complement inhibitor apolipoprotein J (apo J), and markers of AD neuropathology. Abeta42-labeled diffuse plaques were first detected in a 12-year-old DS subject and were not labeled by any of the complement antibodies. Colocalization of Abeta42 with Clq, C3, C4d, and/or apo J was first detected in compacted plaques in the brain of a 15-year-old DS patient with features of mature AD pathology, such as reactive astrocytes, activated microglia, dystrophic neurites, and a few NFTs. IR for C4d and C5b-9 (membrane attack complex, MAC) was observed in small numbers of plaque-associated dystrophic neurites and in focal regions of pyramidal neurons in this 15-year-old. The only other young (&lt;/=30 years) DS brain to show extensive complement IR was that of a 29-year-old DS subject who also displayed the full range of AD neuropathological features. All middle-aged and old DS brains showed IR for Clq and C3, primarily in compacted plaques. In these cases, C4d IR was found in a subset of Abeta42 plaques and, along with C5b-9 IR, was localized to dystrophic neurites in a subset of neuritic plaques, neurons, and some NFTs. Our data suggest that in AD and DS, the classical complement cascade is activated after compaction of Abeta42 deposits and, in some instances, can progress to the local neuronal expression of the MAC as a response to Abeta plaque maturation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stoltzner</LastName><ForeName>S E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenfell</LastName><ForeName>T J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>K E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15408</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015408</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003181">Complement C4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015938">Complement Membrane Attack Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-50-7</RegistryNumber><NameOfSubstance UI="D015935">Complement C4b</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-52-9</RegistryNumber><NameOfSubstance UI="C032261">complement C4d</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003181" MajorTopicYN="N">Complement C4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015935" MajorTopicYN="Y">Complement C4b</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015938" MajorTopicYN="N">Complement Membrane Attack Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="Y">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10666378</ArticleId><ArticleId IdType="pmc">PMC1850044</ArticleId><ArticleId IdType="doi">10.1016/S0002-9440(10)64753-0</ArticleId><ArticleId IdType="pii">S0002-9440(10)64753-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kosik KS, Joachim CL, Selkoe DJ: Microtubule-associated protein, tau, is a major antigenic component of paired helical filaments in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA 1986, 83:4044-4048</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Quinlan M, Tung Y-C, Zaidi MS, Wisniewski HM: Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 1986a, 261:6084-6089</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M: Tau mutations cause frontotemporal dementias. Neuron 1998, 21:955-958</Citation><ArticleIdList><ArticleId IdType="pubmed">9856453</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer&#x2019;s disease. Nature 1999, 399:A23-A31</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL: Amyloid A4 protein, and its precursor in Down&#x2019;s syndrome and Alzheimer&#x2019;s disease. N Engl J Med 1989, 320:1446-1452</Citation><ArticleIdList><ArticleId IdType="pubmed">2566117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA: Cerebral amyloidosis, aging and Alzheimer&#x2019;s disease: a contribution from studies on Down&#x2019;s syndrome. Neurobiol Aging 1989, 10:397-399</Citation><ArticleIdList><ArticleId IdType="pubmed">2530459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski K, Wisniewski H, Wen G: Occurrence of neuropathological changes and dementia of Alzheimer&#x2019;s disease in Down&#x2019;s syndrome. Ann Neurol 1985, 17:278-282</Citation><ArticleIdList><ArticleId IdType="pubmed">3158266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Blustzjan JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ: Sequence of deposition of heterogeneous amyloid &#x3b2;-peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996, 3:16-32</Citation><ArticleIdList><ArticleId IdType="pubmed">9173910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai F, Williams RS: A prospective study of Alzheimer&#x2019;s disease in Down syndrome. Arch Neurol 1989, 46:849-853</Citation><ArticleIdList><ArticleId IdType="pubmed">2527024</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Yuonis N, Jones D, Stoddart RW: The time course of pathological events in Down&#x2019;s syndrome with particular reference to the involvement of microglial cells and deposits of &#x3b2;/A4. Neurodegeneration 1992, 1:201-215</Citation></Reference><Reference><Citation>Tagliavini F, Giaccone G, Linoli G, Frangione B, Bugiani O: Cerebral extracellular preamyloid deposits in Alzheimer&#x2019;s disease, Down syndrome and nondemented elderly individuals. Prog Clin Biol Res 1989, 317:1001-1005</Citation><ArticleIdList><ArticleId IdType="pubmed">2532368</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Stam FC: Immunoglobulins and complement factors in senile plaques: an immunoperoxidase study. Acta Neuropathol 1982, 57:239-242</Citation><ArticleIdList><ArticleId IdType="pubmed">6812382</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG: Complement proteins and complement inhibitors in Alzheimer&#x2019;s disease. Res Immunol 1992, 143:621-624</Citation><ArticleIdList><ArticleId IdType="pubmed">1455053</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Schultz J, Brachova L, Lue L-F, Webster S, Bradt B, Cooper NR, Moss DE: Complement activation and &#x3b2;-amyloid-mediated neurotoxicity in Alzheimer&#x2019;s disease. Res Immunol 1992, 143:624-630</Citation><ArticleIdList><ArticleId IdType="pubmed">1455054</ArticleId></ArticleIdList></Reference><Reference><Citation>Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ: Localization and cell association of Clq in Alzheimer&#x2019;s disease brain. Exp Neurol 1996, 138:22-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8593893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuby J, Ed: The Complement System. Immunology. New York, W. H. Freeman and Company, 1998, pp. 335&#x2013;355</Citation></Reference><Reference><Citation>Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM, Krafft GA, Holzman RB, Holzman TF: Complement Clq does not bind monomeric &#x3b2;-amyloid. Exp Neurol 1994, 128:136-142</Citation><ArticleIdList><ArticleId IdType="pubmed">8070518</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Cooper NR, Websger S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I: Complement activation by &#x3b2;-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992, 89:10016-10020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50268</ArticleId><ArticleId IdType="pubmed">1438191</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Burdick D, Glabe C, Cotman C, Tenner A: &#x3b2;-amyloid activates complement by binding to a specific region of the collagen-like domain of the Clq A chain. J Immunol 1994, 152:5050-5059</Citation><ArticleIdList><ArticleId IdType="pubmed">8176223</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Glabe C, Rogers J: Multivalent binding of complement protein Clq to the amyloid &#x3b2;-peptide promotes the nucleation phase of A&#x3b2; aggregation. Biochem Biophys Res Commun 1995, 217:869-875</Citation><ArticleIdList><ArticleId IdType="pubmed">8554610</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Frederickson RCA, Brunden KR: Neuroglial-mediated immunoinflammatory responses in Alzheimer&#x2019;s disease: complement activation and therapeutic approaches. Neurobiol Aging 1996, 17:781-787</Citation><ArticleIdList><ArticleId IdType="pubmed">8892352</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez P, Cribbs D, Poulos T, Tenner A: Aspartate residue 7 in amyloid &#x3b2;-protein is critical for classical complement pathway activation: implications for Alzheimer&#x2019;s disease pathogenesis. Nature Med 1997, 3:77-79</Citation><ArticleIdList><ArticleId IdType="pubmed">8986745</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Bonnell B, Rogers J: Charge-based binding of complement component Clq to the Alzheimer amyloid &#x3b2;-peptide. Am J Pathol 1997, 150:1531-1536</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858209</ArticleId><ArticleId IdType="pubmed">9137079</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Velazquez P, Soreghan B, Glabe CG, Tenner AJ: Complement activation by cross-linked truncated and chimeric full-length &#x3b2;-amyloid. NeuroReport 1997, 8:3457-3462</Citation><ArticleIdList><ArticleId IdType="pubmed">9427307</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Hack CE, Rozemuller JM, Stam FC: Complement activation in amyloid plaques in Alzheimer&#x2019;s dementia. Virchows Arch B Cell Pathol 1989, 56:259-262</Citation><ArticleIdList><ArticleId IdType="pubmed">2565620</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Akiyama H, Itagaki S, McGeer EG: Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989, 107:341-346</Citation><ArticleIdList><ArticleId IdType="pubmed">2559373</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Schwab C, McGeer EG, McGeer PL: Up-regulated production and activation of the complement system in Alzheimer&#x2019;s disease brain. Am J Pathol 1999, 154:927-936</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866427</ArticleId><ArticleId IdType="pubmed">10079271</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Akiyama H, Itagaki S, McGreer EG: Immune system response in Alzheimer&#x2019;s disease. Can J Neurol Sci 1989, 16:516-527</Citation><ArticleIdList><ArticleId IdType="pubmed">2804814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayakima H, Yamada T, Kawamata T, McGeer PL: Association of amyloid P component with complement proteins in neurologically diseased brain tissue. Brain Res 1991, 548:349-352</Citation><ArticleIdList><ArticleId IdType="pubmed">1831062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kida E, Miura-Choi N, Wisniewski KE: Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer&#x2019;s disease and Down&#x2019;s syndrome brain. Brain Res 1995, 685:211-216</Citation><ArticleIdList><ArticleId IdType="pubmed">7583250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiso J, Matsubara E, Koudinov A, Choi-Miura N, Tomita M, Wisniewski T: The cerebrospinal-fluid soluble form of Alzheimer&#x2019;s amyloid &#x3b2; is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993, 293:27-30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1134315</ArticleId><ArticleId IdType="pubmed">8328966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradt BM, Kolb WP, Cooper NR: Complement-dependent pro-inflammatory properties of the Alzheimer&#x2019;s disease &#x3b2;-peptide. J Exp Med 1998, 188:431-438</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212467</ArticleId><ArticleId IdType="pubmed">9687521</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L: Amyloid precursor protein processing and A&#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 1997, 94(4):1550&#x2013;1555</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb WB, Morrow PR, Jensen FC, Tamerius JD: Development of a highly sensitive capture EIA for the quantitation of the SC5b-9 complex in human plasma using a monoclonal antibody reactive with a poly-C9 neoantigenic determinant. Complement 1988, 5:213</Citation></Reference><Reference><Citation>Walker DG, Kim WU, McGeer PL: Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res 1995, 40:478-493</Citation><ArticleIdList><ArticleId IdType="pubmed">7616608</ArticleId></ArticleIdList></Reference><Reference><Citation>Terai K, Walker DG, McGeer EG, McGeer PL: Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 1997, 769:385-390</Citation><ArticleIdList><ArticleId IdType="pubmed">9374211</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadman ED, Puttfarcken PS: &#x3b2;-amyloid peptides initiate the complement cascade without producing a comparable effect on the terminal pathway in vitro. Exp Neurol 1997, 146:388-394</Citation><ArticleIdList><ArticleId IdType="pubmed">9270049</ArticleId></ArticleIdList></Reference><Reference><Citation>May P, Finch CE: Sulfated glycoprotein 2: new relationships to this multifunctional protein to neurodegeneration. Trends Neurosci 1992, 15:391-396</Citation><ArticleIdList><ArticleId IdType="pubmed">1279864</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE: Purification and characterization of brain clusterin. Biochem Biophys Res Commun 1994, 204:1131-1136</Citation><ArticleIdList><ArticleId IdType="pubmed">7980587</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara E, Soto C, Governale S, Frangione B, Ghiso J: Apolipoprotein J and Alzheimer&#x2019;s amyloid &#x3b2; solubility. Biochem J 1996, 316:671-679</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217400</ArticleId><ArticleId IdType="pubmed">8687416</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG: Neuroimmune mechanisms in the pathogenesis of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Disease. Edited by Z. S. Khachaturian and T. S. Radebaugh. CRC Press, Boca Raton, FL, 1996, pp. 217&#x2013;225</Citation></Reference><Reference><Citation>McGeer PL, Walker DJ, Akiyama H, Kawamata T, Guan AL, Parker CJ, Okada N, McGeer EG: Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res 1991, 544:315-320</Citation><ArticleIdList><ArticleId IdType="pubmed">1710165</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, McGeer PL: Inhibition of respiratory burst in macrophages by complement receptor blockade. Eur J Pharmacol 1994, 260:273-277</Citation><ArticleIdList><ArticleId IdType="pubmed">7988657</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995, 21:195-218</Citation><ArticleIdList><ArticleId IdType="pubmed">8866675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10668686</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>295</StartPage><EndPage>301</EndPage><MedlinePgn>295-301</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">AD, the most prevalent cause of dementia, affects twice as many women as men. Therapeutic options are limited, but results of prior studies support the hypothesis that estrogen treatment may improve symptoms of women with this disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-two women with mild-to-moderate dementia due to AD were enrolled into a randomized, double-blind, placebo-controlled, parallel-group trial of unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Outcome data were available for 40 women at 4 weeks and 36 women at 16 weeks. At both 4 and 16 weeks, there were no significant differences or statistical trends between treatment groups on the primary outcome measure (the cognitive subscale of the Alzheimer's Disease Assessment Scale), clinician-rated global impression of change, or caregiver-rated functional status. Exploratory analyses of mood and specific aspects of cognitive performance also failed to demonstrate substantial group differences.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although conclusions are limited by small sample size and the possibility of a type II error, results suggest that short-term estrogen therapy does not improve symptoms of most women with AD. These findings do not address possible long-term effects of estrogen in AD, possible interactions between estrogen and other treatment modalities, or putative effects of estrogen in preventing or delaying onset of this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>V W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles 90089, USA. vhenders@hsc.usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganini-Hill</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Elble</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>P F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Shoupe</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McCleary</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Hake</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004966">Estrogens, Conjugated (USP)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="Y">Estrogen Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004966" MajorTopicYN="N">Estrogens, Conjugated (USP)</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10668686</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.2.295</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10668712</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging.</ArticleTitle><Pagination><StartPage>447</StartPage><EndPage>451</EndPage><MedlinePgn>447-51</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the importance of vascular cognitive impairment and its three subgroups (cognitive impairment, no dementia; vascular dementia; and AD with a vascular component) to the prevalence and burden of cognitive impairment in elderly people.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vascular lesions may produce a spectrum of cognitive changes. Omitting elderly patients whose cognitive impairment falls short of dementia (vascular cognitive impairment, no dementia) may give a falsely low indication of the prevalence and burden of disease. To test this proposition, we compared the rates of adverse outcomes for patients with no cognitive impairment, vascular cognitive impairment (and its subgroups), and probable AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Canadian Study of Health and Aging is a prospective cohort study of 10,253 randomly selected community-dwelling and institution-dwelling respondents aged 65 years or older. In the community, all participants (n = 9,008) were screened for cognitive impairment; those who screened positive and a sample of those who screened negative received a clinical assessment (n = 1,659). All patients living in institutions received a clinical assessment (n = 1,255). Participants were reassessed 5 years after the original survey.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Vascular cognitive impairment without dementia was the most prevalent form of vascular cognitive impairment among those aged 65 to 84 years. Rates of institutionalization and mortality for those with vascular cognitive impairment were significantly higher than those of people who had no cognitive impairment, and the mortality rate for patients with vascular cognitive impairment was similar to that of patients with AD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Failure to consider vascular cognitive impairment without dementia underestimates the prevalence of impairment and the risk for adverse outcomes associated with vascular cognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rockwood</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. rockwood@is.dal.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wentzel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hachinski</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Hogan</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>MacKnight</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>McDowell</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10668712</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.2.447</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10676851</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-0186</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurochemistry international</Title><ISOAbbreviation>Neurochem Int</ISOAbbreviation></Journal><ArticleTitle>In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>191</EndPage><MedlinePgn>185-91</MedlinePgn></Pagination><Abstract><AbstractText>Glutathione deficiency has been associated with a number of neurodegenerative diseases including Lou Gehrig's disease, Parkinson's disease, and HIV. A crucial role for glutathione is as a free radical scavenger. Alzheimer's disease (AD) brain is characterized by oxidative stress, manifested by protein oxidation, lipid oxidation, oxidized glutathione, and decreased activity of glutathione S-transferase, among others. Reasoning that elevated levels of endogenous glutathione would offer protection against free radical-induced oxidative stress, rodents were given in vivo injections of N-acetylcysteine (NAC), a known precursor of glutathione, to study the vulnerability of isolated synaptosomal membranes treated with Fe2+/H2O2, a known hydroxyl free radical producer. Protein carbonyls, a marker of protein oxidation, were measured. NAC significantly increased endogenous glutathione levels in cortical synaptosome cytosol (P &lt; 0.01). As reported previously, protein carbonyl levels of the Fe2+/H2O2-treated synaptosomes were significantly higher compared to that of non-treated controls (P &lt; 0.01), consistent with increased oxidative stress. In contrast, protein carbonyl levels in Fe2+/H2O2-treated synaptosomes isolated from NAC-injected animals were not significantly different from saline-injected non-treated controls, demonstrating protection against hydroxyl radical induced oxidative stress. These results are consistent with the notion that methods to increase endogenous glutathione levels in neurodegenerative diseases associated with oxidative stress, including AD, may be promising.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pocernich</LastName><ForeName>C B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Kentucky, Lexington 40506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Fontaine</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Butterfield</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-05119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-10836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurochem Int</MedlineTA><NlmUniqueID>8006959</NlmUniqueID><ISSNLinking>0197-0186</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005296">Ferrous Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3352-57-6</RegistryNumber><NameOfSubstance UI="D017665">Hydroxyl Radical</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>GAN16C9B8O</RegistryNumber><NameOfSubstance UI="D005978">Glutathione</NameOfSubstance></Chemical><Chemical><RegistryNumber>WYQ7N0BPYC</RegistryNumber><NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000111" MajorTopicYN="N">Acetylcysteine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005296" MajorTopicYN="N">Ferrous Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017665" MajorTopicYN="N">Hydroxyl Radical</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10676851</ArticleId><ArticleId IdType="doi">10.1016/s0197-0186(99)00126-6</ArticleId><ArticleId IdType="pii">S0197-0186(99)00126-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10677483</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.</ArticleTitle><Pagination><StartPage>1456</StartPage><EndPage>1460</EndPage><MedlinePgn>1456-60</MedlinePgn></Pagination><Abstract><AbstractText>The cDNAs of two new human membrane-associated aspartic proteases, memapsin 1 and memapsin 2, have been cloned and sequenced. The deduced amino acid sequences show that each contains the typical pre, pro, and aspartic protease regions, but each also has a C-terminal extension of over 80 residues, which includes a single transmembrane domain and a C-terminal cytosolic domain. Memapsin 2 mRNA is abundant in human brain. The protease domain of memapsin 2 cDNA was expressed in Escherichia coli and was purified. Recombinant memapsin 2 specifically hydrolyzed peptides derived from the beta-secretase site of both the wild-type and Swedish mutant beta-amyloid precursor protein (APP) with over 60-fold increase of catalytic efficiency for the latter. Expression of APP and memapsin 2 in HeLa cells showed that memapsin 2 cleaved the beta-secretase site of APP intracellularly. These and other results suggest that memapsin 2 fits all of the criteria of beta-secretase, which catalyzes the rate-limiting step of the in vivo production of the beta-amyloid (Abeta) peptide leading to the progression of Alzheimer's disease. Recombinant memapsin 2 also cleaved a peptide derived from the processing site of presenilin 1, albeit with poor kinetic efficiency. Alignment of cleavage site sequences of peptides indicates that the specificity of memapsin 2 resides mainly at the S(1)' subsite, which prefers small side chains such as Ala, Ser, and Asp.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Protein Studies Program, Oklahoma Medical Research Foundation, and Department of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koelsch</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Downs</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dashti</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AF200192</AccessionNumber><AccessionNumber>AF200193</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10677483</ArticleId><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.4.1456</ArticleId><ArticleId IdType="pii">97/4/1456</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Nature (London) 1999;399A:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T, Selkoe D J. Nature (London) 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt D R, Lee M K, Slunt H H, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, et al. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny M B, Citron M, Amarante P, Sherrington R, Xia W, Zhang J, Diehl T, Levesque G, Fraser P, Haass C, et al. Neurobiol Dis. 1997;3:325&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Lieberburg I. Proc Natl Acad Sci USA. 1999;96:11049&#x2013;11053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34239</ArticleId><ArticleId IdType="pubmed">10500121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Lin Y, Tang J. Methods Enzymol. 1994;241:195&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">7854179</ArticleId></ArticleIdList></Reference><Reference><Citation>Fersht A. Enzyme Structure and Mechanism. New York: Freeman; 1985.</Citation></Reference><Reference><Citation>Lin X, Dashti A, Schinazi R F, Tang J. FASEB J. 1993;7:1070&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">8370478</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez R G, Squazzo S L, Koo E H. J Biol Chem. 1996;271:9100&#x2013;9107.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621560</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Wong R N S. J Cell Biochem. 1987;33:53&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">3546346</ArticleId></ArticleIdList></Reference><Reference><Citation>Koelsch G, Loy J, Lin X, Tang J. Adv Exp Med Biol. 1998;436:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">9561226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, Houlden H, Windelspecht M, Fidani L, Lombardi C, Diaz P, Rossor M, Crook R, Hardy J, Duff K, et al. Nat Genet. 1992;2:340&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303291</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung A Y, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe D J. Nature (London) 1992;260:672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Knops J, Suomensaari S, Lee M, McConlogue L, Serbert P, Sinha S. J Biol Chem. 1995;270:2419&#x2013;2422.</Citation><ArticleIdList><ArticleId IdType="pubmed">7852298</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett B D, Babu-Khan S, Kahn S, Mendiaz E A, Denis P, Teplow D B, Ross S, Amarante P, Loeloff R, et al. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewji N N, Singer S J. Proc Natl Acad Sci USA. 1997;94:1425&#x2013;1430.</Citation></Reference><Reference><Citation>De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, Cordell B, Moechars D, Bollen M, Fraser P, George-Hyslop P S, et al. J Biol Chem. 1997;272:3590&#x2013;3598.</Citation><ArticleIdList><ArticleId IdType="pubmed">9013610</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Taplow D B, Selkoe D J. Neuron. 1995;14:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695913</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10678753</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8993</ISSN><JournalIssue CitedMedium="Print"><Volume>852</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Brain research</Title><ISOAbbreviation>Brain Res</ISOAbbreviation></Journal><ArticleTitle>Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>278</EndPage><MedlinePgn>274-8</MedlinePgn></Pagination><Abstract><AbstractText>Excess brain zinc has been implicated in Alzheimer's neuropathology. Here we evaluated that hypothesis by searching the brains of Alzheimer's patients for abnormal zinc deposits. Using histochemical methods, we found vivid Zn2+ staining in the amyloid deposits of dense-core (senile) plaques, in the amyloid angiopathy surrounding diseased blood vessels, and in the somata and dendrites of neurons showing the characteristic neurofibrillary tangles (NFT) of Alzheimer's. In contrast, brains from age-matched, non-demented subjects showed only occasional staining for Zn2+ in scattered neurons and possible plaques. A role of abnormal zinc metabolism in Alzheimer's neuropathology is suggested.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>S W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering, Anatomy and Neuroscience, Jennie-Sealy Hospital, University of Texas Medical Branch, Galveston, 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>K B</ForeName><Initials>KB</Initials></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Kesslak</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Danscher</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Frederickson</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Res</MedlineTA><NlmUniqueID>0045503</NlmUniqueID><ISSNLinking>0006-8993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000634">Aminoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013440">Sulfides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014105">Tosyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>7SWW052N6R</RegistryNumber><NameOfSubstance UI="C061730">N-(6-methoxy-8-quinolyl)-4-toluenesulfonamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000634" MajorTopicYN="N">Aminoquinolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019581" MajorTopicYN="N">Neuropil</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016622" MajorTopicYN="N">Silver Staining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013440" MajorTopicYN="N">Sulfides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014105" MajorTopicYN="N">Tosyl Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10678753</ArticleId><ArticleId IdType="doi">10.1016/s0006-8993(99)02096-x</ArticleId><ArticleId IdType="pii">S0006-8993(99)02096-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10678833</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>287</Volume><Issue>5456</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.</ArticleTitle><Pagination><StartPage>1265</StartPage><EndPage>1269</EndPage><MedlinePgn>1265-9</MedlinePgn></Pagination><Abstract><AbstractText>To elucidate the role of the synaptic protein alpha-synuclein in neurodegenerative disorders, transgenic mice expressing wild-type human alpha-synuclein were generated. Neuronal expression of human alpha-synuclein resulted in progressive accumulation of alpha-synuclein-and ubiquitin-immunoreactive inclusions in neurons in the neocortex, hippocampus, and substantia nigra. Ultrastructural analysis revealed both electron-dense intranuclear deposits and cytoplasmic inclusions. These alterations were associated with loss of dopaminergic terminals in the basal ganglia and with motor impairments. These results suggest that accumulation of wild-type alpha-synuclein may play a causal role in Parkinson's disease and related conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Department of Pathology, University of California San Diego, La Jolla, CA 92093-0624, USA. emasliah@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockenstein</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Veinbergs</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mallory</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sagara</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sisk</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10678833</ArticleId><ArticleId IdType="doi">10.1126/science.287.5456.1265</ArticleId><ArticleId IdType="pii">8276</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10679792</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0360-4012</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>533</EndPage><MedlinePgn>528-33</MedlinePgn></Pagination><Abstract><AbstractText>To facilitate studies of the normal biology of alpha-synuclein, a member of a family of neuronal proteins of unknown function, and to elucidate the role of alpha-synuclein pathologies in neurodegenerative diseases, we generated and characterized a panel of anti-synuclein antibodies. Here we demonstrate that these antibodies recognize defined epitopes spanning the entire length of human alpha-synuclein, and that some of these antibodies also cross-react with zebra finch and rodent synucleins. Since alpha-synuclein has been reported to be a major component of Lewy bodies (LBs) in Parkinson's disease (PD), dementia with LBs and common variants of Alzheimer's disease, we performed immunohistochemical studies showing that these antibodies label numerous LBs in the PD substantia nigra, thereby localizing protein domains throughout human alpha-synuclein in LBs. Taken together, our data indicate that this panel of antibodies can be exploited to probe the normal biology of alpha-synuclein as well as the role of pathological forms of this protein in PD and related neurodegenerative synucleinopathies.</AbstractText><CopyrightInformation>Copyright 2000 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>B I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104-4283, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakes</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Duda</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Leight</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>V M</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10679792</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1097-4547(20000215)59:4&lt;528::AID-JNR8&gt;3.0.CO;2-0</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1097-4547(20000215)59:4&lt;528::AID-JNR8&gt;3.0.CO;2-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10680786</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Memory and MRI-based hippocampal volumes in aging and AD.</ArticleTitle><Pagination><StartPage>581</StartPage><EndPage>587</EndPage><MedlinePgn>581-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To demonstrate structural-functional relationships between MRI-based volumetric measurements of medial temporal lobe structures and cognitive function.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous work has documented the ability of MRI-based measurements of the hippocampus to discriminate between age-matched control subjects and patients with very mild AD. Relatively less is known about the correlation between medial temporal lobe structures and cognitive functions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We evaluated structural-functional relationships among the hippocampal formation, parahippocampal gyrus, and amygdala, and measures of memory, language, and general cognitive performance in 220 probable AD patients and normal control subjects. Standardized instruments of memory and general cognitive function were used to assess subjects enrolled in a longitudinal study of aging and dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The volume of the hippocampal formation predicted performance on most acquisition and recall measures across the spectrum of normal aging and AD. If the groups were segregated, most of the expected associations between medial temporal lobe structures and memory measures were observed in the AD patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MRI-based hippocampal volumetry accurately depicts the structural-functional relationships between memory loss and hippocampal damage across the spectrum from normal aging to dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>R C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>C R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Y C</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Waring</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Ivnik</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Tangalos</LastName><ForeName>E G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>B F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Kokmen</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08031</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10680786</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.3.581</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10680787</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.</ArticleTitle><Pagination><StartPage>588</StartPage><EndPage>593</EndPage><MedlinePgn>588-93</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Laboratory and epidemiologic studies suggest that anti-inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of low to moderate dose prednisone was found to suppress peripheral inflammatory markers without adverse effects in subjects with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a randomized, placebo-controlled multicenter trial to determine whether prednisone treatment slowed the rate of cognitive decline in AD. The active treatment regimen consisted of an initial dose of 20 mg of prednisone daily for 4 weeks tapered to a maintenance dose of 10 mg daily for 1 year, followed by gradual withdrawal during an additional 16 weeks. The primary outcome measure was the 1-year change in the cognitive subscale of the AD Assessment Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 138 subjects were randomized to the drug and placebo groups. There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only. Subjects treated with prednisone showed behavioral decline compared with those in the placebo group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A low-dose regimen of prednisone is not useful in the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>P S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2000 Oct 10;55(7):1067. doi: 10.1212/wnl.55.7.1067.</RefSource><PMID Version="1">11061280</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10680787</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.3.588</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10681076</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability.</ArticleTitle><Pagination><StartPage>191</StartPage><EndPage>196</EndPage><MedlinePgn>191-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several clinical criteria have been developed to standardize the diagnosis of vascular dementia (VaD). Significant differences in patient classification have been reported, depending on the criteria used. Few studies have examined interrater reliability.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the concordance in classification and interrater reliability for the following 4 clinical definitions of VaD: the Hachinski Ischemic Score (HIS), the Alzheimer Disease Diagnostic and Treatment Centers (ADDTC), National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN), and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Structured diagnostic checklists were developed for 4 criteria for VaD, 2 criteria for Alzheimer disease (AD), and 4 criteria for dementia. Twenty-five case vignettes, representing a spectrum of cognitive impairment and subtypes of dementia, were prepared in a standardized clinical format. Concordance in case classification using different criteria and interrater reliability among 7 ADDTCs given a specific set of criteria was assessed using the kappa statistic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The frequency of a diagnosis of VaD was highest using the modified HIS or DSM-IV criteria, intermediate using the original HIS and ADDTC criteria, and lowest using the NINDS-AIREN criteria. Scores for interrater reliability ranged from kappa = 0.30 (ADDTC) to kappa = 0.61 (original HIS).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical criteria for VaD are not interchangeable. Depending on the criteria selected, the reported prevalence of VaD will vary significantly. The traditional HIS has higher interrater reliability than the newer criteria for VaD. Prospective longitudinal studies with clinical-pathological correlation are needed to compare validity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>H C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Geriatric Neurobehavior and Alzheimer Center, Rancho Los Amigos National Rehabilitation Center, Downey, CA 90242, USA. chui@hsc.usc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Mungas</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>B R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>F L</ForeName><Initials>FL</Initials></Author><Author ValidYN="Y"><LastName>Skinner</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tasaki</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1P01 AG12435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P30 AG10129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2000 Feb;57(2):170-1. doi: 10.1001/archneur.57.2.170.</RefSource><PMID Version="1">10681073</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2000 Sep;57(9):1382-3. doi: 10.1001/archneur.57.9.1382-a.</RefSource><PMID Version="1">10987916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007596" MajorTopicYN="N">Joints</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10681076</ArticleId><ArticleId IdType="doi">10.1001/archneur.57.2.191</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10681402</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-2275</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of lipid research</Title><ISOAbbreviation>J Lipid Res</ISOAbbreviation></Journal><ArticleTitle>Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>198</EndPage><MedlinePgn>195-8</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by the presence of senile plaques, neurofibrillary tangles, and neuronal cell loss associated with membrane cholesterol release. 24S-hydroxycholesterol (24S-OH-Chol) is an enzymatically oxidized product of cholesterol mainly synthesized in the brain. We tested the hypothesis that plasma levels of this oxysterol could be used as a putative biochemical marker for an altered cholesterol homeostasis in the brain of AD patients. Thirty patients with clinical criteria for AD, 30 healthy volunteers, 18 depressed patients, and 12 patients with vascular dementia (non-Alzheimer demented) were studied. Plasma concentrations of 24S-OH-Chol were assayed by isotope dilution;-mass spectrometry, cholesterol was measured enzymatically, and apolipoprotein E (apoE) was genotyped by polymerase chain reaction and restricted fragment length polymorphism. The concentration of 24S-OH-Chol in AD and non-Alzheimer demented patients was modestly but significantly higher than in healthy controls and in depressed patients. There was no significant difference in the concentrations of 24S-OH-Chol between depressed patients and healthy controls nor between AD and non-Alzheimer demented patients. The apoE straightepsilon4 allele influences plasma 24S-OH-Chol. However, this influence could be completely accounted for by the elevated plasma cholesterol in apoE4 hetero- or homozygotes. Plasma 24S-OH-Chol levels correlated negatively with the severity of dementia. AD and vascular demented patients appear to have higher circulating levels of 24S-OH-Chol than depressed patients and healthy controls. We speculate that 24S-OH-Chol plasma levels may potentially be used as an early biochemical marker for an altered cholesterol homeostasis in the central nervous system. 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xfc;tjohann</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papassotiropoulos</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bj&#xf6;rkhem</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bagli</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Oehring</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Schlegel</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>von Bergmann</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Heun</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Lipid Res</MedlineTA><NlmUniqueID>0376606</NlmUniqueID><ISSNLinking>0022-2275</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006888">Hydroxycholesterols</NameOfSubstance></Chemical><Chemical><RegistryNumber>47IMW63S3F</RegistryNumber><NameOfSubstance UI="C044563">24-hydroxycholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006888" MajorTopicYN="N">Hydroxycholesterols</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10681402</ArticleId><ArticleId IdType="pii">S0022-2275(20)32052-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10681271</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9165</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of clinical nutrition</Title><ISOAbbreviation>Am J Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Vitamin E and Alzheimer disease: the basis for additional clinical trials.</ArticleTitle><Pagination><StartPage>630S</StartPage><EndPage>636S</EndPage><MedlinePgn>630S-636S</MedlinePgn></Pagination><Abstract><AbstractText>Many lines of evidence suggest that oxidative stress is important in the pathogenesis of Alzheimer disease. In particular, beta-amyloid, which is found abundantly in the brains of Alzheimer disease patients, is toxic in neuronal cell cultures through a mechanism involving free radicals. Vitamin E prevents the oxidative damage induced by beta-amyloid in cell culture and delays memory deficits in animal models. A placebo-controlled, clinical trial of vitamin E in patients with moderately advanced Alzheimer disease was conducted by the Alzheimer's Disease Cooperative Study. Subjects in the vitamin E group were treated with 2000 IU (1342 alpha-tocopherol equivalents) vitamin E/d. The results indicated that vitamin E may slow functional deterioration leading to nursing home placement. A new clinical trial is planned that will examine whether vitamin E can delay or prevent a clinical diagnosis of Alzheimer disease in elderly persons with mild cognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Cooperative Study, 9500 Gilman Drive 0949, La Jolla, CA, 92093-0949, USA. mgrundman@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Clin Nutr</MedlineTA><NlmUniqueID>0376027</NlmUniqueID><ISSNLinking>0002-9165</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>2K1V7GP655</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012642" MajorTopicYN="N">Selegiline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>94</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10681271</ArticleId><ArticleId IdType="doi">10.1093/ajcn/71.2.630s</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10681533</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>8</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>5535</StartPage><EndPage>5544</EndPage><MedlinePgn>5535-44</MedlinePgn></Pagination><Abstract><AbstractText>Hyperphosphorylated tau, which is the major protein of the neurofibrillary tangles in Alzheimer's disease brain, is most probably the result of an imbalance of tau kinase and phosphatase activities in the affected neurons. By using metabolically competent rat brain slices as a model, we found that selective inhibition of protein phosphatase 2A by okadaic acid induced an Alzheimer-like hyperphosphorylation and accumulation of tau. The hyperphosphorylated tau had a reduced ability to bind to microtubules and to promote microtubule assembly in vitro. Immunocytochemical staining revealed hyperphosphorylated tau accumulation in pyramidal neurons in cornu ammonis and in neocortical neurons. The topography of these changes recalls the distribution of neurofibrillary tangles in Alzheimer's disease brain. Selective inhibition of protein phosphatase 2B with cyclosporin A did not have any significant effect on tau phosphorylation, accumulation, or function. These studies suggest that protein phosphatase 2A participates in regulation of tau phosphorylation, processing, and function in vivo. A down-regulation of protein phosphatase 2A activity can lead to Alzheimer-like abnormal hyperphosphorylation of tau.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>C X</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314-6399, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lidsky</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wegiel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zuck</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Grundke-Iqbal</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG05892</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14875</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>1W21G5Q4N2</RegistryNumber><NameOfSubstance UI="D019319">Okadaic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.27</RegistryNumber><NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D010749">Phosphoprotein Phosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007770" MajorTopicYN="N">L-Lactate Dehydrogenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019319" MajorTopicYN="N">Okadaic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010749" MajorTopicYN="N">Phosphoprotein Phosphatases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10681533</ArticleId><ArticleId IdType="doi">10.1074/jbc.275.8.5535</ArticleId><ArticleId IdType="pii">S0021-9258(18)30579-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10682216</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Molecular genetics of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>183</StartPage><EndPage>199</EndPage><MedlinePgn>183-99</MedlinePgn></Pagination><Abstract><AbstractText>Application of genetic paradigms to Alzheimer's disease (AD) has led to confirmation that genetic factors play a role in this disease. Additionally, researchers now understand that AD is genetically heterogeneous and that some genetic isoforms appear to have similar or related biochemical consequences. Genetic epidemiologic studies indicate that first-degree relatives of AD probands have an age-dependent risk for AD approximately equal to 38% by age 90 years (range 10% to 50%). This incidence strongly suggests that transmission may be more complicated than a simple autosomal dominant trait. Nevertheless, a small proportion of AD cases with unequivocal autosomal dominant transmission have been identified. Studies of these autosomal dominant familial AD (FAD) pedigrees have thus far identified four distinct FAD genes. The beta-amyloid precursor protein (beta APP) gene (on chromosome 21), the presenilin 1 (PS1) gene (on chromosome 14), and the presenilin 2 (PS2) gene (on chromosome 1) gene are all associated with early-onset AD. Missense mutations in these genes cause abnormal beta APP processing with resultant overproduction of A beta 42 peptides. In addition, the epsilon 4 allele of apolipoprotein E (APOE) is associated with a increased risk for late-onset AD. Although attempts to develop symptomatic treatments based on neurotransmitter replacement continue, some laboratories are attempting to design treatments that will modulate production or disposition of A beta peptides.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>P H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002869" MajorTopicYN="N">Chromosome Aberrations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025063" MajorTopicYN="N">Chromosome Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002878" MajorTopicYN="N">Chromosomes, Human, Pair 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002883" MajorTopicYN="N">Chromosomes, Human, Pair 14</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="N">Chromosomes, Human, Pair 21</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>155</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10682216</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(99)00301-7</ArticleId><ArticleId IdType="pii">S0006-3223(99)00301-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10681545</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>8</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.</ArticleTitle><Pagination><StartPage>5626</StartPage><EndPage>5632</EndPage><MedlinePgn>5626-32</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease pathology is characterized by the presence of neuritic plaques and the loss of cholinergic neurons in the brain. The underlying mechanisms leading to these events are unclear, but the 42-amino acid beta-amyloid peptide (Abeta(1-42)) is involved. Immunohistochemical studies on human sporadic Alzheimer's disease brains demonstrate that Abeta(1-42) and a neuronal pentameric cation channel, the alpha7 nicotinic acetylcholine receptor (alpha7nAChR), are both present in neuritic plaques and co-localize in individual cortical neurons. Using human brain tissues and cells that overexpress either alpha7nAChR or amyloid precursor protein as the starting material, Abeta(1-42) and alpha7nAChR can be co-immunoprecipitated by the respective specific antibodies, suggesting that they are tightly associated. The formation of the alpha7nAChR.Abeta(1-42) complex can be efficiently suppressed by Abeta(12-28), implying that this Abeta sequence region contains the binding epitope. Receptor binding experiments show that Abeta(1-42) and alpha7nAChR bind with high affinity, and this interaction can be inhibited by alpha7nAChR ligands. Human neuroblastoma cells overexpressing alpha7nAChR are readily killed by Abeta(1-42), whereas alpha7nAChR agonists such as nicotine and epibatidine offered protection. Because Abeta(1-42) inhibits alpha7nAChR-dependent calcium activation and acetylcholine release, two processes critically involved in memory and cognitive functions, and the distribution of alpha7nAChR correlates with neuritic plaques in Alzheimer's disease brains, we propose that interaction of the alpha7nAChR and Abeta(1-42) is a pivotal mechanism involved in the pathophysiology of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477-0776, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>D H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>D'Andrea</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Shank</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH31862</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS31862</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016895">Culture Media, Serum-Free</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105813">nicotinic acetylcholine receptor alpha4 subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>88813-36-9</RegistryNumber><NameOfSubstance UI="D019004">Galanin</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016895" MajorTopicYN="N">Culture Media, Serum-Free</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019004" MajorTopicYN="N">Galanin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018722" MajorTopicYN="N">Nicotinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011233" MajorTopicYN="N">Precipitin Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10681545</ArticleId><ArticleId IdType="doi">10.1074/jbc.275.8.5626</ArticleId><ArticleId IdType="pii">S0021-9258(18)30591-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10683441</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-5793</ISSN><JournalIssue CitedMedium="Print"><Volume>468</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>FEBS letters</Title><ISOAbbreviation>FEBS Lett</ISOAbbreviation></Journal><ArticleTitle>The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region.</ArticleTitle><Pagination><StartPage>59</StartPage><EndPage>64</EndPage><MedlinePgn>59-64</MedlinePgn></Pagination><Abstract><AbstractText>We applied cDNA selection methods to a genomic clone (YAC 761B5) from chromosome 21 located in the so-called 'Down critical region' in 21q22.3. Starting from human fetal heart and brain mRNAs we obtained and sequenced several cDNA clones. One of these clones (Down region aspartic protease (DRAP), named also BACE2 according to the gene nomenclature) revealed a striking nucleotide and amino acid sequence identity with several motifs present in members of the aspartic protease family. In particular the amino acid sequences comprising the two catalytic sites found in all mammalian aspartic proteases are perfectly conserved. Interestingly, the predicted protein shows a typical membrane spanning region; this is at variance with most other known aspartic proteases, which are soluble molecules. We present preliminary evidence, on the basis of in vitro translation studies and cell transfection, that this gene encodes a glycosylated protein which localizes mainly intracellularly but to some extent also to the plasma membrane. Furthermore DRAP/BACE2 shares a high homology with a newly described beta-secretase enzyme (BACE-1) which is a transmembrane aspartic protease. The implications of this finding for Down syndrome are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Acquati</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento Biologia Strutturale e Funzionale, Universita' Insubria, via Dunant 3, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Accarino</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nucci</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jovine</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ottolenghi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Taramelli</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>FEBS Lett</MedlineTA><NlmUniqueID>0155157</NlmUniqueID><ISSNLinking>0014-5793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002474" MajorTopicYN="N">Cell-Free System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018244" MajorTopicYN="N">Chromosomes, Artificial, Yeast</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="N">Chromosomes, Human, Pair 21</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005810" MajorTopicYN="N">Multigene Family</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10683441</ArticleId><ArticleId IdType="doi">10.1016/s0014-5793(00)01192-3</ArticleId><ArticleId IdType="pii">S0014-5793(00)01192-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10684867</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.</ArticleTitle><Pagination><StartPage>1657</StartPage><EndPage>1665</EndPage><MedlinePgn>1657-65</MedlinePgn></Pagination><Abstract><AbstractText>Progressive cerebral accumulation of amyloid beta-protein (Abeta) is an early and invariant feature of Alzheimer's disease. Little is known about how Abeta, after being secreted, is degraded and cleared from the extracellular space of the brain. Defective Abeta degradation could be a risk factor for the development of Alzheimer's disease in some subjects. We reported previously that microglial cells release substantial amounts of an Abeta-degrading protease that, after purification, is indistinguishable from insulin-degrading enzyme (IDE). Here we searched for and characterized a role for IDE in Abeta degradation by neurons, the principal cell type that produces Abeta. Whole cultures of differentiated pheochromocytoma (PC12) cells and primary rat cortical neurons actively degraded endogenously secreted Abeta via IDE. However, unlike that in microglia, IDE in differentiated neurons was not released but localized to the cell surface, as demonstrated by biotinylation. Undifferentiated PC12 cells released IDE into their medium, whereas after differentiation, IDE was cell associated but still degraded Abeta in the medium. Overexpression of IDE in mammalian cells markedly reduced the steady-state levels of extracellular Abeta(40) and Abeta(42), and the catalytic site mutation (E111Q) abolished this effect. We observed a novel membrane-associated form of IDE that is approximately 5 kDa larger than the known cytosolic form in a variety of cells, including differentiated PC12 cells. Our results support a principal role for membrane-associated and secreted IDE isoforms in the degradation and clearance of naturally secreted Abeta by neurons and microglia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vekrellis</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>W Q</ForeName><Initials>WQ</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hartley</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chesneau</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Rosner</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N 533858</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 12749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011500">Protein Synthesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>6SO6U10H04</RegistryNumber><NameOfSubstance UI="D001710">Biotin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-92-5</RegistryNumber><NameOfSubstance UI="D005934">Glucagon</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001710" MajorTopicYN="N">Biotin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005934" MajorTopicYN="N">Glucagon</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011500" MajorTopicYN="N">Protein Synthesis Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10684867</ArticleId><ArticleId IdType="pmc">PMC6772918</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.20-05-01657.2000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Yokono K, Shii K, Ogawa W, Taniguchi H, Baba S, Kasuga M. Natural regulatory mechanisms of insulin degradation by insulin degrading enzyme. Biochem Biophys Res Commun. 1990;170:1325&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">2202301</ArticleId></ArticleIdList></Reference><Reference><Citation>Authier F, Bergeron JJ, Ou WJ, Rachubinski RA, Posner BI, Walton PA. Degradation of the cleaved leader peptide of thiolase by a peroxisomal proteinase. Proc Natl Acad Sci USA. 1995;92:3859&#x2013;3863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42061</ArticleId><ArticleId IdType="pubmed">7731996</ArticleId></ArticleIdList></Reference><Reference><Citation>Authier F, Cameron PH, Taupin V. Association of insulin-degrading enzyme with a 70 kDa cytosolic protein in hepatoma cells. Biochem J. 1996a;319:149&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217748</ArticleId><ArticleId IdType="pubmed">8870662</ArticleId></ArticleIdList></Reference><Reference><Citation>Authier F, Posner BI, Bergeron JJM. Insulin-degrading enzyme. Clin Invest Med. 1996b;19:149&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">8724818</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumeister H, Muller D, Rehbein M, Richter D. The rat insulin-degrading enzyme. Molecular cloning and characterization of tissue-specific transcripts. FEBS Lett. 1993;317:250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8425612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein HG, Ansorge S, Riederer P, Reiser M, Frolich L, Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett. 1999;263:161&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213160</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, Kosmoski J, Knauer MF, Glabe CG. Preferential absorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A&#x3b2;1&#x2013;42, in differentiated PC12. Brain Res. 1997;740:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9037507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesneau V, Perlman RK, Li W, Keller G-A, Rosner MR. Insulin-degrading enzyme does not require peroxisomal localization for insulin degradation. Endocrinology. 1997;138:3444&#x2013;3451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9231799</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenka D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George-Hyslop P, Selkoe DJ. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid &#x3b2;-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D., Jr Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50:164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443474</ArticleId></ArticleIdList></Reference><Reference><Citation>Duckworth WC. Insulin degradation by liver cell membranes. Endocrinology. 1979;104:1758&#x2013;1763.</Citation><ArticleIdList><ArticleId IdType="pubmed">446394</ArticleId></ArticleIdList></Reference><Reference><Citation>Duckworth WC. Insulin degradation: mechanisms, products and significance. Endocr Rev. 1988;9:319&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">3061785</ArticleId></ArticleIdList></Reference><Reference><Citation>Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm. 1998;105:423&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">9720972</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia JV, Stoppelli MP, Decker SJ, Rosner MR. An insulin epidermal growth factor-binding protein from Drosophila has insulin-degrading activity. J Cell Biol. 1989;108:177&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115360</ArticleId><ArticleId IdType="pubmed">2492023</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfine ID, Williams JA, Bailey AC, Wong KY, Iwamoto Y, Yokono K, Baba S, Roth RA. Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell surface protease activity. Diabetes. 1984;33:64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">6360769</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface &#x3b2;-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 1992;357:500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley DM, Kurth MC, Bjerkness L, Weiss JH, Choi DW. Glutamate receptor-induced 45Ca2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J Neurosci. 1993;13:1993&#x2013;2000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576563</ArticleId><ArticleId IdType="pubmed">7683048</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsonwood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and a-beta(42) deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchler K, Thorner J. Secretion of peptides and proteins lacking hydrophobic signal sequences: the role of adenosine triphosphate-driven membrane translocators. Endocr Rev. 1992;13:499&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">1425485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo W-L, Gehm BD, Rosner MR, Li W, Keller G. Inducible expression and cellular localization of insulin-degrading enzyme in a stably transfected cell line. J Biol Chem. 1994;269:22599&#x2013;22606.</Citation><ArticleIdList><ArticleId IdType="pubmed">8077210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurochkin IV, Goto S. Alzheimer's &#x3b2;-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 1994;345:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">8194595</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott JR, Gibson AM. Degradation of Alzheimer's beta-amyloid protein by human cathepsin D. NeuroReport. 1996;7:2163&#x2013;2166.</Citation><ArticleIdList><ArticleId IdType="pubmed">8930981</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott JR, Gibson AM. Degradation of Alzheimer's beta-amyloid protein by serine protease activity in brain microvessels. Neurosci Res Commun. 1997;20:93&#x2013;102.</Citation></Reference><Reference><Citation>McKenzie RA, Burghen GA. Partial purification and characterization of insulin protease and its intracellular inhibitor from rat liver. Arch Biochem Biophys. 1984;229:604&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">6367662</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentlein R, Ludwig R, Martensen I. Proteolytic degradation of Alzheimer's disease amyloid &#x3b2;-peptide by a metalloproteinase from microglia cells. J Neurochem. 1998;70:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9453567</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli L, Giambartolomei GH, Prat MI, Casta&#xf1;o EM. Internalization and resistance to degradation of Alzheimer's A&#x3b2; 1&#x2013;42 at nanomolar concentrations in THP-1 human monocytic cell line. Neurosci Lett. 1999;262:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10076859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa W, Shii K, Yonezawa K, Baba S, Yokono K. Affinity purification of insulin-degrading enzyme and its endogenous inhibitor from rat liver. J Biol Chem. 1992;267:1310&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730651</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlman RK, Rosner MR. Identification of zinc ligands of the insulin-degrading enzyme. J Biol Chem. 1994;269:33140&#x2013;33145.</Citation><ArticleIdList><ArticleId IdType="pubmed">7806544</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlman RK, Gehm BD, Kuo WL, Rosner MR. Functional analysis of conserved residues in the active site of insulin-degrading enzyme. J Biol Chem. 1993;268:21538&#x2013;21544.</Citation><ArticleIdList><ArticleId IdType="pubmed">8104941</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydel RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid &#x3b2;-protein into SDS-stable oligomers in cell culture. J Biol Chem. 1995;270:9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Walsh DM, Amarante P, Ostaszewski BL, Stimson ER, Maggio JE, Teplow DB, Selkoe DJ. Oligomerization of endogenous and synthetic amyloid &#x3b2;-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry. 1998;37:3602&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521679</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. Degradation of amyloid &#x3b2;-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem. 1997;272:6641&#x2013;6646.</Citation><ArticleIdList><ArticleId IdType="pubmed">9045694</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny M, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of amyloid &#x3b2;-protein by degradation. J Biol Chem. 1998;273:32730&#x2013;32738.</Citation><ArticleIdList><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399:A23&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Seta KA, Roth RA. Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. Biochem Biophys Res Commun. 1997;231:167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">9070242</ArticleId></ArticleIdList></Reference><Reference><Citation>Shii K, Baba S, Yokono K, Roth RA. Covalent linkage of 125I-insulin to a cytosolic insulin-degrading enzyme. J Biol Chem. 1985;260:6503&#x2013;6506.</Citation><ArticleIdList><ArticleId IdType="pubmed">3888982</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolk RP, Breteler MMB, Ott A, Pols HAP, Lamberts SWJ, Grobbee DE, Hofman A. Insulin and cognitive function in an elderly population. Diabetes Care. 1997;20:792&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">9135944</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamin R, Malgeri EG, Sloane JA, McGraw WT, Abraham CR. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-&#x3b2; peptide degradation. J Biol Chem. 1999;274:18777&#x2013;18784.</Citation><ArticleIdList><ArticleId IdType="pubmed">10373494</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokono K, Roth RA, Baba S. Identification of insulin-degrading enzyme on the surface of cultured human lymphocytes, rat hepatoma cells, and primary cultures of rat hepatocytes. Endocrinology. 1982;111:1102&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">6749484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10693932</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>74</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia.</ArticleTitle><Pagination><StartPage>1017</StartPage><EndPage>1025</EndPage><MedlinePgn>1017-25</MedlinePgn></Pagination><Abstract><AbstractText>Activated microglia surrounding amyloid beta-containing senile plaques synthesize interleukin-1, an inflammatory cytokine that has been postulated to contribute to Alzheimer's disease pathology. Studies have demonstrated that amyloid beta treatment causes increased cytokine release in microglia and related cell cultures. The present work evaluates the specificity of this cellular response by comparing the effects of amyloid beta to that of amylin, another amyloidotic peptide. Both lipopolysaccharide-treated THP-1 monocytes and mouse microglia showed significant increases in mature interleukin-1beta release 48 h following amyloid beta or human amylin treatment, whereas nonfibrillar rat amylin had no effect on interleukin-1beta production by THP-1 cells. Lipopolysaccharide-stimulated THP-1 cells treated with amyloid beta or amylin also showed increased release of the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-6, as well as the chemokines interleukin-8 and macrophage inflammatory protein-1alpha and -1beta. THP-1 cells incubated with fibrillar amyloid beta or amylin in the absence of lipopolysaccharide also showed significant increases of both interleukin-1beta and tumor necrosis factor-alpha mRNA. Furthermore, treatment of THP-1 cells with amyloid fibrils resulted in an elevated expression of the immediate-early genes c-fos and junB. These studies provide further evidence that fibrillar amyloid peptides can induce signal transduction pathways that initiate an inflammatory response that is likely to contribute to Alzheimer's disease pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Gliatech Inc., Cleveland, Ohio 44122, USA. yatess@gliatech.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>L H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Kocsis-Angle</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Antal</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Dority</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Embury</LastName><ForeName>P B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Piotrkowski</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Brunden</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058228">Islet Amyloid Polypeptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016760">Proto-Oncogene Proteins c-fos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016755">Proto-Oncogene Proteins c-jun</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058228" MajorTopicYN="N">Islet Amyloid Polypeptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016760" MajorTopicYN="N">Proto-Oncogene Proteins c-fos</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016755" MajorTopicYN="N">Proto-Oncogene Proteins c-jun</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10693932</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0741017.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10694577</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2892</StartPage><EndPage>2897</EndPage><MedlinePgn>2892-7</MedlinePgn></Pagination><Abstract><AbstractText>Apolipoprotein E (apoE) alleles determine the age-adjusted relative risk (epsilon4 &gt; epsilon3) for Alzheimer's disease (AD). ApoE may affect AD pathogenesis by promoting deposition of the amyloid-beta (Abeta) peptide and its conversion to a fibrillar form. To determine the effect of apoE on Abeta deposition and AD pathology, we compared APP(V717F) transgenic (TG) mice expressing mouse, human, or no apoE (apoE(-/-)). A severe, plaque-associated neuritic dystrophy developed in APP(V717F) TG mice expressing mouse or human apoE. Though significant levels of Abeta deposition also occurred in APP(V717F) TG, apoE(-/-) mice, neuritic degeneration was virtually absent. Expression of apoE3 and apoE4 in APP(V717F) TG, apoE(-/-) mice resulted in fibrillar Abeta deposits and neuritic plaques by 15 months of age and substantially (&gt;10-fold) more fibrillar deposits were observed in apoE4-expressing APP(V717F) TG mice. Our data demonstrate a critical and isoform-specific role for apoE in neuritic plaque formation, a pathological hallmark of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for the Study of Nervous System Injury, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Tenkova</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Parsadanian</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sartorius</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Mackey</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Olney</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McKeel</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="Y">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10694577</ArticleId><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="doi">10.1073/pnas.050004797</ArticleId><ArticleId IdType="pii">050004797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Science. 1997;275:630&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">9019820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury P T J. Neuron. 1997;19:1151&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427238</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles R B, Wyart C, Buldyrev S V, Cruz L, Urbanc B, Hasselmo M E, Stanley H E, Hyman B T. Proc Natl Acad Sci USA. 1999;96:5274&#x2013;5279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21854</ArticleId><ArticleId IdType="pubmed">10220456</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature (London) 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Youkin S, Yang F, Cole G. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. J Neurosci. 1996;16:5795&#x2013;5811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry M C, McNamara M, Fedorchak K, Hsiao K, Hyman B T. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K R, Verina T, Dodel R C, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone E M, Little S P, Cummins D J, et al. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wu S, Bu G, Onifade M K, Patel S N, LaDu M J, Fagan A M, Holtzman D M. J Neurosci. 1998;18:3261&#x2013;3272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792658</ArticleId><ArticleId IdType="pubmed">9547235</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D M, Bales K R, Wu S, Bhat P, Parsadanian M, Fagan A M, Chang L K, Sun Y, Paul S M. J Clin Invest. 1999;103:R15&#x2013;R21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak D F, Brosnan-Watters G, Nardi A, McEwen M, Corso T D, Olney J W, Fix A S. Brain Res. 1996;707:165&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">8919293</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Brain Res. 1991;541:163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Frangione B. Neurosci Lett. 1992;135:235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">1625800</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K R, Verina T, Cummins D J, Du Y, Fishman C E, DeLong C A, Piccardo P, Petegnief V, Ghetti B, Paul S M. Proc Natl Acad Sci USA. 1999;96:15233&#x2013;15238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer H B, Das S, Potter H. Nature (London) 1994;372:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Castano E M, Prelli F, Wisniewski T, Golabek A, Kumar R A, Soto C, Frangione B. Biochem J. 1995;306:599&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1136559</ArticleId><ArticleId IdType="pubmed">7534068</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W J, Saunders A M, Schmechel D, Pericak-Vance M, Enghild J, Salvesen G S, Roses A D. Proc Natl Acad Sci USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel D E, Saunders A M, Strittmattter W J, Crain B J, Hulette C M, Joo S H, Pericak-Vance M A, Goldgaber D, Roses A D. Proc Natl Acad Sci USA. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck G W, Reiter J S, Strickland D K, Hyman B T. Neuron. 1993;11:575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart J-C, Meziane H, Mathis C, Bales K R, Paul S M, Ungerer A. Behav Neurosci. 1999;113:982&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571480</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A M, Holtzman D M, Munson G, Mathur T, Schneider D, Chang L K, Getz G S, Reardon C A, Lukens J, Shah J A, et al. J Biol Chem. 1999;274:30001&#x2013;30007.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514484</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu M J, Falduto M T, Manelli A M, Reardon C A, Getz G S, Frail D E. J Biol Chem. 1994;269:23404&#x2013;23406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089103</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, Chen S, Teller J K, Zaccheo D, Gambetti P, et al. Proc Natl Acad Sci USA. 1998;95:15598&#x2013;15602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28089</ArticleId><ArticleId IdType="pubmed">9861015</ArticleId></ArticleIdList></Reference><Reference><Citation>Permanne B, Perez C, Soto C, Frangione B, Wisniewski T. Biochem Biophys Res Commun. 1997;240:715&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">9398632</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi-Miura N H, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M. Acta Neuropathol. 1992;83:260&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">1373021</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu W Q, Borth W, Ye Z, Haass C, Teplow D B, Selkoe D J. J Biol Chem. 1996;271:8443&#x2013;8451.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626544</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Ni B, Glinn M, Dodel R C, Bales K R, Zhang Z, Hyslop P, Paul S M. J Neurochem. 1997;69:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202323</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita N, Holtzman D M, Schwartz A L, Bu G. J Neurochem. 1997;69:1904&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349534</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgaber D, Schwarzman A I, Bhasin R, Gregori L, Schmechel D, Saunders A M, Roses A D, Strittmatter W J. Ann NY Acad Sci. 1993;695:139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239272</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10697060</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0098-7484</ISSN><JournalIssue CitedMedium="Print"><Volume>283</Volume><Issue>8</Issue><PubDate><Year>2000</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.</ArticleTitle><Pagination><StartPage>1007</StartPage><EndPage>1015</EndPage><MedlinePgn>1007-15</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD) in women.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether estrogen replacement therapy affects global, cognitive, or functional decline in women with mild to moderate AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">The Alzheimer's Disease Cooperative Study, a randomized, double-blind, placebo-controlled clinical trial conducted between October 1995 and January 1999.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Thirty-two study sites in the United States.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 120 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 28 who had had a hysterectomy.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants were randomized to estrogen, 0.625 mg/d (n = 42), or 1.25 mg/d (n = 39), or to identically appearing placebo (n = 39). One subject withdrew after randomization but before receiving medication; 97 subjects completed the trial.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome measure was change on the Clinical Global Impression of Change (CGIC) 7-point scale, analyzed by intent to treat; secondary outcome measures included other global measures as well as measures of mood, specific cognitive domains (memory, attention, and language), motor function, and activities of daily living; compared by the combined estrogen groups vs the placebo group at 2, 6, 12, and 15 months of follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CGIC score for estrogen vs placebo was 5.1 vs 5.0 (P = .43); 80% of participants taking estrogen vs 74% of participants taking placebo worsened (P = .48). Secondary outcome measures also showed no significant differences, with the exception of the Clinical Dementia Rating Scale, which suggested worsening among patients taking estrogen (mean posttreatment change in score for estrogen, 0.5 vs 0.2 for placebo; P = .01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD. The study does not support the role of estrogen for the treatment of this disease. The potential role of estrogen in the prevention of AD, however, requires further research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mulnard</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Institute for Brain Aging and Dementia, University of California, Irvine 92697-4540, USA. ramulnar@uci.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>C W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Koss</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gamst</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004966">Estrogens, Conjugated (USP)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA 2000 Nov 22-29;284(20):2597</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2000 Feb 23;283(8):1055-6. doi: 10.1001/jama.283.8.1055.</RefSource><PMID Version="1">10697067</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2000 Jul 19;284(3):307; author reply 308.</RefSource><PMID Version="1">10891956</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2000 Jul 19;284(3):307-8.</RefSource><PMID Version="1">10891957</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="Y">Estrogen Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004966" MajorTopicYN="N">Estrogens, Conjugated (USP)</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007044" MajorTopicYN="N">Hysterectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10697060</ArticleId><ArticleId IdType="doi">10.1001/jama.283.8.1007</ArticleId><ArticleId IdType="pii">joc91949</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10702315</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>7410</StartPage><EndPage>7415</EndPage><MedlinePgn>7410-5</MedlinePgn></Pagination><Abstract><AbstractText>Beta-amyloid peptide (Abeta), which plays a central role in the pathogenesis of Alzheimer's disease, is derived from the transmembrane beta-amyloid precursor protein (APP) by proteolytic processing. Although mechanisms associated with Abeta generation are not fully understood, it is known that Abeta can be generated within endosomal compartments upon internalization of APP from the cell surface. The low density lipoprotein receptor-related protein (LRP) was previously shown to mediate the endocytosis of APP isoforms containing the Kunitz proteinase inhibitor domain (Kounnas, M. Z., Moir, R. D., Rebeck, G. W., Bush, A. I., Argraves, W. S., Tanzi, R. E., Hyman, B. T., and Strickland, D. K. (1995) Cell 82, 331-340; Knauer, M. F., Orlando, R. A., and Glabe, C. G. (1996) Brain Res. 740, 6-14). The objective of the current study was to test the hypothesis that LRP-mediated internalization of cell surface APP can modulate APP processing and thereby affect Abeta generation. Here, we show that long term culturing of cells in the presence of the LRP-antagonist RAP leads to increased cell surface levels of APP and a significant reduction in Abeta synthesis. Further, restoring LRP function in LRP-deficient cells results in a substantial increase in Abeta production. These findings demonstrate that LRP contributes to Abeta generation and suggest novel pharmacological approaches to reduce Abeta levels based on selective LRP blockade.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ulery</LastName><ForeName>P G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Vascular Biology, Holland Laboratory, American Red Cross, Rockville, Maryland 20855, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beers</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mikhailenko</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Rebeck</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Strickland</LastName><ForeName>D K</ForeName><Initials>DK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG12406</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL50784</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL54710</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10702315</ArticleId><ArticleId IdType="doi">10.1074/jbc.275.10.7410</ArticleId><ArticleId IdType="pii">S0021-9258(18)30439-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10702411</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9440</ISSN><JournalIssue CitedMedium="Print"><Volume>156</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice.</ArticleTitle><Pagination><StartPage>951</StartPage><EndPage>964</EndPage><MedlinePgn>951-64</MedlinePgn></Pagination><Abstract><AbstractText>Epidemiological studies have established that the epsilon 4 allele of the ApoE gene (ApoE4) constitutes an important risk factor for Alzheimer's disease and might influence the outcome of central nervous system injury. The mechanism by which ApoE4 contributes to the development of neurodegeneration remains unknown. To test one hypothesis or mode of action of ApoE, we generated transgenic mice that overexpressed human ApoE4 in different cell types in the brain, using four distinct gene promoter constructs. Many transgenic mice expressing ApoE4 in neurons developed motor problems accompanied by muscle wasting, loss of body weight, and premature death. Overexpression of human ApoE4 in neurons resulted in hyperphosphorylation of the microtubule-associated protein tau. In three independent transgenic lines from two different promoter constructs, increased phosphorylation of protein tau was correlated with ApoE4 expression levels. Hyperphosphorylation of protein tau increased with age. In the hippocampus, astrogliosis and ubiquitin-positive inclusions were demonstrated. These findings demonstrate that expression of ApoE in neurons results in hyperphosphorylation of protein tau and suggests a role for ApoE in neuronal cytoskeletal stability and metabolism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tesseur</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Experimental Genetics Group, Center for Human Genetics, Flemish Institute for Biotechnology, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Dorpe</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Spittaels</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Van den Haute</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Moechars</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Van Leuven</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10702411</ArticleId><ArticleId IdType="pmc">PMC1876840</ArticleId><ArticleId IdType="doi">10.1016/S0002-9440(10)64963-2</ArticleId><ArticleId IdType="pii">S0002-9440(10)64963-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 1993, 261:921-923</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD: Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:11183-11186</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45191</ArticleId><ArticleId IdType="pubmed">7972031</ArticleId></ArticleIdList></Reference><Reference><Citation>Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ: The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer&#x2019;s disease and Lewy body variant. Neurology 1996, 47:190-196</Citation><ArticleIdList><ArticleId IdType="pubmed">8710076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD: Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer&#x2019;s disease. Neuroscience 1995, 69:757-761</Citation><ArticleIdList><ArticleId IdType="pubmed">8596645</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing M, Mori H, Mirra SS: A beta-peptide length and apolipoprotein E genotype in Alzheimer&#x2019;s disease. Ann Neurol 1996, 39:395-399</Citation><ArticleIdList><ArticleId IdType="pubmed">8602762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebremedhin E, Schultz C, Braak E, Braak H: High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer&#x2019;s disease-related neurofibrillary changes. Exp Neurol 1998, 153:152-155</Citation><ArticleIdList><ArticleId IdType="pubmed">9743577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed AR, MacGowan SH, Culpan D, Jones RW, Wilcock GK: The &#x2212;491 A/T polymorphism of the apolipoprotein E gene is associated with the ApoEepsilon4 allele, and Alzheimer&#x2019;s disease. Neurosci Lett 1999, 263:217-219</Citation><ArticleIdList><ArticleId IdType="pubmed">10213175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC: A new polymorphism in the ApoE promoter associated with risk of developing Alzheimer&#x2019;s disease. Hum Mol Genet 1998, 7:533-540</Citation><ArticleIdList><ArticleId IdType="pubmed">9467014</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, Morris JC, Frank A, Vazquez J, Goate A, Valdivieso F: A polymorphism in the regulatory region of ApoE associated with risk for Alzheimer&#x2019;s dementia. Nat Genet 1998, 18:69-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9425904</ArticleId></ArticleIdList></Reference><Reference><Citation>Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, Vazquez J, Valdivieso F: Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 1998, 421:105-108</Citation><ArticleIdList><ArticleId IdType="pubmed">9468288</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Perez-Tur J, Mouroux V, Mohr M, Cecyre D, Galasko D, Lendon C, Poirier J, Hardy J, Mann D, Amouyel P, Chartier-Harlin MC: Pronounced impact of Th1/E47cs mutation compared with &#x2212;491 AT mutation on neural APOE gene expression and risk of developing Alzheimer&#x2019;s disease. Hum Mol Genet 1998, 7:1511-1516</Citation><ArticleIdList><ArticleId IdType="pubmed">9700208</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberts MJ, Graffagnino C, McClenny C, DeLong D, Strittmatter W, Saunders AM, Roses AD: ApoE genotype, and survival from intracerebral haemorrhage. Lancet 1995, 346:575.</Citation><ArticleIdList><ArticleId IdType="pubmed">7658797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S: Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. J Am Med Assoc 1997, 278:136-140</Citation><ArticleIdList><ArticleId IdType="pubmed">9214529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, Chun M, Tycko B, Shelanski M: Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer&#x2019;s disease. Neurology 1995, 45:555-557</Citation><ArticleIdList><ArticleId IdType="pubmed">7898715</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Roberts GW, Graham DI: Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid &#x3b2;-protein following head injury. Nat Med 1995, 1:135-137</Citation><ArticleIdList><ArticleId IdType="pubmed">7585009</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed T, Carmelli D, Swan GE, Breitner JC, Welsh KA, Jarvik GP, Deeb S, Auwerx J: Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch Neurol 1994, 51:1189-1192</Citation><ArticleIdList><ArticleId IdType="pubmed">7986172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardiff BE, Newman MF, Saunders AM, Strittmatter WJ, Blumenthal JA, White WD, Croughwell ND, Davis RD, Jr, Roses AD, Reves JG: Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg 1997, 64:715-720</Citation><ArticleIdList><ArticleId IdType="pubmed">9307463</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SH, Hulette C, Saunders AM, Einstein G, Pericak-Vance M, Strittmatter WJ, Roses AD, Schmechel DE: Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer&#x2019;s disease, and in age-matched controls. Exp Neurol 1994, 128:13-26</Citation><ArticleIdList><ArticleId IdType="pubmed">8070517</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzger RE, LaDu MJ, Pan JB, Getz GS, Frail DE, Falduto MT: Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer&#x2019;s disease. J Neuropathol Exp Neurol 1996, 55:372-380</Citation><ArticleIdList><ArticleId IdType="pubmed">8786396</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu PT, Gilbert JR, Qiu HL, Ervin J, Rothrock-Christian TR, Hulette C, Schmechel DE: Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol 1999, 154:601-611</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850012</ArticleId><ArticleId IdType="pubmed">10027417</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu PT, Gilbert JR, Qiu HL, Rothrock-Christian T, Settles DL, Roses AD, Schmechel DE: Regionally specific neuronal expression of human APOE gene in transgenic mice. Neurosci Lett 1998, 246:65-68</Citation><ArticleIdList><ArticleId IdType="pubmed">9627181</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu PT, Schmechel D, Rothrock-Christian T, Burkhart DS, Qiu HL, Popko B, Sullivan P, Maeda N, Saunders AM, Roses AD, Gilbert JR: Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis 1996, 3:229-245</Citation><ArticleIdList><ArticleId IdType="pubmed">8980023</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Gilbert J, Xu PT, Sullivan P, Popko B, Burkhart DS, Christian-Rothrock T, Saunders AM, Maeda N, Schmechel DE: cis-acting human ApoE tissue expression element is associated with human pattern of intraneuronal ApoE in transgenic mice. Neurobiol Aging 1998, 19:S53-S58</Citation><ArticleIdList><ArticleId IdType="pubmed">9562469</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein G, Patel V, Bautista P, Kenna M, Melone L, Fader R, Karson K, Mann S, Saunders AM, Hulette C, Mash D, Roses AD, Schmechel DE: Intraneuronal ApoE in human visual cortical areas reflects the staging of Alzheimer disease pathology. J Neuropathol Exp Neurol 1998, 57:1190-1201</Citation><ArticleIdList><ArticleId IdType="pubmed">9862642</ArticleId></ArticleIdList></Reference><Reference><Citation>Souli&#xe9; Cathia VM, Dupont-Wallois L, Chartier-Harlin M-C, Beauvillain JC, Delacourte A, Caillet-Boudin ML: Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE. Neurosci Lett 1999, 265:147&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pubmed">10327190</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont-Wallois L, Soulie C, Sergeant N, Wavrant-de Wrieze N, Chartier-Harlin M-C, Delacourte A, Caillet-Boudin ML: ApoE synthesis in human neuroblastoma cells. Neurobiol Dis 1997, 4:356&#x2013;364</Citation><ArticleIdList><ArticleId IdType="pubmed">9440124</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsburgh K, Nicoll JA: Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat. Neuropathol Appl Neurobiol 1996, 22:342-349</Citation><ArticleIdList><ArticleId IdType="pubmed">8875469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali SM, Dunn E, Oostveen JA, Hall ED, Carter DB: Induction of apolipoprotein E mRNA in the hippocampus of the gerbil after transient global ischemia. Brain Res Mol Brain Res 1996, 38:37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8737665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimaru H, Ishikawa K, Ohe Y, Takahashi A, Maruyama Y: Cystatin C, and apolipoprotein E immunoreactivities in CA1 neurons in ischemic gerbil hippocampus. Brain Res 1996, 709:155-162</Citation><ArticleIdList><ArticleId IdType="pubmed">8833751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Victoroff J: Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol 1998, 149:79-86</Citation><ArticleIdList><ArticleId IdType="pubmed">9454617</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Curtiss LK, Williams DL: A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem 1998, 273:4206-4212</Citation><ArticleIdList><ArticleId IdType="pubmed">9461617</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, Bu G, Schwartz AL: Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA 1995, 92:9480-9484</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40825</ArticleId><ArticleId IdType="pubmed">7568158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan BP, Chang KC, Bellosta S, Brisch E, Ge N, Mahley RW, Pitas RE: The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995, 270:19791-19799</Citation><ArticleIdList><ArticleId IdType="pubmed">7649988</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE: Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994, 264:850-852</Citation><ArticleIdList><ArticleId IdType="pubmed">8171342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellosta S, Nathan BP, Orth M, Dong LM, Mahley RW, Pitas RE: Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem 1995, 270:27063-27071</Citation><ArticleIdList><ArticleId IdType="pubmed">7592957</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttfarcken PS, Manelli AM, Falduto MT, Getz GS, LaDu MJ: Effect of apolipoprotein E on neurite outgrowth and &#x3b2;-amyloid-induced toxicity in developing rat primary hippocampal cultures. J Neurochem 1997, 68:760-769</Citation><ArticleIdList><ArticleId IdType="pubmed">9003067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Bu G, Sun Y, Daugherty A, Holtzman DM: Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth, and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 1996, 271:30121-30125</Citation><ArticleIdList><ArticleId IdType="pubmed">8939961</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DY, Goedert M, Jakes R, Weisgraber KH, Garner CC, Saunders AM, Pericak-Vance MA, Schmechel DE, Roses AD, Strittmatter WJ: Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer&#x2019;s disease. Neurosci Lett 1994, 182:55-58</Citation><ArticleIdList><ArticleId IdType="pubmed">7891887</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F: Expression in brain of amyloid precursor protein mutated in the &#x3b1;-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 1996, 15:1265-1274</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450029</ArticleId><ArticleId IdType="pubmed">8635459</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A: GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 1994, 14:1030-1037</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577554</ArticleId><ArticleId IdType="pubmed">8120611</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Nadsworth S, Wolozin B, Zhao J: Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature 1995, 373:523-527</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>te Riele H, Maandag ER, Berns A: Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc Natl Acad Sci USA 1992, 89:5128-5132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49242</ArticleId><ArticleId IdType="pubmed">1594621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasahara M, Fries JW, Raines EW, Gown AM, Westrum LE, Frosch MP, Bonthron DT, Ross R, Collins T: PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 1991, 64:217-227</Citation><ArticleIdList><ArticleId IdType="pubmed">1986868</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WB, Ruppe MD, Rockenstein EM, Price J, Sarthy VP, Verderber LC, Mucke L: Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: in vivo comparison of distinct GFAP-lacZ transgenes. Glia 1995, 13:174-184</Citation><ArticleIdList><ArticleId IdType="pubmed">7782103</ArticleId></ArticleIdList></Reference><Reference><Citation>Umans L, Serneels L, Overbergh L, Lorent K, Van Leuven F, Van den Berghe H: Targeted inactivation of the mouse &#x3b1; 2-macroglobulin gene. J Biol Chem 1995, 1978, 270:19778-19785</Citation><ArticleIdList><ArticleId IdType="pubmed">7544347</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans GA, Ingraham HA, Lewis K, Cunningham K, Seki T, Moriuchi T, Chang HC, Silver J, Hyman R: Expression of the Thy-1 glycoprotein gene by DNA-mediated gene transfer. Proc Natl Acad Sci USA 1984, 81:5532-5536</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391740</ArticleId><ArticleId IdType="pubmed">6147849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingraham HA, Lawless GM, Evans GA: The mouse Thy-1.2 glyco-protein gene: complete sequence and identification of an unusual promoter. J Immunol 1986, 136:1482-1489</Citation><ArticleIdList><ArticleId IdType="pubmed">2868059</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R: Thy-1, the enigmatic extrovert on the neuronal surface. BioEssays 1992, 14:715-722</Citation><ArticleIdList><ArticleId IdType="pubmed">1285421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley KA, Friedrich VL, Jr, Sonshine A, Hu Y, Lax J, Li J, Drinkwater D, Dressler H, Herrup K: Expression of Thy-1/lacZ fusion genes in the CNS of transgenic mice. Brain Res Mol Brain Res 1994, 24:261-274</Citation><ArticleIdList><ArticleId IdType="pubmed">7968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon JW, Chesa PG, Nishimura H, Rettig WJ, Maccari JE, Endo T, Seravalli E, Seki T, Silver J: Regulation of Thy-1 gene expression in transgenic mice. Cell 1987, 50:445-452</Citation><ArticleIdList><ArticleId IdType="pubmed">2886226</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinou JC, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowski H, Missotten M, Albertini P, Talabot D, Catsicas S, Pietra C, Huarte J: Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994, 13:1017-1030</Citation><ArticleIdList><ArticleId IdType="pubmed">7946326</ArticleId></ArticleIdList></Reference><Reference><Citation>Latham KE, Rambhatla L: Expression of X-linked genes in androgenetic, gynogenetic, and normal mouse preimplantation embryos. Dev Genet 1995, 17:212-222</Citation><ArticleIdList><ArticleId IdType="pubmed">8565328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr BA, Vicente JS: Age-related phosphorylation and fragmentation events influence the distribution profiles of distinct tau isoforms in mouse brain. J Neuropathol Exp Neurol 1998, 57:111-121</Citation><ArticleIdList><ArticleId IdType="pubmed">9600203</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro K, Hasegawa M, Ihara Y, Iwatsubo T: Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex. Neuroreport 1997, 8:2797-2801</Citation><ArticleIdList><ArticleId IdType="pubmed">9295120</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L: Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA 1998, 95:10914-10919</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27995</ArticleId><ArticleId IdType="pubmed">9724804</ArticleId></ArticleIdList></Reference><Reference><Citation>Genis I, Gordon I, Sehayek E, Michaelson DM: Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett 1995, 199:5-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8584225</ArticleId></ArticleIdList></Reference><Reference><Citation>Genis I, Fisher A, Michaelson DM: Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem 1999, 72:206-213</Citation><ArticleIdList><ArticleId IdType="pubmed">9886071</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken L, Brion JP: Phosphorylation of tau protein is not affected in mice lacking apolipoprotein E. Neuroreport 1995, 6:2381-2384</Citation><ArticleIdList><ArticleId IdType="pubmed">8747158</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ, Fagan AM, Holtzman DM: Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998, 18:3261-3272</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792658</ArticleId><ArticleId IdType="pubmed">9547235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM: Tau and ubiquitin immunoreactivity at different stages of formation of Alzheimer neurofibrillary tangles. Prog Clin Biol Res 1989, 317:837-848</Citation><ArticleIdList><ArticleId IdType="pubmed">2557644</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlees J, Irving NG, Brion JP, Gibb BJ, Wagner U, Woodgett J, Miller CC: Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3&#x3b2; transgenes. Neuroreport 1997, 8:3251-3255</Citation><ArticleIdList><ArticleId IdType="pubmed">9351652</ArticleId></ArticleIdList></Reference><Reference><Citation>James ND, Davis DR, Sindon J, Hanger DP, Brion JP, Miller CC, Rosenberg MP, Anderton BH, Propst F: Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase Mos. Neurobiol Aging 1996, 17:235-241</Citation><ArticleIdList><ArticleId IdType="pubmed">8744404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayyali US, Zhang W, Yee AG, Seidman JG, Potter H: Cytoskeletal changes in the brains of mice lacking calcineurin A &#x3b1;. J Neurochem 1997, 68:1668-1678</Citation><ArticleIdList><ArticleId IdType="pubmed">9084440</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP, Tremp G, Octave JN: Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer&#x2019;s disease. Am J Pathol 1999, 154:255-270</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853433</ArticleId><ArticleId IdType="pubmed">9916940</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, Goedert M: Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 1995, 14:1304-1313</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F: Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 1999, 155:2153-2165</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866931</ArticleId><ArticleId IdType="pubmed">10595944</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E: Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging 1995, 16:271-284</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E: Evolution of the neuropathology of Alzheimer&#x2019;s disease. Acta Neurol Scand Suppl 1996, 165:3-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridet JL, Malhotra SK, Privat A, Gage FH: Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997, 20:570-577</Citation><ArticleIdList><ArticleId IdType="pubmed">9416670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Reiter JS, Strickland DK, Hyman BT: Apolipoprotein E in sporadic Alzheimer&#x2019;s disease: allelic variation and receptor interactions. Neuron 1993, 11:575-580</Citation><ArticleIdList><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to &#x3b2;-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977-1981</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Frangione B: Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992, 135:235-238</Citation><ArticleIdList><ArticleId IdType="pubmed">1625800</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH, Dong LM, Jakes R, Alberts MJ, Gilbert JR, Hans H, Hulette C, Einstein G, Schmechel DE, Pericak-Vance MA, Roses AD: Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994, 125:163-174</Citation><ArticleIdList><ArticleId IdType="pubmed">8313935</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Thorngate FE, Williams DL: A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. J Neurosci 1999, 19:2464-2473</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786055</ArticleId><ArticleId IdType="pubmed">10087061</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, Berr C, Vidal O, Roques P, Gourlet V, Fruchart JC, Delacourte A, Rosser M, Amoyel P. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer&#x2019;s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994, 3:569&#x2013;574</Citation><ArticleIdList><ArticleId IdType="pubmed">8069300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Perez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P, Hardy J, Delacourte A, Chartier-Harlin MC: Distortion of allelic expression of apolipoprotein E in Alzheimer&#x2019;s disease. Hum Mol Genet 1997, 6:2151-2154</Citation><ArticleIdList><ArticleId IdType="pubmed">9328480</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo SE, Neal M, Schwankhaus J: A closely linked gene to apolipoprotein E may serve as an additional risk factor for Alzheimer&#x2019;s disease. Neurosci Lett 1995, 201:81-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8830319</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws SM, Taddei K, Martins G, Paton A, Fisher C, Clarnette R, Hallmayer J, Brooks WS, Gandy SE, Martins RN: The &#x2212;491 AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer&#x2019;s disease. Neuroreport 1999, 10:879-882</Citation><ArticleIdList><ArticleId IdType="pubmed">10208564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mui S, Briggs M, Chung H, Wallace RB, Gomez-Isla T, Rebeck GW, Hyman BT: A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer&#x2019;s disease and strongly with the epsilon 4 allele. Neurology 1996, 47:196-201</Citation><ArticleIdList><ArticleId IdType="pubmed">8710077</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques MA, Tolar M, Harmony JA, Crutcher KA: A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport 1996, 7:2529-2532</Citation><ArticleIdList><ArticleId IdType="pubmed">8981417</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolar M, Marques MA, Harmony JAK, Crutcher KA: Neurotoxicity of the 22 kd thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci 1997, 17:5678-5686</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573216</ArticleId><ArticleId IdType="pubmed">9221767</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutcher KA, Clay MA, Scott SA, Tian X, Tolar M, Harmony JA: Neurite degeneration elicited by apolipoprotein E peptides. Exp Neurol 1994, 130:120-126</Citation><ArticleIdList><ArticleId IdType="pubmed">7821387</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10706614</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.</ArticleTitle><Pagination><StartPage>2910</StartPage><EndPage>2915</EndPage><MedlinePgn>2910-5</MedlinePgn></Pagination><Abstract><AbstractText>Hyperphosphorylation of microtubule-associated proteins such as tau and neurofilament may underlie the cytoskeletal abnormalities and neuronal death seen in several neurodegenerative diseases including Alzheimer's disease. One potential mechanism of microtubule-associated protein hyperphosphorylation is augmented activity of protein kinases known to associate with microtubules, such as cdk5 or GSK3beta. Here we show that tau and neurofilament are hyperphosphorylated in transgenic mice that overexpress human p25, an activator of cdk5. The p25 transgenic mice display silver-positive neurons using the Bielschowsky stain. Disturbances in neuronal cytoskeletal organization are apparent at the ultrastructural level. These changes are localized predominantly to the amygdala, thalamus/hypothalamus, and cortex. The p25 transgenic mice display increased spontaneous locomotor activity and differences from control in the elevated plus-maze test. The overexpression of an activator of cdk5 in transgenic mice results in increased cdk5 activity that is sufficient to produce hyperphosphorylation of tau and neurofilament as well as cytoskeletal disruptions reminiscent of Alzheimer's disease and other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahlijanian</LastName><ForeName>M K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Departments of CNS Discovery, Pathology, and Genetic Technologies, Pfizer Central Research, Eastern Point Road, Groton, CT 06340, USA. michael_k_ahlijanian@groton.pfizer.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrezueta</LastName><ForeName>N X</ForeName><Initials>NX</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Jakowski</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kowsz</LastName><ForeName>K P</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Coskran</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Carlo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Seymour</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Burkhardt</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>McNeish</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000715594">CBX5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089495">neuronal Cdk5 activator (p25-p35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>107283-02-3</RegistryNumber><NameOfSubstance UI="D000090266">Chromobox Protein Homolog 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495905">CDK5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495906">Cdk5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090266" MajorTopicYN="N">Chromobox Protein Homolog 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018844" MajorTopicYN="N">Cyclin-Dependent Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016622" MajorTopicYN="N">Silver Staining</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10706614</ArticleId><ArticleId IdType="pmc">PMC16029</ArticleId><ArticleId IdType="doi">10.1073/pnas.040577797</ArticleId><ArticleId IdType="pii">040577797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Crowther R A, Spillantini M G. Neuron. 1998;21:955&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856453</ArticleId></ArticleIdList></Reference><Reference><Citation>Imahori K, Uchida T. J Biochem. 1997;121:179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">9089387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro K, Takamatsu M, Tomizawa K, Omori A, Takahashi M, Arioka M, Uchida T, Imahori K. J Biol Chem. 1992;267:10897&#x2013;10901.</Citation><ArticleIdList><ArticleId IdType="pubmed">1587865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoi T, Uchiyama M, Okumura E, Saito T, Ishiguro K, Uchida T, Okuyama A, Kishimoto T, Hisanaga S. J Biochem. 1995;117:741&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner U, Utton M, Gallo J M, Miller C C. J Cell Sci. 1996;109:1537&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">8799840</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel G, Mercken M, Murayama M, Noguchi K, Ishiguro K, Imahori K, Takashima A. Biochim Biophys Acta. 1998;1380:177&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9565682</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai L H, Delalle I, Caviness V S, Jr, Chae T, Harlow E. Nature (London) 1994;371:419&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090221</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew J, Huang Q-Q, Qi Z, Winkfein R J, Aebersold R, Hunt T, Wang J H. Nature (London) 1994;371:423&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8090222</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Lee K Y, Qi Z, Matsuura I, Wang J H. Biochem Cell Biol. 1996;74:419&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">8960348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Yeung J, Lee K Y, Matsushita M, Matsui H, Tomizawa K, Hatase O, Wang J H. J Biol Chem. 1995;270:26897&#x2013;26903.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, Ward J M, Huh C G, Longenecker G, Veeranna, Pant H C, Brady R O, Martin L J, Kulkarni A B. Proc Natl Acad Sci USA. 1996;93:11173&#x2013;11178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38303</ArticleId><ArticleId IdType="pubmed">8855328</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae T, Kwon Y T, Bronson R, Dikkes P, Li E, Tsai L H. Neuron. 1997;18:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010203</ArticleId></ArticleIdList></Reference><Reference><Citation>Paudel H K, Lew J, Ali Z, Wang J H. J Biol Chem. 1993;268:23512&#x2013;23518.</Citation><ArticleIdList><ArticleId IdType="pubmed">8226879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D, Leung C L, Liem R K H. J Biol Chem. 1996;271:14245&#x2013;14251.</Citation><ArticleIdList><ArticleId IdType="pubmed">8662984</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara M, Kusubata M, Ishiguro K, Uchida T, Titani K, Taniguchi H. J Biol Chem. 1996;271:21108&#x2013;21113.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702879</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuang R, Zhang L, Fletcher A, Groblewski G E, Pevsner J, Stuenkel E L. J Biol Chem. 1998;273:4957&#x2013;4966.</Citation><ArticleIdList><ArticleId IdType="pubmed">9478941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. 2nd Ed. Plainview, NY: Cold Spring Harbor Lab. Press; 1994.</Citation></Reference><Reference><Citation>Tsai L H, Takahashi T, Caviness V S, Jr, Harlow E. Development. 1993;119:1029&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">8306873</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli U K. Nature (London) 1970;227:680&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes K, Monaghan M M, Barrezueta N X, Nawaschik S, Bekele-Arcuri Z, Matos M F, Nakahira K, Schechter L E, Trimmer J S. J Neurosci. 1996;16:4846&#x2013;4860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579302</ArticleId><ArticleId IdType="pubmed">8756417</ArticleId></ArticleIdList></Reference><Reference><Citation>Fix A S, Ross J F, Stitzel S R, Switzer R C. Toxicol Pathol. 1996;24:291&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">8736385</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers R E, Wilson R D. J Histotechnol. 1996;19:235&#x2013;240.</Citation></Reference><Reference><Citation>Dalton A J. Anat Rec. 1955;121:281.</Citation></Reference><Reference><Citation>Biernat J, Mandelkow E-M, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, et al. EMBO J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, R., Lee, V. M.-Y., Leight, S., Varga, I. &amp; Otvos, L. Biochemistry 36, 8114&#x2013;8124.</Citation><ArticleIdList><ArticleId IdType="pubmed">9201960</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberger L A, Sternberger N H. Proc Natl Acad Sci USA. 1983;80:6126&#x2013;6130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534374</ArticleId><ArticleId IdType="pubmed">6577472</ArticleId></ArticleIdList></Reference><Reference><Citation>Szendrei G I, Lee V M, Otvos L., Jr J Neurosci Res. 1993;334:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680727</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti P, Szuchet S, Papasozomenos S C, Zinkowski R P, Binder L I. Proc Natl Acad Sci USA. 1995;92:10369&#x2013;10373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Viale G, Gambacorta M, Coggi G, Dell'Orto P, Milani M, Doglioni C. Virchows Arch A Pathol Anat Histopathol. 1991;418:339&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">1708927</ArticleId></ArticleIdList></Reference><Reference><Citation>Forss-Petter S, Danielson P E, Catsicas S, Battenberg E, Price J, Nerenberg M, Sutcliffe J G. Neuron. 1990;5:187&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">2116814</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin S. Psychopharmacologia. 1968;13:222&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">5679627</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns L H, Annett L, Kelley A E, Everitt B J, Robbins T W. Behav Neurosci. 1996;110:1. , 60&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">8652073</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartzwelder H S. Physiol Behav. 1981;26:323&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">7232538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H, Dickson D W, Davies P, Yen S-H. Proc Natl Acad Sci USA. 1987;84:3410&#x2013;3414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304880</ArticleId><ArticleId IdType="pubmed">2437579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Sternberger N H, Rubinstein L J, Herman M M, Binder L I, Sternberger L A. Proc Natl Acad Sci USA. 1989;86:8045&#x2013;8049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298211</ArticleId><ArticleId IdType="pubmed">2813376</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Gustke N, Drewes G, Mandelkow E M, Mandelkow E. Neuron. 1993;11:153&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett G T, Goedert M, Jakes R, Merrick S E, Trojanowski J Q, Lee V M. Neuron. 1993;10:1089&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E, Braak H, Mandelkow E-M. Acta Neuropathol. 1994;87:554&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522386</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmel G, Mager E M, Binder L I, Kuret J. J Biol Chem. 1996;271:32789&#x2013;32795.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister R G. Psychopharmacology. 1987;92:180&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">3110839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Probst A, Spillantini M G, Schafer T, Jakes R, Burki K, Goedert M. EMBO J. 1995;14:1304&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion J-P, Tremp G, Octave J-N. Am J Pathol. 1999;154:255&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853433</ArticleId><ArticleId IdType="pubmed">9916940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayyali U S, Zhang W, Yee A G, Seidman J G, Potter H. J Neurochem. 1997;68:1668&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">9084440</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlees J, Irving N G, Brion J-P, Gibb B J M, Wagner U, Woodgett J, Miller C C J. NeuroReport. 1997;8:3251&#x2013;3255.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351652</ArticleId></ArticleIdList></Reference><Reference><Citation>James N D, Davis D R, Sindon J, Hanger D P, Brion J-P, Miller C C J, Rosenberg M P, Anderton B H, Propst F. Neurobiol Aging. 1996;17:235&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744404</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Holzer M, Fruth R, Bruckner M K, Gartner U. Neuroscience. 1995;69:691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596639</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10713108</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism.</ArticleTitle><Pagination><StartPage>7918</StartPage><EndPage>7924</EndPage><MedlinePgn>7918-24</MedlinePgn></Pagination><Abstract><AbstractText>In Alzheimer's disease, beta-amyloid (Abeta) plaques are surrounded by activated astrocytes and microglia. A growing body of evidence suggests that these activated glia contribute to neurotoxicity through the induction of inflammatory cytokines such as interleukin (IL)-1beta and tumor necrosis factor-alpha (TNFalpha) and the production of neurotoxic free radicals, mediated in part by the expression of inducible nitric-oxide synthase (iNOS). Here, we address the possibility that Abeta-stimulated iNOS expression might result from an initial induction of IL-1beta and TNFalpha. We find that in Abeta-stimulated astrocyte cultures, IL-1beta and TNFalpha production occur before iNOS production, new protein synthesis is required for increased iNOS mRNA levels, and the IL-1 receptor antagonist IL-1ra can inhibit nitrite accumulation. Likewise, dominant-negative mutants of tumor necrosis factor-alpha receptor-associated factor (TRAF) 6, TRAF2, and NFkappaB-inducing kinase (NIK), intracellular proteins involved in IL-1 and TNFalpha receptor signaling cascades, inhibit Abeta-stimulated iNOS promoter activity. Our data suggest that Abeta stimulation of astrocyte iNOS is mediated in part by IL-1beta and TNFalpha, and involves a TRAF6-, TRAF2-, and NIK-dependent signaling mechanism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akama</LastName><ForeName>K T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Northwestern University Medical School, Chicago, Illinois 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Eldik</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG13939</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM08061</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009573">Nitrites</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047992">TNF Receptor-Associated Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048029">TNF Receptor-Associated Factor 6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="C496318">Nos2 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019001" MajorTopicYN="N">Nitric Oxide Synthase</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009573" MajorTopicYN="N">Nitrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047992" MajorTopicYN="N">TNF Receptor-Associated Factor 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048029" MajorTopicYN="N">TNF Receptor-Associated Factor 6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097782" MajorTopicYN="N">NF-kappaB-Inducing Kinase</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10713108</ArticleId><ArticleId IdType="doi">10.1074/jbc.275.11.7918</ArticleId><ArticleId IdType="pii">S0021-9258(18)30295-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10714659</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.</ArticleTitle><Pagination><StartPage>339</StartPage><EndPage>344</EndPage><MedlinePgn>339-44</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the rate of brain atrophy calculated from serial magnetic resonance imaging (MRI) registration as a surrogate marker of disease progression for use in clinical trials in Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighteen patients with mild to moderate AD and 18 age-matched normal controls underwent 2 MRI brain scans separated by a 12-month interval. Each individual's later scan was registered to their first scan, and the volume of cerebral tissue loss calculated directly from the registered and subtracted MRI scan pairs. The mean and SD of the rate of brain volume changes were used to estimate the sample sizes that would be needed in a clinical trial with a drug anticipated to modify disease progression by varying degrees. Comparable sample size estimates were performed with data for other methods of monitoring rates of brain atrophy, extracted from published papers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean (SD) rate of brain atrophy for the patients with AD was 2.37% (1.11%) per year, while in the control group it was 0.41% (0.47%) per year. Based on these figures, to have 90% power to detect a drug effect equivalent to a 20% reduction in the rate of atrophy, 207 patients would be needed in each treatment arm. This assumes a 1-year placebo-controlled trial with a 10% patient dropout rate, and that 10% of scan pairs are unusable.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Registration of serial MRI volume images provides a powerful method of quantification of brain atrophy that can be used to monitor progression of AD in clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>N C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurology, Institute of Neurology, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cousens</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Scahill</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>M N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2000 Mar;57(3):312-4. doi: 10.1001/archneur.57.3.312.</RefSource><PMID Version="1">10714654</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10714659</ArticleId><ArticleId IdType="doi">10.1001/archneur.57.3.339</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10716257</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of interleukin-1 gene polymorphisms with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>368</EndPage><MedlinePgn>365-8</MedlinePgn></Pagination><Abstract><AbstractText>Interleukin-1 (IL-1) is markedly overexpressed in Alzheimer's disease. We found the IL-1A 2,2 genotype in 12.9% of 232 neuropathologically confirmed Alzheimer's disease patients and 6.6% of 167 controls from four centers in the United Kingdom and United States (odds ratio, 3.0; controlled for age and for ApoE [apolipoprotein E] genotype). Homozygosity for both allele 2 of IL-1A and allele 2 of IL-1B conferred even greater risk (odds ratio, 10.8). IL-1 genotypes may confer risk for Alzheimer's disease through IL-1 overexpression and IL-1-driven neurodegenerative cascades.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicoll</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mrak</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>D I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>MacGowan</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Esiri</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>L S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Dewar</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>W S</ForeName><Initials>WS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG012411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2000 Mar;47(3):283-5.</RefSource><PMID Version="1">10716246</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2000 Nov;48(5):817-9.</RefSource><PMID Version="1">11079552</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10716257</ArticleId><ArticleId IdType="mid">NIHMS525093</ArticleId><ArticleId IdType="pmc">PMC3833599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin M-C, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing mis-sense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, Sherrington R, Rogaeva EA. Familial Alzheimer&#x2019;s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer&#x2019;s disease type 3 gene. Nature. 1995;376:775&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:7611&#x2013;7615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer&#x2019;s disease: the potential role of a &#x201c;cytokine cycle&#x201d; in disease progression. Brain Pathol. 1998;8:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer&#x2019;s disease: initial results of a co-twin control study. Neurology. 1994;44:227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">8309563</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics. 1994;19:382&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">8188271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pociot F, Molvig J, Wogensen L, et al. TaqI polymorphism in the human interleukin-1&#x3b2; (IL-1&#x3b2;) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest. 1992;22:396&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">1353022</ArticleId></ArticleIdList></Reference><Reference><Citation>McDowell TL, Symons JA, Ploski R, et al. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum. 1995;38:221&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">7848312</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenham PR, Price WH, Blandell G. Apolipoprotein E geno-typing by one-stage PCR. Lancet. 1991;11:1158&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">1674030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17:761&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886636</ArticleId><ArticleId IdType="pubmed">8892349</ArticleId></ArticleIdList></Reference><Reference><Citation>Forloni G, Demicheli F, Giorgi S, et al. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Mol Brain Res. 1992;16:128&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">1334190</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA. 1992;89:10075&#x2013;10078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50280</ArticleId><ArticleId IdType="pubmed">1359534</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JT, Leiter LM, McPhee J, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5&#x2032;-untranslated region sequences. J Biol Chem. 1999;274:6421&#x2013;6431.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037734</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 1997;28:878&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278049</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Gentleman SM, et al. Microglial interleukin-1&#x3b1; expression in human head injury: correlations with neuronal and neuritic &#x3b2;-amyloid precursor protein expression. Neurosci Lett. 1994;176:133&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833643</ArticleId><ArticleId IdType="pubmed">7830934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer&#x2019;s disease: a collaborative re-analysis of case-control studies: EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(Suppl):S28&#x2013;S35.</Citation><ArticleIdList><ArticleId IdType="pubmed">1833351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med. 1995;1:135&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10720273</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.</ArticleTitle><Pagination><StartPage>1050</StartPage><EndPage>1058</EndPage><MedlinePgn>1050-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the validity of a clinical diagnosis of probable or possible dementia with Lewy bodies (DLB) made using International Consensus criteria.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Validation studies based on retrospective chart reviews of autopsy-confirmed cases have suggested that diagnostic specificity for DLB is acceptable but case detection rates as low as 0.22 have been suggested.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the first 50 cases reaching neuropathologic autopsy in a cohort to which Consensus clinical diagnostic criteria for DLB, National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for AD, and National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria for vascular dementia (VaD) had been prospectively applied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six clinical diagnoses of DLB, 19 of AD, and 5 of VaD were made. At autopsy, 29 DLB cases, 15 AD, 5 VaD, and 1 progressive supranuclear palsy were identified. The sensitivity and specificity of a clinical diagnosis of probable DLB in this sample were 0.83 and 0.95. Of the five cases receiving a false-negative diagnosis of DLB, significant fluctuation was present in four but visual hallucinations and spontaneous motor features of parkinsonism were generally absent. Thirty-one percent of the DLB cases had additional vascular pathology and in two cases this contributed to a misdiagnosis of VaD. No correlations were found between the distribution of Lewy bodies and clinical features.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The Consensus criteria for DLB performed as well in this prospective study as those for AD and VaD, with a diagnostic sensitivity substantially higher than that reported by previous retrospective studies. DLB occurs in the absence of extrapyramidal features and in the presence of comorbid cerebrovascular disease. Fluctuation is an important diagnostic indicator, reliable measures of which need to be developed further.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Institute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>C G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Ince</LastName><ForeName>P G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Neill</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lowery</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jaros</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fairbairn</LastName><ForeName>A F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>E K</ForeName><Initials>EK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003245" MajorTopicYN="N">Consensus Development Conferences as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="Y">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="Y">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10720273</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.5.1050</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10720281</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.</ArticleTitle><Pagination><StartPage>1099</StartPage><EndPage>1102</EndPage><MedlinePgn>1099-102</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Decreased levels of Abeta1-42 are found in CSF of patients with AD. Because early stages of Creutzfeldt-Jakob disease (CJD) and AD share several clinical features, we investigated Abeta1-42 levels in CSF of these groups, inferring that this might give additional help in differentiating patients with CJD from AD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We investigated 27 patients with CJD, 14 patients with AD, 19 patients with other dementias, and 20 nondemented controls (NDC) for Abeta1-42 in CSF. Twenty-four of the 27 CJD patients were neuropathologically verified. All the neuropathologically verified patients presented with a type 1 prion protein pattern. CJD patients were all homozygous for methionine at codon 129. Except in five CJD patients, no beta-amyloid plaques were seen. Additionally, APOE status was determined in patients with CJD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Levels of Abeta1-42 in CSF were decreased in patients with AD as well as in CJD. Levels of Abeta1-42 in CSF of patients with CJD and AD were significantly different from the other dementia and NDC groups. There was no substantial difference between the CJD and AD groups (p = 0.66). Decreased levels of Abeta1-42 did not correlate with the APOE epsilon4 load in patients with CJD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Low levels of Abeta1-42 in CSF do not exclude a diagnosis of CJD. Decreased levels of Abeta1-42 in CSF can occur without beta-amyloid plaque formation in the brain. However, the underlying mechanism of this phenomenon must be elucidated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurologische Klinik und Poliklinik, Georg-August-Universit&#xe4;t G&#xf6;ttingen, Germany. motto@gwdg.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esselmann</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schulz-Shaeffer</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schr&#xf6;ter</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ratzka</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cepek</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zerr</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Steinacker</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Windl</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Poser</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10720281</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.5.1099</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10725383</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>7</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus.</ArticleTitle><Pagination><StartPage>3602</StartPage><EndPage>3607</EndPage><MedlinePgn>3602-7</MedlinePgn></Pagination><Abstract><AbstractText>Estrogen replacement therapy in women is associated with improvement of cognitive deficits and reduced incidence of Alzheimer's disease. The present study indicates that estrogen is neuroprotective against N-methyl-d-aspartate (NMDA)- and kainate-mediated neurotoxicity, an effect mediated by tyrosine kinase/mitogen-activated protein kinase (MAPK) pathways. Estrogen also stimulates tyrosine phosphorylation of NMDA receptors via an src tyrosine kinase/MAPK pathway. Finally, estrogen-mediated enhancement of long-term potentiation in hippocampal slices is mediated by activation of an src tyrosine kinase pathway. Thus, estrogen, by activating an src tyrosine kinase and the extracellular signal-related protein kinase/MAPK signaling pathway, both enhances NMDA receptor function and long-term potentiation and retains neuroprotective properties against excitotoxicity. These findings warrant further evaluation of the usefulness of estrogenic compounds for the treatment of Alzheimer's disease and other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuroscience Program, University of Southern California, Los Angeles, CA 90089-2520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broutman</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Foy</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Baudry</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG014751</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-14751</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="Y">MAP Kinase Signaling System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10725383</ArticleId><ArticleId IdType="pmc">PMC16286</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.7.3602</ArticleId><ArticleId IdType="pii">060034497</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Henderson V W. Neurology. 1997;48, Suppl. 7:S27&#x2013;S35.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153164</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L S, Farlow M R, Henderson V W, Pogoda J M. Neurology. 1996;46:1580&#x2013;1584.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649552</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy P M, Bieber F, Kaiser L, Krishnan K R, Reuning-Scherer J, Gulanski B. Neurology. 1997;48:1511&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191757</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpkins J W, Green P S, Gridley K E, Singh M, de Fiebre N C, Rajakumar G. Am J Med. 1997;103:19S&#x2013;25S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9344403</ArticleId></ArticleIdList></Reference><Reference><Citation>Teyler T J, Vardaris R M, Lewis D, Rawitch A B. Science. 1980;209:1017&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">7190730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Skinkle K L, Hicks T P. J Physiol. 1999;515:209&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2269127</ArticleId><ArticleId IdType="pubmed">9925890</ArticleId></ArticleIdList></Reference><Reference><Citation>Foy M R, Xu J, Xie X, Brinton R D, Thompson R F, Berger T W. J Neurophysiol. 1999;81:925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">10036289</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss R L, Gu Q. Steroids. 1999;64:14&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10323668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M, Moss R L. J Neurosci. 1992;12:3217&#x2013;3225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575649</ArticleId><ArticleId IdType="pubmed">1353794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Q, Moss R L. J Physiol. 1998;506:745&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230751</ArticleId><ArticleId IdType="pubmed">9503335</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudry M, Davis J L, editors. Long-Term Potentiation. Cambridge, MA: MIT Press; 1997.</Citation></Reference><Reference><Citation>Singer C A, Rogers K L, Strickland T M, Dorsa D M. Neurosci Lett. 1996;212:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">8823751</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman Y, Bruce A J, Cheng B, Mattson M P. J Neurochem. 1996;66:1836&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">8780008</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. EMBO J. 1996;15:1292&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC450032</ArticleId><ArticleId IdType="pubmed">8635462</ArticleId></ArticleIdList></Reference><Reference><Citation>Watters J J, Campbell J S, Cunningham M J, Krebs E G, Dorsa D M. Endocrinology. 1997;138:4030&#x2013;4033.</Citation><ArticleIdList><ArticleId IdType="pubmed">9275096</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer C A, Figueroa-Masot X A, Batchelor R H, Dorsa D M. J Neurosci. 1999;19:2455&#x2013;2463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786088</ArticleId><ArticleId IdType="pubmed">10087060</ArticleId></ArticleIdList></Reference><Reference><Citation>Impey S, Obrietan K, Storm D R. Neuron. 1999;23:11&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10402188</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, Setalo G, Jr, Guan X P, Warren M, Toran-Allerand C D. J Neurosci. 1999;19:1179&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786041</ArticleId><ArticleId IdType="pubmed">9952396</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X M, Askalan R, Keil G J, Salter M W. Science. 1997;275:674&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005855</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng F, Gingrich M B, Traynelis S F, Conn P J. Nat Neurosci. 1998;1:185&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster B, Rogers M V. Eur J Neurosci. 1998;10:2302&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W Y, Xiong Z G, Lei S, Orser B A, Dudek E, Browning M D, MacDonald J F. Nat Neurosci. 1999;2:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">10204539</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter M W. Biochem Pharmacol. 1998;56:789&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774140</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant S G, O'Dell T J, Karl K A, Stein P L, Soriano P, Kandel E R. Science. 1992;258:1903&#x2013;1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361685</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs P A, Muller D. J Neurosci Methods. 1991;37:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce A J, Sakhi S, Schreiber S S, Baudry M. Exp Neurol. 1995;132:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">7540554</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli U K. Nature (London) 1970;227:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Towbin H, Staehelin T, Gordon J. Proc Natl Acad Sci USA. 1979;76:4350&#x2013;4354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411572</ArticleId><ArticleId IdType="pubmed">388439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi X, Rong Y, Chen J, Dang S, Wang Z, Baudry M. Brain Res. 1998;790:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">9593918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi X, Chen J, Baudry M. Brain Res. 1998;781:355&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9507192</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon I S, Apperson M L, Kennedy M B. Proc Natl Acad Sci USA. 1994;91:3954&#x2013;3958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43701</ArticleId><ArticleId IdType="pubmed">7513428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi R, Bi X, Baudry M. Brain Res. 1998;797:154&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630591</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S M, Brugge J F. Annu Rev Cell Dev Biol. 1997;13:513&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">9442882</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Okumura N J. Biochem Biophys Res Commun. 1995;216:582&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">7488151</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins C M, Selcher J C, Petraitis J J, Trzaskos J M, Sweatt J D. Nat Neurosci. 1998;1:602&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196568</ArticleId></ArticleIdList></Reference><Reference><Citation>Orban P C, Chapman P F, Brambilla R. Trends Neurosci. 1999;22:38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088998</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisman J E, Fallon J R. Science. 1999;283:339&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9925495</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum S, Moore A N, Adams F, Dash P K. J Neurosci. 1999;19:3535&#x2013;3544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782236</ArticleId><ArticleId IdType="pubmed">10212313</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10727245</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-2960</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>12</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Two-dimensional structure of beta-amyloid(10-35) fibrils.</ArticleTitle><Pagination><StartPage>3491</StartPage><EndPage>3499</EndPage><MedlinePgn>3491-9</MedlinePgn></Pagination><Abstract><AbstractText>Beta-amyloid (Abeta) peptides are the main protein component of the pathognomonic plaques found in the brains of patients with Alzheimer's disease. These heterogeneous peptides adopt a highly organized fibril structure both in vivo and in vitro. Here we use solid-state NMR on stable, homogeneous fibrils of Abeta(10-35). Specific interpeptide distance constraints are determined with dipolar recoupling NMR on fibrils prepared from a series of singly labeled peptides containing (13)C-carbonyl-enriched amino acids, and skipping no more that three residues in the sequence. From these studies, we demonstrate that the peptide adopts the structure of an extended parallel beta-sheet in-register at pH 7.4. Analysis of DRAWS data indicates interstrand distances of 5.3 +/- 0.3 A (mean +/- standard deviation) throughout the entire length of the peptide, which is compatible only with a parallel beta-strand in-register. Intrastrand NMR constraints, obtained from peptides containing labels at two adjacent amino acids, confirm the secondary structural findings obtained using DRAWS. Using peptides with (13)C incorporated at the carbonyl position of adjacent amino acids, structural transitions from alpha-helix to beta-sheet were observed at residues 19 and 20, but using similar techniques, no evidence for a turn could be found in the putative turn region comprising residues 25-29. Implications of this extended parallel organization for Abeta(10-35) for overall fibril formation, stability, and morphology based upon specific amino acid contacts are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>T L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Department of Chemistry, The University of Chicago, Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Burkoth</LastName><ForeName>T S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Miller-Auer</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lynn</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Botto</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Meredith</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5 T32 GM07281</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 T32 HL07237</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 RR 12723</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002247">Carbon Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C407125">amyloid beta-protein (10-35)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002247" MajorTopicYN="N">Carbon Isotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10727245</ArticleId><ArticleId IdType="doi">10.1021/bi991527v</ArticleId><ArticleId IdType="pii">bi991527v</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10731508</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9165</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of clinical nutrition</Title><ISOAbbreviation>Am J Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study.</ArticleTitle><Pagination><StartPage>993</StartPage><EndPage>998</EndPage><MedlinePgn>993-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies suggested that low concentrations of folate in the blood are related to poor cognitive function, dementia, and Alzheimer disease-related neurodegeneration of the brain.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our aim was to determine whether serum folate is inversely associated with the severity of atrophy of the neocortex.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Nutrients, lipoproteins, and nutritional markers were measured in the blood of 30 participants in the Nun Study from one convent who later died when they were 78-101 y old (mean: 91 y). At autopsy, several neuropathologic indicators of Alzheimer disease were determined, including the degree of atrophy of 3 lobes of the neocortex (frontal, temporal, and parietal) and the number of neocortical Alzheimer disease lesions (ie, senile plaques and neurofibrillary tangles) as assessed by a neuropathologist.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The correlation between serum folate and the severity of atrophy of the neocortex was -0.40 (P = 0.03). Among a subset of 15 participants with significant numbers of Alzheimer disease lesions in the neocortex, the correlation between folate and atrophy was -0.80 (P = 0.0006). Atrophy may be specific to low folate because none of the 18 other nutrients, lipoproteins, or nutritional markers measured in the blood had significant negative correlations with atrophy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among elderly Catholic sisters who lived in one convent, ate from the same kitchen, and were highly comparable for a wide range of environmental and lifestyle factors, low serum folate was strongly associated with atrophy of the cerebral cortex. Definitive evidence for this relation and its temporal sequence awaits the findings of other studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snowdon</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, and the Departments of Preventive Medicine, Neurology, and Pathology, College of Medicine, University of Kentucky, Lexington 40536-0230, USA. nunnet@aging.coa.uky.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tully</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>C D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>K P</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>Markesbery</LastName><ForeName>W R</ForeName><Initials>WR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>K01AG00633</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K04AG00553</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG09862</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Clin Nutr</MedlineTA><NlmUniqueID>0376027</NlmUniqueID><ISSNLinking>0002-9165</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>935E97BOY8</RegistryNumber><NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Clin Nutr. 2000 Apr;71(4):859-60. doi: 10.1093/ajcn/71.4.859.</RefSource><PMID Version="1">10731489</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Int J Geriatr Psychiatry. 2003 Feb;18(2):187-8. doi: 10.1002/gps.704.</RefSource><PMID Version="1">12571831</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002410" MajorTopicYN="N">Catholicism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10731508</ArticleId><ArticleId IdType="doi">10.1093/ajcn/71.4.993</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10734005</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8950</ISSN><JournalIssue CitedMedium="Print"><Volume>123 ( Pt 4)</Volume><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.</ArticleTitle><Pagination><StartPage>733</StartPage><EndPage>745</EndPage><MedlinePgn>733-45</MedlinePgn></Pagination><Abstract><AbstractText>Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They are commonly viewed as a side-effect of antiparkinsonian treatment, but other factors may be involved. The aim of this study was to determine the phenomenology, prevalence and risk factors of hallucinations in Parkinson's disease. Two-hundred and sixteen consecutive patients fulfilling clinical criteria for Parkinson's disease were studied. Demographic and clinical variables were recorded, including motor and cognitive status, depressive symptoms and sleep-wake disturbances. Patients with and without hallucinations were compared using non-parametric tests, and logistic regression was applied to significant data. Hallucinations had been present during the previous 3 months in 39.8% of the patients, and fell into three categories: minor forms, consisting of a sensation of a presence (person), a sideways passage (commonly of an animal) or illusions were present in 25.5% of the patients (an isolated occurrence in 14.3%), formed visual hallucinations were present in 22.2% (isolated in 9.3%) and auditory hallucinations were present in 9.7% (isolated in 2.3%). Patients with minor hallucinations had a higher depression score than non-hallucinators but did not differ in other respects. Logistic regression analysis identified three factors independently predictive of formed visual hallucinations: severe cognitive disorders, daytime somnolence and a long duration of Parkinson's disease. These findings indicate that, when minor hallucinations are included, the total prevalence is much higher than previously reported. A simple side-effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations. The main risk factor in treated patients is cognitive impairment, although sleep-wake cycle disturbances, and possibly other factors related to the duration of the disease, act as cofactors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>F&#xe9;nelon</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, H&#xf4;pital Tenon, Paris, France. gilles.fenelon@tnn.ap-hop-paris.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahieux</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Huon</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zi&#xe9;gler</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10734005</ArticleId><ArticleId IdType="doi">10.1093/brain/123.4.733</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10735393</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0098-7484</ISSN><JournalIssue CitedMedium="Print"><Volume>283</Volume><Issue>12</Issue><PubDate><MedlineDate>2000 Mar 22-29</MedlineDate></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.</ArticleTitle><Pagination><StartPage>1571</StartPage><EndPage>1577</EndPage><MedlinePgn>1571-7</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Alzheimer disease (AD) is characterized neuropathologically by the presence of amyloid beta-peptide (Abeta)-containing plaques and neurofibrillary tangles composed of abnormal tau protein. Considerable controversy exists as to whether the extent of accumulation of Abeta correlates with dementia and whether Abeta alterations precede or follow changes in tau.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether accumulation of Abeta correlates with the earliest signs of cognitive deterioration and to define the relationship between Abeta accumulation and early tau changes.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">Postmortem cross-sectional study of 79 nursing home residents with Clinical Dementia Rating (CDR) scale scores of 0.0 to 5.0 who died between 1986 and 1997, comparing the levels of Abeta variants in the cortices of the subjects with no (CDR score, 0.0 [n = 16]), questionable (CDR score, 0.5 [n = 11]), mild (CDR score, 1.0 [n = 22]), moderate (CDR score, 2.0 [n = 15]), or severe (CDR score, 4.0 or 5.0 [n = 15]) dementia.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Levels of total Abeta peptides with intact or truncated amino termini and ending in either amino acid 40 (A(beta)x-40) or 42 (A(beta)x-42) in 5 neocortical brain regions as well as levels of tau protein undergoing early conformational changes in frontal cortex, as a function of CDR score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The levels of both A(beta)x-40 and A(beta)x-42 were elevated even in cases classified as having questionable dementia (CDR score = 0.5), and increases of both peptides correlated with progression of dementia. Levels of the more fibril-prone A(beta)x-42 peptide were higher than those of A(beta)x-40 in nondemented cases and remained higher throughout progression of disease in all regions examined. Finally, increases in A(beta)x-40 and A(beta)x-42 precede significant tau pathology at least in the frontal cortex, an area chosen for examination because of the absence of neuritic changes in the absence of disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this study, levels of total A(beta)x-40 and A(beta)x-42 were elevated early in dementia and levels of both peptides were strongly correlated with cognitive decline. Of particular interest, in the frontal cortex, Abeta was elevated before the occurrence of significant tau pathology. These results support an important role for Abeta in mediating initial pathogenic events in AD dementia and suggest that treatment strategies targeting the formation, accumulation, or cytotoxic effects of Abeta should be pursued.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>N&#xe4;slund</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Mohs</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14996</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2000 Mar 22-29;283(12):1615-7. doi: 10.1001/jama.283.12.1615.</RefSource><PMID Version="1">10735401</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId><ArticleId IdType="doi">10.1001/jama.283.12.1571</ArticleId><ArticleId IdType="pii">joc90912</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10737598</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal.</ArticleTitle><Pagination><StartPage>1426</StartPage><EndPage>1433</EndPage><MedlinePgn>1426-33</MedlinePgn></Pagination><Abstract><AbstractText>Inheritance of the apolipoprotein E (apoE) epsilon4 allele increases the risk for Alzheimer's disease and may also influence the pathogenesis of other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The influence of apoE genotype on disease susceptibility must ultimately be explained by the fact that apoE proteins differ in only two amino acids: apoE2 has two cysteine residues, apoE3 has one cysteine residue, and apoE4 has none. We previously reported increased protein modification by the lipid peroxidation product 4-hydroxynonenal (HNE), which covalently binds to proteins on cysteine residues, in human ALS lumbar spinal cord. We now report increased levels of HNE-modified apoE in lumbar spinal cord samples from mice expressing an ALS-linked mutation in Cu/Zn-superoxide dismutase relative to controls. Studies of interactions of pure apoE proteins with HNE showed that the isoforms differ in the amount of HNE they can bind, with the order E2 &gt; E3 &gt; E4. This correlated with the differential ability of apoE isoforms to protect against apoptosis induced by HNE in cultures of mouse spinal cord motor neurons and by the amyloid beta-peptide in cultures of rat hippocampal neurons. These data suggest that apoE plays a major role in detoxifying HNE, and the differential neuroprotective effect of its isoforms may help explain the relationship between apoE genotype and the susceptibility to neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>W A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Sanders-Brown Research Center on Aging and Department of Anatomy and Neurobiology, University of Kentucky, Lexington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000447">Aldehydes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015853">Cysteine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>K1CVM13F96</RegistryNumber><NameOfSubstance UI="C027576">4-hydroxy-2-nonenal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000447" MajorTopicYN="N">Aldehydes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015853" MajorTopicYN="N">Cysteine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007536" MajorTopicYN="N">Isomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10737598</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0741426.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10737616</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta.</ArticleTitle><Pagination><StartPage>1587</StartPage><EndPage>1595</EndPage><MedlinePgn>1587-95</MedlinePgn></Pagination><Abstract><AbstractText>The stress-activated kinases c-Jun N-terminal kinase (JNK) and p38 are members of the mitogen-activated protein (MAP) kinase family and take part in signalling cascades initiated by various forms of stress. Their targets include the microtubule-associated protein tau, which becomes hyperphosphorylated in Alzheimer's disease. It is necessary, as a forerunner for in vivo studies, to identify the protein kinases and phosphatases that are responsible for phosphate turnover at individual sites. Using nanoelectrospray mass spectrometry, we have undertaken an extensive comparison of phosphorylation in vitro by several candidate tau kinases, namely, JNK, p38, ERK2, and glycogen synthase kinase 3beta (GSK3beta). Between 10 and 15 sites were identified for each kinase. The three MAP kinases phosphorylated Ser202 and Thr205 but not detectably Ser199, whereas conversely GSK3beta phosphorylated Ser199 but not detectably Ser202 or Thr205. Phosphorylated Ser404 was found with all of these kinases except JNK. The MAP kinases may not be strictly proline specific: p38 phosphorylated the nonproline sites Ser185, Thr245, Ser305, and Ser356, whereas ERK2 was the most strict. All of the sites detected except Thr245 and Ser305 are known or suspected phosphorylation sites in paired helical filament-tau extracted from Alzheimer brains. Thus, the three MAP kinases and GSK3beta are importantly all strong candidates as tau kinases that may be involved in the pathogenic hyperphosphorylation of tau in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Institute of Psychiatry, King's College London, England. h.reynolds@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Blackstock</LastName><ForeName>W P</ForeName><Initials>WP</Initials></Author><Author ValidYN="Y"><LastName>Nebreda</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Anderton</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.-</RegistryNumber><NameOfSubstance UI="D038341">Glycogen Synthase Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D017871">Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017871" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038341" MajorTopicYN="N">Glycogen Synthase Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007313" MajorTopicYN="N">Insecta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048031" MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10737616</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0741587.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10742146</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor.</ArticleTitle><Pagination><StartPage>397</StartPage><EndPage>404</EndPage><MedlinePgn>397-404</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid beta-protein precursor gives rise to the amyloid beta-protein, the principal constituent of senile plaques and a cytotoxic fragment involved in the pathogenesis of Alzheimer disease. Here we show that amyloid beta-protein precursor was proteolytically cleaved by caspases in the C terminus to generate a second unrelated peptide, called C31. The resultant C31 peptide was a potent inducer of apoptosis. Both caspase-cleaved amyloid beta-protein precursor and activated caspase-9 were present in brains of Alzheimer disease patients but not in control brains. These findings indicate the possibility that caspase cleavage of amyloid beta-protein precursor with the generation of C31 may be involved in the neuronal death associated with Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>D C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Program on Aging, The Burnham Institute, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabizadeh</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shayya</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Ellerby</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Salvesen</LastName><ForeName>G S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Bredesen</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12282</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS37776</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092826">amyloid precursor protein, carboxy-terminal 100 residues</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506433">CASP9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506434">Casp9 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2000 Apr;6(4):385-6. doi: 10.1038/74644.</RefSource><PMID Version="1">10742143</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053453" MajorTopicYN="N">Caspase 9</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10742146</ArticleId><ArticleId IdType="doi">10.1038/74656</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10747881</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>24</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.</ArticleTitle><Pagination><StartPage>18344</StartPage><EndPage>18349</EndPage><MedlinePgn>18344-9</MedlinePgn></Pagination><Abstract><AbstractText>Intracellular proteinaceous aggregates are hallmarks of many common neurodegenerative disorders, and recent studies have shown that alpha-synuclein is a major component of several pathological intracellular inclusions, including Lewy bodies in Parkinson's disease (PD) and glial cell inclusions in multiple system atrophy. However, the molecular mechanisms underlying alpha-synuclein aggregation into filamentous inclusions remain unknown. Since oxidative and nitrative stresses are potential pathogenic mediators of PD and other neurodegenerative diseases, we asked if oxidative and/or nitrative events alter alpha-synuclein and induce it to aggregate. Here we show that exposure of human recombinant alpha-synuclein to nitrating agents (peroxynitrite/CO(2) or myeloperoxidase/H(2)O(2)/nitrite) induces formation of nitrated alpha-synuclein oligomers that are highly stabilized due to covalent cross-linking via the oxidation of tyrosine to form o,o'-dityrosine. We also demonstrate that oxidation and nitration of pre-assembled alpha-synuclein filaments stabilize these filaments to withstand denaturing conditions and enhance formation of SDS-insoluble, heat-stable high molecular mass aggregates. Thus, these data suggest that oxidative and nitrative stresses are involved in mechanisms underlying the pathogenesis of Lewy bodies and glial cell inclusions in PD and multiple system atrophy, respectively, as well as alpha-synuclein pathologies in other synucleinopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Stokes Research Institute Children's Hospital of Philadelphia, Department of Biochemistry and Biophysics, Stokes Research Institute, Children's Hospital of Philadelphia, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>B I</ForeName><Initials>BI</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>V M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Ischiropoulos</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG09215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13966</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009566">Nitrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>CJ9XG8HS20</RegistryNumber><NameOfSubstance UI="C007543">dityrosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009566" MajorTopicYN="N">Nitrates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10747881</ArticleId><ArticleId IdType="doi">10.1074/jbc.M000206200</ArticleId><ArticleId IdType="pii">S0021-9258(19)83192-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10749877</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>27</Issue><PubDate><Year>2000</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Expression analysis of BACE2 in brain and peripheral tissues.</ArticleTitle><Pagination><StartPage>20647</StartPage><EndPage>20651</EndPage><MedlinePgn>20647-51</MedlinePgn></Pagination><Abstract><AbstractText>Beta-site amyloid precursor protein cleaving enzyme (BACE) is a novel transmembrane aspartic protease that possesses all the known characteristics of the beta-secretase involved in Alzheimer's disease (Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. -C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Science 286, 735-741). We have analyzed the sequence and expression pattern of a BACE homolog termed BACE2. BACE and BACE2 are unique among aspartic proteases in that they possess a carboxyl-terminal extension with a predicted transmembrane region and together they define a new family. Northern analysis reveals that BACE2 mRNA is expressed at low levels in most human peripheral tissues and at higher levels in colon, kidney, pancreas, placenta, prostate, stomach, and trachea. Human adult and fetal whole brain and most adult brain subregions express very low or undetectable levels of BACE2 mRNA. In addition, in situ hybridization of adult rat brain shows that BACE2 mRNA is expressed at very low levels in most brain regions. The very low or undetectable levels of BACE2 mRNA in the brain are not consistent with the expression pattern predicted for beta-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>B D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Amgen, Inc., Thousand Oaks, California 91320-1799, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu-Khan</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Loeloff</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Louis</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Curran</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Citron</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AF204944</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509281">Bace1 protein, rat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>19</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10749877</ArticleId><ArticleId IdType="doi">10.1074/jbc.M002688200</ArticleId><ArticleId IdType="pii">S0021-9258(19)79882-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10762153</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.</ArticleTitle><Pagination><StartPage>430</StartPage><EndPage>439</EndPage><MedlinePgn>430-9</MedlinePgn></Pagination><Abstract><AbstractText>We used magnetic resonance imaging (MRI) measurements to determine whether persons in the prodromal phase of Alzheimer's disease (AD) could be accurately identified before they developed clinically diagnosed dementia. Normal subjects (n = 24) and those with mild memory difficulty (n = 79) received an MRI scan at baseline and were then followed annually for 3 years to determine which individuals subsequently met clinical criteria for AD. Patients with mild AD at baseline were also evaluated (n = 16). Nineteen of the 79 subjects with mild memory difficulty "converted" to a diagnosis of probable AD after 3 years of follow-up. Baseline MRI measures of the entorhinal cortex, the banks of the superior temporal sulcus, and the anterior cingulate were most useful in discriminating the status of the subjects on follow-up examination. The accuracy of discrimination was related to the clinical similarity between groups. One hundred percent (100%) of normal subjects and patients with mild AD could be discriminated from one another based on these MRI measures. When the normals were compared with the individuals with memory impairments who ultimately developed AD (the converters), the accuracy of discrimination was 93%, based on the MRI measures at baseline (sensitivity = 0.95; specificity = 0.90). The discrimination of the normal subjects and the individuals with mild memory problems who did not progress to the point where they met clinical criteria for probable AD over the 3 years of follow-up (the "questionables") was 85% and the discrimination of the questionables and converters was 75%. The apolipoprotein E genotype did not improve the accuracy of discrimination. The specific regions selected for each of these discriminations provides information concerning the hierarchical fashion in which the pathology of AD may affect the brain during its prodromal phase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Killiany</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kikinis</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sandor</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Jolesz</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>P01-AG04953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-CA67165</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG08487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2000 Apr;47(4):419-20.</RefSource><PMID Version="1">10762150</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10764048</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1015-6305</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Neuroprotection by the inhibition of apoptosis.</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>292</EndPage><MedlinePgn>283-92</MedlinePgn></Pagination><Abstract><AbstractText>Accumulating evidence strongly suggests that apoptosis contributes to neuronal cell death in a variety of neurodegenerative contexts. Activation of the cysteine protease caspase-3 appears to be a key event in the execution of apoptosis in the central nervous system (CNS). As a result, mice null for caspase-3 display considerable neuronal expansion usually resulting in death by the second week of life. At present, 14 caspase family members have been identified and subdivided into three subgroups on the basis of preference for specific tetrapeptide motifs using a positional scanning combinatorial substrate library. Caspase-3 is a group II member (2, 3, 7) categorized by an absolute substrate requirement for aspartic acid in the P4 position of the scissile bond. The preferred cleavage motif (DExD) for group II caspases is found in many structural, metabolic and repair proteins essential for cellular homeostasis. Consistent with the proposal that apoptosis plays a central in role human neurodegenerative disease, caspase-3 activation has recently been observed in stroke, spinal cord trauma, head injury and Alzheimer's disease. Indeed, peptide-based caspase inhibitors prevent neuronal loss in animal models of head injury and stroke suggesting that these compounds may be the forerunners of non-peptide small molecules that halt apoptosis processes implicated in these neurodegenerative disorders. A clear link between an hereditary neurodegenerative disorder and failed caspase inhibition has recently been proposed for spinal muscular atrophy (SMA). In severe SMA, the neuronal specific inhibitor of apoptosis (IAP) family member known as NAIP is often dysfunctional due to missense and truncation mutations. IAPs such as NAIP potently block the enzymatic activity of group II caspases (3 and 7) suggesting that NAIP mutations may permit unopposed developmental apoptosis to occur in sensory and motor systems resulting in lethal muscular atrophy. Conversely, adenovirally-mediated overexpression of NAIP or the X-linked IAP called XIAP reduces the loss of CA1 hippocampal neurons following transient forebrain ischemia. Taken together, these findings suggest that anti-apoptotic strategies may some day have utility in the treatment of neurodegenerative disease. The present review will summarize some of the recent evidence suggesting that apoptosis inhibitors may become a practical therapeutic approach for both acute and chronic neurodegenerative conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>G S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Merck-Frosst Institute for Therapeutic Research, Department of Pharmacology, Kirkland, Quebec, Canada. george_robertson@merck.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crocker</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C030193">immunosuppressive acidic protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005810" MajorTopicYN="N">Multigene Family</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10764048</ArticleId><ArticleId IdType="pmc">PMC8098500</ArticleId><ArticleId IdType="doi">10.1111/j.1750-3639.2000.tb00262.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Birnbaum MJ , Clem RJ , Miller LK ( 1994. ) An apoptosis&#x2010;inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs . J Virol 68 : 2521 &#x2013; 2528 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236730</ArticleId><ArticleId IdType="pubmed">8139034</ArticleId></ArticleIdList></Reference><Reference><Citation>Boegman RJ , Smith Y , Parent A ( 1987. ) Quinolinic acid does not spare striatal neuropeptide Y&#x2010;immunoreactive neurons . Brain Res 415 : 178 &#x2013; 182 .</Citation><ArticleIdList><ArticleId IdType="pubmed">2957024</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng B , Barger SW , Mattson MP ( 1994. ) Staurosporine, K&#x2010;252a, and K&#x2010;252b stabilize calcium homeostasis and promote survival of CNS neurons in the absence of glucose . J Neurochem 62 : 1319 &#x2013; 1329 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7510777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesselet MF , Gonzales C , Lin CS , Polsky K , Jin BK ( 1990. ) Ischemic damage in the striatum of adult gerbils: relative sparing of somatostatinergic and cholinergic interneurons contrasts with loss of efferent neurons . Exp Neurol 110 : 209 &#x2013; 218 .</Citation><ArticleIdList><ArticleId IdType="pubmed">1977609</ArticleId></ArticleIdList></Reference><Reference><Citation>Clem RJ , Fechheimer M , Miller LK ( 1991. ) Prevention of apoptosis by a baculovirus gene during infection of insect cells . Science 254 : 1388 &#x2013; 1390 .</Citation><ArticleIdList><ArticleId IdType="pubmed">1962198</ArticleId></ArticleIdList></Reference><Reference><Citation>Clem RJ , Miller LK ( 1994. ) Control of programmed cell death by the baculovirus genes p35 and iap . Mol Cell Biol 14 : 5212 &#x2013; 5222 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC359040</ArticleId><ArticleId IdType="pubmed">8035800</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonnier M , Steriade M , Landry P ( 1979. ) Selective resistance of sensory cells of the mesencephalic trigeminal nucleus to kainic acid&#x2010;induced lesions . Brain Res 172 : 552 &#x2013; 556 .</Citation><ArticleIdList><ArticleId IdType="pubmed">476498</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook NE , Clem RJ , Miller LK ( 1993. ) An apoptosis&#x2010;inhibiting baculovirus gene with a zinc finger&#x2010;like motif . J Virol 67 : 2168 &#x2013; 2174 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240327</ArticleId><ArticleId IdType="pubmed">8445726</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Mello SR , Galli C , Ciotti T , Calissano P ( 1993. ) Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin&#x2010;like growth factor I and cAMP . Proc Natl Acad Sci USA 90 : 10989 &#x2013; 10993 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47907</ArticleId><ArticleId IdType="pubmed">8248201</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveraux QL , Leo E , Stennicke HR , Welsh K , Salvesen GS , Reed JC ( 1999. ) Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases . Embo J 18 : 5242 &#x2013; 5251 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171595</ArticleId><ArticleId IdType="pubmed">10508158</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveraux QL , Roy N , Stennicke HR , Van Arsdale T , Zhou Q , Srinivasula SM , Alnemri ES , Salvesen GS , Reed JC ( 1998. ) IAPs block apoptotic events induced by caspase&#x2010;8 and cytochrome c by direct inhibition of distinct caspases . Embo J 17 : 2215 &#x2013; 2223 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170566</ArticleId><ArticleId IdType="pubmed">9545235</ArticleId></ArticleIdList></Reference><Reference><Citation>Deveraux QL , Takahashi R , Salvesen GS , Reed JC ( 1997. ) X&#x2010;linked IAP is a direct inhibitor of cell&#x2010;death proteases . Nature 388 : 300 &#x2013; 304 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9230442</ArticleId></ArticleIdList></Reference><Reference><Citation>Digby MR , Kimpton WG , York JJ , Connick TE , Lowenthal JW ( 1996. ) ITA, a vertebrate homologue of IAP that is expressed in T lymphocytes . DNA Cell Biol 15 : 981 &#x2013; 9888 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8945639</ArticleId></ArticleIdList></Reference><Reference><Citation>Enari M , Sakahira H , Yokoyama H , Okawa K , Iwamatsu A , Nagata S ( 1998. ) A caspase&#x2010;activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD . Nature 391 : 43 &#x2013; 50 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9422506</ArticleId></ArticleIdList></Reference><Reference><Citation>Endres M , Namura S , Shimizu&#x2010;Sasamata M , Waeber C , Zhang L , Gomez&#x2010;Isla T , Hyman BT , Moskowitz MA ( 1998. ) Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family . J Cereb Blood Flow Metab 18 : 238 &#x2013; 247 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9498840</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink K , Zhu J , Namura S , Shimizu&#x2010;Sasamata M , Endres M , Ma J , Dalkara T , Yuan J , Moskowitz MA ( 1998. ) Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation . J Cereb Blood Flow Metab 18 : 1071 &#x2013; 1076 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9778183</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleichmann M , Beinroth S , Reed JC , Krajewski S , Schulz JB , Wullner U , Klockgether T , Weller M ( 1998. ) Potassium deprivation&#x2010;induced apoptosis of cerebellar granule neurons: cytochrome c release in the absence of altered expression of Bcl&#x2010;2 family proteins . Cell Physiol Biochem 8 : 194 &#x2013; 201 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9694346</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman Y , Mattson MP ( 1994. ) Staurosporine and K&#x2010;252 compounds protect hippocampal neurons against amyloid beta&#x2010;peptide toxicity and oxidative injury . Brain Res 650 : 170 &#x2013; 174 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7953671</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara H , Friedlander RM , Gagliardini V , Ayata C , Fink K , Huang Z , Shimizu&#x2010;Sasamata M , Yuan J , Moskowitz MA ( 1997. ) Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage . Proc Natl Acad Sci USA 94 : 2007 &#x2013; 2012 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20033</ArticleId><ArticleId IdType="pubmed">9050895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay BA , Wassarman DA , Rubin GM ( 1995. ) Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death . Cell 83 : 1253 &#x2013; 1262 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8548811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann K , Bucher P , Tschopp J ( 1997. ) The CARD domain: a new apoptotic signalling motif . Trends Biochem Sci 22 : 155 &#x2013; 156 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9175472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko M , Saito Y , Saito H , Matsumoto T , Matsuda Y , Vaught JL , Dionne CA , Angeles TS , Glicksman MA , Neff NT , Rotella DP , Kauer JC , Mallamo JP , Hudkins RL , Murakata C ( 1997. ) Neurotrophic 3, 9&#x2010;bis((alkylthio)methyl)&#x2010;and&#x2010;bis(alkoxymethyl)&#x2010;K&#x2010;252a derivatives . J Med Chem 40 : 1863 &#x2013; 1869 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9191963</ArticleId></ArticleIdList></Reference><Reference><Citation>Knusel B , Hefti F ( 1992. ) K&#x2010;252 compounds: modulators of neurotrophin signal transduction . J Neurochem 59 : 1987 &#x2013; 1996 .</Citation><ArticleIdList><ArticleId IdType="pubmed">1431889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH , Freeman TB , Chen EY , Mufson EJ , San&#x2010;berg PR , Hauser RA , Snow B , Olanow CW ( 1998. ) Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease . Mov Disord 13 : 3833 &#x2013; 93 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9613726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuida K , Haydar TF , Kuan CY , Gu Y , Taya C , Karasuyama H , Su MS , Rakic P , Flavell RA ( 1998. ) Reduced apoptosis and cytochrome c&#x2010;mediated caspase activation in mice lacking caspase 9 . Cell 94 : 325 &#x2013; 337 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9708735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuida K , Zheng TS , Na S , Kuan C , Yang D , Karasuyama H , Rakic P , Flavell RA ( 1996. ) Decreased apoptosis in the brain and premature lethality in CPP32&#x2010;deficient mice . Nature 384 : 368 &#x2013; 372 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8934524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre S , Burglen L , Reboullet S , Clermont O , Burlet P , Viollet L , Benichou B , Cruaud C , Millasseau P , Zeviani M , et al. ( 1995. ) Identification and characterization of a spinal muscular atrophy&#x2010;determining gene . Cell 80 : 155 &#x2013; 165 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7813012</ArticleId></ArticleIdList></Reference><Reference><Citation>Liston P , Roy N , Tamai K , Lefebvre C , Baird S , Cherton&#x2010;Horvat G , Farahani R , McLean M , Ikeda JE , MacKenzie A , Korneluk RG ( 1996. ) Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes . Nature 379 : 349 &#x2013; 353 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8552191</ArticleId></ArticleIdList></Reference><Reference><Citation>MacManus JP , Hill IE , Preston E , Rasquinha I , Walker T , Buchan AM ( 1995. ) Differences in DNA fragmentation following transient cerebral or decapitation ischemia in rats . J Cereb Blood Flow Metab 15 : 728 &#x2013; 737 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7673368</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroney AC , Finn JP , Bozyczko&#x2010;Coyne D , O'Kane TM , Neff NT , Tolkovsky AM , Park DS , Yan CY , Troy CM , Greene LA ( 1999. ) CEP&#x2010;1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults . J Neurochem 73 : 1901 &#x2013; 1912 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10537048</ArticleId></ArticleIdList></Reference><Reference><Citation>McGahan L , Hakim AM , Nakabeppu Y , Robertson GS ( 1998. ) Ischemia&#x2010;induced CA1 neuronal death is preceded by elevated FosB and Jun expression and reduced NGFI&#x2010;A and JunB levels . Mol Brain Res 56 : 146 &#x2013; 161 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9602101</ArticleId></ArticleIdList></Reference><Reference><Citation>Namura S , Zhu J , Fink K , Endres M , Srinivasan A , Tomaselli KJ , Yuan J , Moskowitz MA ( 1998. ) Activation and cleavage of caspase&#x2010;3 in apoptosis induced by experimental cerebral ischemia . J Neurosci 18 : 3659 &#x2013; 3668 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793169</ArticleId><ArticleId IdType="pubmed">9570797</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson DW ( 1999. ) Caspase structure, proteolytic substrates, and function during apoptotic cell death . Cell Death Differ 6 : 1028 &#x2013; 1042 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10578171</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson DW , Ali A , Thornberry NA , Vaillancourt JP , Ding CK , Gallant M , Gareau Y , Griffin PR , Labelle M , Lazebnik YA , Munday NA , Raju SM , Smulson ME , Yamin T&#x2010;T , Yu VL , Miller DK ( 1995. ) Identification and inhibition of the ICE/CED&#x2010;3 protease necessary for mammalian apoptosis . Nature 376 : 37 &#x2013; 43 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7596430</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitatori T , Sato N , Waguri S , Karasawa Y , Araki H , Shibanai K , Kominami E , Uchiyama Y ( 1995. ) Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis . J Neurosci 15 : 1001 &#x2013; 1011 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577848</ArticleId><ArticleId IdType="pubmed">7869078</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW , Kordower JH , Freeman TB ( 1996. ) Fetal nigral transplantation as a therapy for Parkinson's disease . Trends Neurosci 19 : 102 &#x2013; 109 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9054056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellizzoni L , Kataoka N , Charroux B , Dreyfuss G ( 1998. ) A novel function for SMN, the spinal muscular atrophy disease gene product, in pre&#x2010;mRNA splicing . Cell 95 : 615 &#x2013; 624 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9845364</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack S , Young L , Bilsland J , Wilkie N , Ellis S , Hefti F , Broughton H , Harper S ( 1999. ) The staurosporine&#x2010;like compound L&#x2010;753, 000 (NB&#x2010;506) potentiates the neurotrophic effects of neurotrophin&#x2010;3 by acting selectively at the TrkA receptor . Mol Pharmacol 56 : 185 &#x2013; 195 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10385700</ArticleId></ArticleIdList></Reference><Reference><Citation>Raff MC , Barres BA , Burne JF , Coles HS , Ishizaki Y , Jacobson MD ( 1993. ) Programmed cell death and the control of cell survival: lessons from the nervous system . Science 262 : 695 &#x2013; 700 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8235590</ArticleId></ArticleIdList></Reference><Reference><Citation>Rano TA , Timkey T , Peterson EP , Rotonda J , Nicholson DW , Becker JW , Chapman KT , Thornberry NA ( 1997. ) A combinatorial approach for determining protease specificities: application to interleukin&#x2010;1 beta converting enzyme (ICE) . Chem Biol 4 : 149 &#x2013; 155 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9190289</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotonda J , Nicholson DW , Fazil KM , Gallant M , Gareau Y , Labelle M , Peterson EP , Rasper DM , Ruel R , Vaillancourt JP , Thornberry NA , Becker JW ( 1996. ) The three&#x2010;dimensional structure of apopain/CPP32, a key mediator of apoptosis . Nat Struct Biol 3 : 619 &#x2013; 625 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8673606</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy N , Deveraux QL , Takahashi R , Salvesen GS , Reed JC ( 1997. ) The c&#x2010;IAP&#x2010;1 and c&#x2010;IAP&#x2010;2 proteins are direct inhibitors of specific caspases . Embo J 16 : 6914 &#x2013; 6925 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170295</ArticleId><ArticleId IdType="pubmed">9384571</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy N , Mahadevan MS , McLean M , Shutler G , Yaraghi Z , Farahani R , Baird S , Besner&#x2010;Johnston A , Lefebvre C , Kang X , et al. ( 1995. ) The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy . Cell 80 : 167 &#x2013; 178 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7813013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakahira H , Enari M , Nagata S ( 1998. ) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis . Nature 391 : 96 &#x2013; 99 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9422513</ArticleId></ArticleIdList></Reference><Reference><Citation>Schierle GS , Hansson O , Leist M , Nicotera P , Widner H , Brundin P ( 1999. ) Caspase inhibition reduces apoptosis and increases survival of nigral transplants . Nat Med 5 : 97 &#x2013; 100 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9883846</ArticleId></ArticleIdList></Reference><Reference><Citation>Schotte P , Declercq W , Van Huffel S , Vandenabeele P , Beyaert R ( 1999. ) Non&#x2010;specific effects of methyl ketone peptide inhibitors of caspases . FEBS Lett 442 : 117 &#x2013; 121 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9923616</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB , Beinroth S , Weller M , Wullner U , Klockgether T ( 1998. ) Endonucleolytic DNA fragmentation is not required for apoptosis of cultured rat cerebellar granule neurons . Neurosci Lett 245 : 9 &#x2013; 12 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9596343</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB , Weller M , Klockgether T ( 1996. ) Potassium deprivation&#x2010;induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE&#x2010;like protease activity, and reactive oxygen species . J Neurosci 16 : 4696 &#x2013; 4706 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579033</ArticleId><ArticleId IdType="pubmed">8764657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB , Weller M , Matthews RT , Heneka MT , Groscurth P , Martinou JC , Lommatzsch J , von Coelln R , W&#xfc;llner U , L&#xf6;schmann PA , Beal MF , Dichgans J , Klockgether T ( 1998. ) Extended therapeutic window for caspase inhibition and synergy with MK&#x2010;801 in the treatment of cerebral histotoxic hypoxia . Cell Death Differ 5 : 847 &#x2013; 857 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10203688</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M , Beinroth S , Gleichmann M , Liston P , Korneluk RG , MacKenzie AE , Bahr M , Klockgether T , Robertson GS , Weller M , Schulz JB ( 1999. ) Adenovirus&#x2010;mediated gene transfer of inhibitors of apoptosis protein delays apoptosis in cerebellar granule neurons . J Neurochem 72 : 292 &#x2013; 301 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9886081</ArticleId></ArticleIdList></Reference><Reference><Citation>Slee EA , Harte MT , Kluck RM , Wolf BB , Casiano CA , Newmeyer DD , Wang HG , Reed JC , Nicholson DW , Alnemri ES , Green DR , Martin SJ ( 1999. ) Ordering the cytochrome c&#x2010;initiated caspase cascade: hierarchical activation of caspases&#x2010;2, &#x2010;3, &#x2010;6, &#x2010;7, &#x2010;8, and &#x2010;10 in a caspase&#x2010;9&#x2010;dependent manner . J Cell Biol 144 : 281 &#x2013; 292 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132895</ArticleId><ArticleId IdType="pubmed">9922454</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith&#x2010;Swintosky VL , Kraemer PJ , Bruce AJ , McCants N , Maki A , Brown RW , Alcala M , Goodman Y , Slevin JT , Mattson MP ( 1996. ) Bacterial alkaloids mitigate seizureinduced hippocampal damage and spatial memory deficits . Exp Neurol 141 : 287 &#x2013; 296 .</Citation><ArticleIdList><ArticleId IdType="pubmed">8812162</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer JE , Azbill RD , Knapp PE ( 1999. ) Activation of the caspase&#x2010;3 apoptotic cascade in traumatic spinal cord injury . Nat Med 5 : 943 &#x2013; 946 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10426320</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R , Deveraux Q , Tamm I , Welsh K , Assa&#x2010;Munt N , Salvesen GS , Reed JC ( 1998. ) A single BIR domain of XIAP sufficient for inhibiting caspases . J Biol Chem 273 : 7787 &#x2013; 7790 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9525868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari M , Quan LT , O'Rourke K , Desnoyers S , Zeng Z , Beidler DR , Poirier GG , Salvesen GS , Dixit VM ( 1995. ) Yama/CPP32 beta, a mammalian homolog of CED&#x2010;3, is a CrmA&#x2010;inhibitable protease that cleaves the death substrate poly (ADP&#x2010;ribose) polymerase . Cell 81 : 801 &#x2013; 809 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7774019</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornberry NA , Rano TA , Peterson EP , Rasper DM , Timkey T , Garcia&#x2010;Calvo M , Houtzager VM , Nordstrom PA , Roy S , Vaillancourt JP , Chapman KT , Nicholson DW ( 1997. ) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis . J Biol Chem 272 : 17907 &#x2013; 17911 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9218414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiese S , Digby MR , Gunnersen JM , Gotz R , Pei G , Holtmann B , Lowenthal J , Sendtner M ( 1999. ) The anti&#x2010;apoptotic protein ITA is essential for NGF&#x2010;mediated survival of embryonic chick neurons . Nat Neurosci 2 : 978 &#x2013; 983 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10526336</ArticleId></ArticleIdList></Reference><Reference><Citation>Worley PF , Christy BA , Nakabeppu Y , Bhat RV , Cole AJ , Baraban JM ( 1991. ) Constitutive expression of zif268 in neocortex is regulated by synaptic activity . Proc Natl Acad Sci USA 88 : 5106 &#x2013; 5110 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51820</ArticleId><ArticleId IdType="pubmed">1828891</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D , Bureau Y , McIntyre DC , Nicholson DW , Liston P , Zhu Y , Fong WG , Crocker SJ , Korneluk RG , Robertson GS ( 1999. ) Attenuation of ischemia&#x2010;induced cellular and behavioral deficits by X chromosome&#x2010;linked inhibitor of apoptosis protein overexpression in the rat hippocampus . J Neurosci 19 : 5026 &#x2013; 5033 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782658</ArticleId><ArticleId IdType="pubmed">10366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu DG , Crocker SJ , Doucet JP , St&#x2010;Jean M , Tamai K , Hakim AM , Ikeda JE , Liston P , Thompson CS , Korneluk RG , MacKenzie A , Robertson GS ( 1997. ) Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus . Nat Med 3 : 997 &#x2013; 1004 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu DG , Korneluk RG , Tamai K , Wigle N , Hakim A , Mackenzie A , Robertson GS ( 1997. ) Distribution of neuronal apoptosis inhibitory protein&#x2010;like immunoreactivity in the rat central nervous system . J Comp Neurol 382 : 247 &#x2013; 259 .</Citation><ArticleIdList><ArticleId IdType="pubmed">9183692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakovlev AG , Knoblach SM , Fan L , Fox GB , Goodnight R , Faden AI ( 1997. ) Activation of CPP32&#x2010;like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury . J Neurosci 17 : 7415 &#x2013; 7424 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573442</ArticleId><ArticleId IdType="pubmed">9295387</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan GM , Ni B , Weller M , Wood KA , Paul SM ( 1994. ) Depolarization or glutamate receptor activation blocks apoptotic cell death of cultured cerebellar granule neurons . Brain Res 656 : 43 &#x2013; 51 .</Citation><ArticleIdList><ArticleId IdType="pubmed">7804844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10764737</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>24</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons.</ArticleTitle><Pagination><StartPage>18195</StartPage><EndPage>18200</EndPage><MedlinePgn>18195-200</MedlinePgn></Pagination><Abstract><AbstractText>Many cases of early-onset inherited Alzheimer's disease (AD) are caused by mutations in the presenilin-1 (PS1) gene. PS1 mutations may perturb cellular Ca(2+) homeostasis and thereby render neurons vulnerable to excitotoxicity and apoptosis. We now report that PC12 cells expressing PS1 mutations and primary hippocampal neurons from PS1 mutant knockin mice exhibit greatly increased levels of ryanodine receptors (RyR) and enhanced Ca(2+) release following stimulation with caffeine. Double-labeling immunostaining and co-immunoprecipitation analyses indicate that PS1 and RyR are colocalized and interact physically. Caffeine treatment sensitizes neurons expressing mutant PS1 to apoptosis induced by amyloid beta-peptide, a neurotic peptide linked to the pathogenesis of AD. When taken together with recent evidence for alterations in RyR in brains of AD patients, our data suggest that PS1 mutations may promote neuronal degeneration in AD by increasing transcription and translation of RyR and altering functional properties of ryanodine-sensitive Ca(2+) pools.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Sanders-Brown Research Center on Aging, University of Kentucky, Lexington, Kentucky 40536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayne</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Holden</LastName><ForeName>C P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Geiger</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG10386</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10764737</ArticleId><ArticleId IdType="doi">10.1074/jbc.M000040200</ArticleId><ArticleId IdType="pii">S0021-9258(19)83172-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10768568</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J Nucl Med</ISOAbbreviation></Journal><ArticleTitle>PET: the merging of biology and imaging into molecular imaging.</ArticleTitle><Pagination><StartPage>661</StartPage><EndPage>681</EndPage><MedlinePgn>661-81</MedlinePgn></Pagination><Abstract><AbstractText>PET and SPECT are molecular imaging techniques that use radiolabeled molecules to image molecular interactions of biological processes in vivo. PET imaging technologies have been developed to provide a pathway to the patient from the experimental paradigms of biological and pharmaceutical sciences in genetically engineered and tissue transplanted mouse models of disease. PET provides a novel way for molecular therapies and molecular diagnostics to come together in the discovery of molecules that can be used in low mass amounts to image the function of a target and, by elevating the mass, to pharmacologically modify the function of the target. In both cases, the molecules are the same or analogs of each other. PET can be used to titrate drugs to their sites of action within organ systems in vivo and to assay biological outcomes of the processes being modified in the mouse and the patient. The goal is to provide a novel way to improve the rates of discovery and approval of radiopharmaceuticals and pharmaceuticals. Extending this relationship into clinical practice can improve drug use by providing molecular diagnostics in concert with molecular therapeutics. Diseases are biological processes, and molecular imaging with PET is sensitive and informative to these processes. This sensitivity is exemplified by the detection of disease with PET without evidence of anatomic changes on CT and MRI. These biological changes are seen early in the course of disease, even in asymptomatic stages, as illustrated by the metabolic abnormalities detected with PET and FDG in Huntington's and familial Alzheimer's diseases 7 and 5 y, respectively, before symptoms appear. Differentiation of viable from nonviable tissue is fundamentally a metabolic question, as shown by the use of PET to differentiate patients with coronary artery disease who will benefit from revascularization from those who will not. Although beginning within a specific organ, cancer is a systemic disease the most devastating consequences of which result from metastases. Whole-body PET imaging with FDG enables inspection of glucose metabolism in all organ systems in a single examination to improve the detection and staging of cancer, selection of therapy, and assessment of therapeutic response. In lung and colorectal cancers, melanoma, and lymphoma, PET FDG improves the accuracy of detection and staging from 8% to 43% over conventional work-ups and results in treatment changes in 20%-40% of the patients, depending on the clinical question. Approximately 65% are upstaged because unsuspected metastases are detected, and 35% are downstaged because a structural diagnosis of lesions is changed from malignant to benign. Similar results are now being shown for other cancers. The main difference between CT, sonography, MRI, and PET or SPECT is not technologic but, rather, a difference between detecting and characterizing a disease by its anatomic features as opposed to its biology. The importance and success of developing new molecular imaging probes is increasing as PET becomes integral to the study of the integrative mammalian biology of disease and as molecular therapies targeting the biological processes of disease are developed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, School of Medicine, UCLA, Los Angeles, California 90095-1735, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003327" MajorTopicYN="N">Coronary Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="Y">Tomography, Emission-Computed</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>78</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10768568</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10771010</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-2999</ISSN><JournalIssue CitedMedium="Print"><Volume>393</Volume><Issue>1-3</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>170</EndPage><MedlinePgn>165-70</MedlinePgn></Pagination><Abstract><AbstractText>The basic symptoms of Alzheimer's dementia, i.e., a loss in cognitive function, are due to impaired nicotinic cholinergic neurotransmission. To compensate for this impairment by drug treatment, blockers of the acetylcholine-degrading enzyme acetylcholinesterase are applied, even though this approach obviously is prone to many side-effects, including those of muscarinic nature. We have recently described a novel class of nicotinic acetylcholine receptor ligands which, similar to the action of benzodiazepines on GABA(A) receptors, allosterically potentiate submaximal nicotinic responses. The sensitizing effect is a consequence of facilitated channel opening in the presence of allosterically potentiating ligand (APL). Representative members of this class of ligands are the plant alkaloids physostigmine, galanthamine, and codeine. Because APLs could enhance nicotinic neurotransmission under conditions of reduced secretion and/or increased degradation of acetylcholine or reduced acetylcholine-sensitivity of nicotinic acetylcholine receptors, they could have a preventive and corrective action on impaired but still functioning nicotinic neurotransmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maelicke</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Institute of Physiological Chemistry and Pathobiochemistry, Johannes-Gutenberg University Medical School, 6 Duesbergweg, D-55099, Mainz, Germany. alfred.maelicke@uni-mainz.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albuquerque</LastName><ForeName>E X</ForeName><Initials>EX</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018678">Cholinergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018678" MajorTopicYN="N">Cholinergic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>19</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10771010</ArticleId><ArticleId IdType="doi">10.1016/s0014-2999(00)00093-5</ArticleId><ArticleId IdType="pii">S0014-2999(00)00093-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10781096</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.</ArticleTitle><Pagination><StartPage>4897</StartPage><EndPage>4902</EndPage><MedlinePgn>4897-902</MedlinePgn></Pagination><Abstract><AbstractText>Filamentous inclusions made of alpha-synuclein constitute the defining neuropathological characteristic of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Rare familial cases of Parkinson's disease are associated with mutations A53T and A30P in alpha-synuclein. We report here the assembly properties and secondary structure characteristics of recombinant alpha-synuclein. Carboxy-terminally truncated human alpha-synuclein (1-87) and (1-120) showed the fastest rates of assembly, followed by human A53T alpha-synuclein, and rat and zebra finch alpha-synuclein. Wild-type human alpha-synuclein and the A30P mutant showed slower rates of assembly. Upon shaking, filaments formed within 48 h at 37 degrees C. The related proteins beta- and gamma-synuclein only assembled after several weeks of incubation. Synthetic human alpha-synuclein filaments were decorated by an antibody directed against the carboxy-terminal 10 amino acids of alpha-synuclein, as were filaments extracted from dementia with Lewy bodies and multiple system atrophy brains. Circular dichroism spectroscopy indicated that alpha-synuclein undergoes a conformational change from random coil to beta-sheet structure during assembly. X-ray diffraction and electron diffraction of the alpha-synuclein assemblies showed a cross-beta conformation characteristic of amyloid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serpell</LastName><ForeName>L C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berriman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jakes</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497606">Snca protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051845">gamma-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020308" MajorTopicYN="N">Songbirds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051845" MajorTopicYN="N">gamma-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10781096</ArticleId><ArticleId IdType="pmc">PMC18329</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.9.4897</ArticleId><ArticleId IdType="pii">97/9/4897</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lewy F. In: Handbuch der Neurologie. Lewandowsky M, Abelsdorff G, editors. Vol. 3. Berlin: Springer; 1912. pp. 920&#x2013;933.</Citation></Reference><Reference><Citation>Tr&#xe9;tiakoff M C. Ph.D. thesis. University of Paris; 1919.</Citation></Reference><Reference><Citation>Okazaki H, Lipkin L E, Aronson S M. J Neuropathol Exp Neurol. 1961;21:442&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">13730588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosaka K. Acta Neuropathol. 1978;42:127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">654884</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy P E, Tennyson V M. J Neuropathol Exp Neurol. 1965;24:398&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">6022132</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos M H, Lavedan C, Leroy E, Ide S E, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Science. 1997;276:2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M G, Schmidt M L, Lee V M-Y, Trojanowski J Q, Jakes R, Goedert M. Nature (London) 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M G, Crowther R A, Jakes R, Hasegawa M, Goedert M. Proc Natl Acad Sci USA. 1998;95:6469&#x2013;6473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Neurosci Lett. 1998;249:180&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezey E, Dehejia A, Harta G, Papp M I, Polymeropoulos M H, Brownstein M J. Nat Med. 1998;4:755&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662355</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M G, Crowther R A, Jakes R, Cairns N J, Lantos P L, Goedert M. Neurosci Lett. 1998;251:205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu P-H, Galvin J E, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski J Q, Lee V M-Y. Ann Neurol. 1998;44:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749615</ArticleId></ArticleIdList></Reference><Reference><Citation>U&#xe9;da K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero D A, Kondo J, Ihara Y, Saitoh T. Proc Natl Acad Sci USA. 1993;90:11282&#x2013;11286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47966</ArticleId><ArticleId IdType="pubmed">8248242</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes R, Spillantini M G, Goedert M. FEBS Lett. 1994;345:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8194594</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobe T, Nakajo S, Tanaka A, Mitoya A, Omata K, Nakaya K, Tomita M, Nakamura Y. J Neurochem. 1992;59:1624&#x2013;1629.</Citation><ArticleIdList><ArticleId IdType="pubmed">1402909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Liu Y E, Jia T, Wang M, Liu J, Xiao G, Joseph B K, Rosen C, Shi Y E. Cancer Res. 1997;57:759&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">9044857</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman V L, Hunter H J A, Pinon L G P, Thompson J, Privalova E M, Ninkina N N, Davies A M. J Neurosci. 1998;18:9335&#x2013;9341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792889</ArticleId><ArticleId IdType="pubmed">9801372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R, Kuhn W, M&#xfc;ller T, Woitalla D, Graeber M, K&#xf6;sel S, Przuntek H, Epplen J T, Sch&#xf6;ls L, Riess O. Nat Genet. 1998;18:106&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroteaux L, Scheller R H. Mol Brain Res. 1991;11:335&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">1661825</ArticleId></ArticleIdList></Reference><Reference><Citation>George J M, Jin H, Woods W S, Clayton D F. Neuron. 1995;15:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646890</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther R A, Jakes R, Spillantini M G, Goedert M. FEBS Lett. 1998;436:309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">9801138</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf O M A, Jakes R, Curran M D, Wallace A. FEBS Lett. 1998;440:67&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862427</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway K A, Harper J D, Lansbury P T. Nat Med. 1998;4:1318&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson B I, Uryu K, Trojanowski J Q, Lee V M-Y. J Biol Chem. 1999;274:7619&#x2013;7622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075647</ArticleId></ArticleIdList></Reference><Reference><Citation>Narhi L, Wood S J, Steavenson S, Jiang Y, Wu G M, Anafi D, Kaufman S A, Martin F, Sitney K, Denis P, et al. J Biol Chem. 1999;274:9843&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood S J, Wypych J, Steavenson S, Louis J-C, Citron M, Biere A L. J Biol Chem. 1999;274:19509&#x2013;19512.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391881</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway K A, Lee S-J, Rochet J-C, Ding T T, Williamson R E, Lansbury P T. Proc Natl Acad Sci USA. 2000;97:571&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15371</ArticleId><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen P H, Nielsen M H, Jakes R, Dotti C G, Goedert M. J Biol Chem. 1998;273:26292&#x2013;26294.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen A S, Calkins E. Nature (London) 1959;183:1202&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">13657054</ArticleId></ArticleIdList></Reference><Reference><Citation>Eanes E D, Glenner G G. J Histochem Cytochem. 1968;16:673&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">5723775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, Serpell L C, Bartlam M, Fraser P E, Pepys M B, Blake C C F. J Mol Biol. 1997;273:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes R, Crowther R A, Lee V M-Y, Trojanowski J Q, Iwatsubo T, Goedert M. Neurosci Lett. 1999;269:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821633</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie A G W. Joint CCP4 and ESF&#x2013;EAMCB Newsletter on Protein Crystallography. 1992. , No. 26.</Citation></Reference><Reference><Citation>Crowther R A. Proc Natl Acad Sci USA. 1991;88:2288&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M, Nakajo S, Tu P-H, Tomita T, Nakaya K, Lee V M-Y, Trojanowski J Q, Iwatsubo T. Am J Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Gai W P, Power J H T, Blumbergs P C, Culvenor J G, Jensen P H. J Neurochem. 1999;73:2093&#x2013;2100.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537069</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini M G, Cairns N J, Crowther R A. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Kabat J, Wischik C M. EMBO J. 1993;12:365&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC413214</ArticleId><ArticleId IdType="pubmed">7679073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoln S, Gwinn-Hardy K, Goudreau J, Chartier-Harlin M C, Baker M, Mouroux V, Richard F, Dest&#xe9;e A, Becquet E, Amouyel P, et al. Neurosci Lett. 1999;259:65&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoln S, Crook R, Chartier-Harlin M C, Gwinn-Hardy K, Baker M, Mouroux V, Richard F, Becquet E, Amouyel P, Dest&#xe9;e A, et al. Neurosci Lett. 1999;269:107&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430516</ArticleId></ArticleIdList></Reference><Reference><Citation>Flowers J M, Leigh P N, Davies A M, Ninkina N N, Buchman V L, Vaughan J, Wood N W, Powell J F. Neurosci Lett. 1999;274:21&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10530510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C M, Bishop J F, Leng Y, Chock P B, Chase T N, Mouradian M M. J Biol Chem. 1999;274:33855&#x2013;33858.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567343</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagorski M G, Yang J, Shao H, Ma K, Zeng H, Hong A. Methods Enzymol. 1999;309:189&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507025</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio T R, Cashikar A G, Moslehi J J, Kowal A S, Lindquist S L. Methods Enzymol. 1999;309:649&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507053</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb P H, Zhen W, Poon A W, Conway K A, Lansbury P T. Biochemistry. 1996;35:13709&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan K-M, Baldwin M A, Nguyen J T, Gaseet M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick R J, Cohen F E, Prusiner S B. Proc Natl Acad Sci USA. 1993;90:10962&#x2013;10966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47901</ArticleId><ArticleId IdType="pubmed">7902575</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrow C J, Zagorski M G. Science. 1991;253:179&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1853202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbich C, Kisters-Woike B, Reed J, Masters C L, Beyreuther K. J Mol Biol. 1991;218:149&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">2002499</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes A J, Parker K D, Atkins E D T, Beighton E A J. J Mol Biol. 1968;32:343&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">5643439</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake C C F, Serpell L C. Structure. 1996;4:989&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">8805583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, Blake C C F. Quart Rev Biophys. 1998;31:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9717197</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini M G, Davies S W. Curr Opin Neurobiol. 1998;8:619&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">9811617</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz M F. Trends Biochem Sci. 1999;24:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10098399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner D A, Inouye H, Duffy L K, Sinclair A, Lind M, Selkoe D J. Proc Natl Acad Sci USA. 1987;84:6953&#x2013;6957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299203</ArticleId><ArticleId IdType="pubmed">3477820</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweers O, Sch&#xf6;nbrunn-Hanebeck E, Marx A, Mandelkow E. J Biol Chem. 1994;269:24290&#x2013;24297.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10781099</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred.</ArticleTitle><Pagination><StartPage>4920</StartPage><EndPage>4925</EndPage><MedlinePgn>4920-5</MedlinePgn></Pagination><Abstract><AbstractText>Familial Danish dementia (FDD), also known as heredopathia ophthalmo-oto-encephalica, is an autosomal dominant disorder characterized by cataracts, deafness, progressive ataxia, and dementia. Neuropathological findings include severe widespread cerebral amyloid angiopathy, hippocampal plaques, and neurofibrillary tangles, similar to Alzheimer's disease. N-terminal sequence analysis of isolated leptomeningeal amyloid fibrils revealed homology to ABri, the peptide originated by a point mutation at the stop codon of gene BRI in familial British dementia. Molecular genetic analysis of the BRI gene in the Danish kindred showed a different defect, namely the presence of a 10-nt duplication (795-796insTTTAATTTGT) between codons 265 and 266, one codon before the normal stop codon 267. The decamer duplication mutation produces a frame-shift in the BRI sequence generating a larger-than-normal precursor protein, of which the amyloid subunit (designated ADan) comprises the last 34 C-terminal amino acids. This de novo-created amyloidogenic peptide, associated with a genetic defect in the Danish kindred, stresses the importance of amyloid formation as a causative factor in neurodegeneration and dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, New York University School of Medicine, New York 10016, USA. vidalr01@popmail.med.nyu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rostagno</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Holton</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Bek</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bojsen-M&#xf8;ller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Braendgaard</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Plant</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ghiso</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Frangione</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AF246221</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>AG10953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008721</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08721</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG005891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120083">ITM2B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020413" MajorTopicYN="N">3' Untranslated Regions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020440" MajorTopicYN="N">Gene Duplication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10781099</ArticleId><ArticleId IdType="pmc">PMC18333</ArticleId><ArticleId IdType="doi">10.1073/pnas.080076097</ArticleId><ArticleId IdType="pii">080076097</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Str&#xf6;mgrem E, Dalby A, Dalby M, Ranheim B. Acta Neurol Scand. 1970;46,(Suppl. 43):97&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">5457846</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf6;mgrem E. In: Handbook of Clinical Neurology. Vinken P J, Bruyn G W, editors. Amsterdam: Elsevier; 1981. pp. 150&#x2013;152.</Citation></Reference><Reference><Citation>Plant G, Esiri M M. In: The Neuropathology of Dementia. Esiri M M, Morris J H, editors. Cambridge, U.K.: Cambridge Univ. Press; 1997. pp. 260&#x2013;276.</Citation></Reference><Reference><Citation>Vidal R, Frangione B, Rostagno A, Mead S, R&#xe9;v&#xe9;sz T, Plant G, Ghiso J. Nature (London) 1999;399:776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391242</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleersnijder W, Hong G, Cortvrindt R, Poirier C, Tylzanowski P, Pittois K, Van Marck E, Merregaert J. J Biol Chem. 1996;271:19475&#x2013;19482.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702637</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittois K, Deleersnijder W, Merregaert J. Gene. 1998;217:141&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">9795190</ArticleId></ArticleIdList></Reference><Reference><Citation>Price D. Nature (London) 1999;399:A3&#x2013;A5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392574</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, Garzuly F, Budka H, Lalowski M, Linke R, Brittig F, Frangione B, Wisniewski T. Am J Pathol. 1996;148:361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861701</ArticleId><ArticleId IdType="pubmed">8579098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B, Piccardo P, Spillantini M,G, Ichimiya Y, Porro M, Perini F, Kitamoto T, Tateishi J, Seiler C, Frangione B, et al. Proc Natl Acad Sci USA. 1996;93:744&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40125</ArticleId><ArticleId IdType="pubmed">8570627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendon C, Ashall F, Goate A. J Am Med Assoc. 1997;277:825&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052714</ArticleId></ArticleIdList></Reference><Reference><Citation>Plant G T, R&#xe9;v&#xe9;sz T, Barnard R O, Harding A E, Gautier-Smith P C. Brain. 1990;113:721&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2364266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-H, Wang R, Gordon D, Bass J, Steiner D, Lynn D, Thinakaran G, Meredith S, Sisodia S. Nat Neurosci. 1999;2:984&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou A, Webb G, Zhu X, Steiner D F. J Biol Chem. 1999;274:20745&#x2013;20748.</Citation><ArticleIdList><ArticleId IdType="pubmed">10409610</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R, Verkkoniemi A, Perez-Tur J, Metha N, Baker M, Houlden H, Farrer M, Hutton M, Lincoln S, Hardy J, et al. Nat Med. 1998;4:452&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiso J, Haltia M, Prelli F, Novello J, Frangione B. Biochem J. 1990;272:827&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149782</ArticleId><ArticleId IdType="pubmed">2176481</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R B, Goren H, Cohen M, Richardson L, Tresser N, Lynn A, Gali M, Estes M, Gambetti P. Ann Neurol. 1997;41:307&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">9066351</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, Uchino M, Ando M. Pathol Int. 1995;45:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704238</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10783238</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch.</ArticleTitle><Pagination><StartPage>205</StartPage><EndPage>211</EndPage><MedlinePgn>205-11</MedlinePgn></Pagination><Abstract><AbstractText>Mutations in the presenilin-1 (PS1) gene are associated with Alzheimer's disease and cause increased secretion of the neurotoxic amyloid-beta peptide (Abeta). Critical intramembraneous aspartates at residues 257 and 385 are required for the function of PS1 protein. Here we investigate the biological function of a naturally occurring PS1 splice variant (PS1 Deltaexon 8), which lacks the critical aspartate 257. Cell lines that stably express PS1 Deltaexon 8 or a PS1 protein in which aspartate residue 257 is mutated secrete significant levels of Abeta, whereas Abeta generation is severely reduced in cells transfected with PS1 containing a mutation of aspartate 385. In contrast, endoproteolytic processing of Notch is almost completely inhibited in cell lines expressing any of the PS1 variants that lack one of the critical aspartates. These data indicate that PS1 may differentially facilitate gamma-secretase-mediated generation of Abeta and endoproteolysis of Notch.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Adolf Butenandt-Institute, Department of Biochemistry, Laboratory for Alzheimer's Disease Research, Ludwig-Maximilians-University, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Romig</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Baader</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grim</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Baumeister</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="Y">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10783238</ArticleId><ArticleId IdType="doi">10.1038/35008626</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10784462</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging.</ArticleTitle><Pagination><StartPage>708</StartPage><EndPage>714</EndPage><MedlinePgn>708-14</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors report findings from a study of 5,092 community residents who constituted 90% of the elderly resident population of Cache County, Utah.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The 5,092 participants, who were 65 years old or older, were screened for dementia. Based on the results of this screen, 1,002 participants (329 with dementia and 673 without dementia) underwent comprehensive neuropsychiatric examinations and were rated on the Neuropsychiatric Inventory, a widely used method for ascertainment and classification of dementia-associated mental and behavioral disturbances.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 329 participants with dementia, 214 (65%) had Alzheimer's disease, 62 (19%) had vascular dementia, and 53 (16%) had another DSM-IV dementia diagnosis; 201 (61%) had exhibited one or more mental or behavioral disturbances in the past month. Apathy (27%), depression (24%), and agitation/aggression (24%) were the most common in participants with dementia. These disturbances were almost four times more common in participants with dementia than in those without. Only modest differences were observed in the prevalence of mental or behavioral disturbances in different types of dementia or at different stages of illness: participants with Alzheimer's disease were more likely to have delusions and less likely to have depression. Agitation/aggression and aberrant motor behavior were more common in participants with advanced dementia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">On the basis of their findings in this large community population of elderly people, the authors conclude that a wide range of dementia-associated mental and behavioral disturbances afflict the majority of individuals with dementia. Because of their frequency and their adverse effects on patients and their caregivers, these disturbances should be ascertained and treated in all cases of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>C G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Neuropsychiatry Service, Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA. kostas@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tschanz</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Steffens</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG11380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH56511</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014589" MajorTopicYN="N" Type="Geographic">Utah</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.157.5.708</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10794848</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Midlife blood pressure and dementia: the Honolulu-Asia aging study.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>55</EndPage><MedlinePgn>49-55</MedlinePgn></Pagination><Abstract><AbstractText>We studied the association of mid-life blood pressure to late age dementia, specifically Alzheimer's disease and vascular dementia. Data are from the cohort of 3703 Japanese-American men who were followed in the Honolulu Heart Program (HHP;1965-1971), and subsequently re-examined in 1991 for dementia. We assessed the risk (odds ratio (95% CI)) for dementia associated with categories of systolic (SBP) and diastolic blood pressure (DBP), stratified by never/ever treatment with anti-hypertensive medications, and adjusting for age, education, apolipoprotein epsilon allele, smoking and alcohol intake. Among those never treated (57% sample), the risk for dementia was OR 95% CI 3.8 (1.6-8.7) for DBP of 90-94 mm Hg, and 4. 3 (1.7-10.8) for DBP of 95 mmHg and over compared to those with DBP of 80 to 89 mm Hg. Compared to those with SBP of 110 to 139 mm Hg, the risk for dementia was 4.8 (2.0-11.0) in those with SBP 160 mm Hg and higher. Blood pressure was not associated with the risk for dementia in treated men. These results were consistent for Alzheimer's disease and vascular dementia. This study suggests elevated levels of blood pressure in middle age can increase the risk for late age dementia in men never treated with anti-hypertensive medication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>L J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Epidemiology, Demography and Biometry Program, National Institute on Aging, National Institutes of Health, Gateway Building 3C-309, 7201 Wisconsin Avenue, Bethesda, MD 20892, USA. LaunerL@exmur.nia.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Petrovitch</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Masaki</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Foley</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>L R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Havlik</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01-AG-42149</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HR-02901</GrantID><Acronym>HR</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001213" MajorTopicYN="N">Asian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="Y">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003971" MajorTopicYN="N">Diastole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006254" MajorTopicYN="N" Type="Geographic">Hawaii</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013599" MajorTopicYN="N">Systole</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10794848</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(00)00096-8</ArticleId><ArticleId IdType="pii">S0197-4580(00)00096-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10797534</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0360-4012</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons.</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>327</EndPage><MedlinePgn>321-7</MedlinePgn></Pagination><Abstract><AbstractText>It has been shown that estrogen replacement in menopausal women is effective in slowing down the progression of cognitive impairment in Alzheimer's disease. Although recent studies have demonstrated the neuroprotective effects of estrogen, the precise mechanism of neuroprotection has not been elucidated. In the present study, we show that the phosphatidylinositol 3-kinase (PI3-K) cascade is involved in the neuroprotective mechanism stimulated by estrogen. Exposure to glutamate reduced the viability of rat primary cortical neurons. Pretreatment with 10 nM 17beta-estradiol significantly attenuated the glutamate-induced toxicity. This neuroprotective effect of 17beta-estradiol was blocked by co-administration with LY294002, a selective PI3-K inhibitor, but not by co-administration with PD98059, a selective mitogen activated protein kinase kinase inhibitor. Pretreatment with ICI182780, a specific estrogen receptor antagonist, also blocked the neuroprotection. Immunoblotting assay revealed that treatment with 17beta-estradiol induced the phosphorylation of Akt/PKB, an effector immediately downstream of PI3-K. These results suggest that PI3-K mediates the neuroprotective effect of 17beta-estradiol against glutamate-induced neurotoxicity.</AbstractText><CopyrightInformation>Copyright 2000 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawada</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kihara</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nakamizo</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Akaike</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shimohama</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002867">Chromones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004965">Estrogen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009025">Morpholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>22X328QOC4</RegistryNumber><NameOfSubstance UI="D000077267">Fulvestrant</NameOfSubstance></Chemical><Chemical><RegistryNumber>31M2U1DVID</RegistryNumber><NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>SJE1IO5E3I</RegistryNumber><NameOfSubstance UI="C093973">2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004965" MajorTopicYN="N">Estrogen Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077267" MajorTopicYN="N">Fulvestrant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10797534</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1097-4547(20000501)60:3&lt;321::AID-JNR6&gt;3.0.CO;2-T</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1097-4547(20000501)60:3&lt;321::AID-JNR6&gt;3.0.CO;2-T</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10799482</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>19</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line.</ArticleTitle><Pagination><StartPage>14077</StartPage><EndPage>14083</EndPage><MedlinePgn>14077-83</MedlinePgn></Pagination><Abstract><AbstractText>A growing number of reports suggest that elevated levels of extracellular Alzheimer's beta-amyloid protein alter the homeostasis of free [Ca(2+)](i) in different cell types of the mammalian brain. In line with these results, we have previously shown that AbetaP[1-40] forms cation-selective channels (Ca(2+) included) across artificial planar bilayers formed from acidic phospholipids and across excised membrane patches from immortalized hypothalamic GnRH neurons (GT1-7 cells), suggesting that the nonregulated Ca(2+)-influx through these spontaneously formed "amyloid channels" may provide a mechanism to explain its toxicity (1). We have now found and report here that the application of AbetaP[1-40] to GT1-7 neurons consistently elevates [Ca(2+)](i) levels. We also found that human islet amylin and the prion protein fragment (PrP106-126), peptides that acquire beta-pleated sheet conformation in water solutions and have been reported to form ion channels across planar bilayer membranes, also increase cytosolic free calcium in GT1-7 neurons. Searching for protective agents, we found that soluble cholesterol, known to decrease the fluidity of the cell membrane, inhibits AbetaP[1-40]-evoked [Ca(2+)](i) rise. These results suggest that unregulated Ca(2+) entry across amyloid channels may be a common mechanism causing cell death, not only in diseases of the third age, including Alzheimer's disease and type 2 diabetes mellitus, but also in prion-induced diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawahara</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neurobiology, Tokyo Metropolitan Institute for Neuroscience, 2-6 Musashidai, Fuchu, Tokyo 183-8526, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Arispe</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058228">Islet Amyloid Polypeptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>33515-09-2</RegistryNumber><NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058228" MajorTopicYN="N">Islet Amyloid Polypeptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007515" MajorTopicYN="N">Islets of Langerhans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10799482</ArticleId><ArticleId IdType="doi">10.1074/jbc.275.19.14077</ArticleId><ArticleId IdType="pii">S0021-9258(19)80571-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10801872</PMID><DateCompleted><Year>2000</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>40</Issue><PubDate><Year>2000</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Maturation and pro-peptide cleavage of beta-secretase.</ArticleTitle><Pagination><StartPage>30849</StartPage><EndPage>30854</EndPage><MedlinePgn>30849-54</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid beta-peptide is generated by two sequential proteolytic cleavages mediated by beta-secretase (BACE) and gamma-secretase. BACE was recently identified as a membrane-associated aspartyl protease. We have now analyzed the maturation and pro-peptide cleavage of BACE. Pulse-chase experiments revealed that BACE is post-translationally modified during transport to the cell surface, which can be monitored by a significant increase in the molecular mass. The increase in molecular mass is caused by complex N-glycosylation. Treatment with tunicamycin and N-glycosidase F led to a BACE derivative with a molecular weight corresponding to an unmodified version. In contrast, the mature form of BACE was resistant to endoglycosidase H treatment. The cytoplasmic tail of BACE was required for efficient maturation and trafficking through the Golgi; a BACE variant lacking the cytoplasmic tail undergoes inefficient maturation. In contrast a soluble BACE variant that does not contain a membrane anchor matured more rapidly than full-length BACE. Pro-BACE was predominantly located within the endoplasmic reticulum. Pro-peptide cleavage occurred immediately before full maturation and trafficking through the Golgi.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Adolf Butenandt-Institute, Department of Biochemistry, Laboratory for Alzheimer's Disease Research, Ludwig-Maximilians-University, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lammich</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Multhaup</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>11089-65-9</RegistryNumber><NameOfSubstance UI="D014415">Tunicamycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.-</RegistryNumber><NameOfSubstance UI="D006026">Glycoside Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.-</RegistryNumber><NameOfSubstance UI="D000581">Amidohydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.52</RegistryNumber><NameOfSubstance UI="D043524">Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000581" MajorTopicYN="N">Amidohydrolases</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015723" MajorTopicYN="N">Gene Library</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006026" MajorTopicYN="N">Glycoside Hydrolases</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043524" MajorTopicYN="N">Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011233" MajorTopicYN="N">Precipitin Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014415" MajorTopicYN="N">Tunicamycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10801872</ArticleId><ArticleId IdType="doi">10.1074/jbc.M003202200</ArticleId><ArticleId IdType="pii">S0021-9258(20)89350-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10801774</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>26</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc.</ArticleTitle><Pagination><StartPage>19439</StartPage><EndPage>19442</EndPage><MedlinePgn>19439-42</MedlinePgn></Pagination><Abstract><AbstractText>Abeta binds Zn(2+), Cu(2+), and Fe(3+) in vitro, and these metals are markedly elevated in the neocortex and especially enriched in amyloid plaque deposits of individuals with Alzheimer's disease (AD). Zn(2+) precipitates Abeta in vitro, and Cu(2+) interaction with Abeta promotes its neurotoxicity, correlating with metal reduction and the cell-free generation of H(2)O(2) (Abeta1-42 &gt; Abeta1-40 &gt; ratAbeta1-40). Because Zn(2+) is redox-inert, we studied the possibility that it may play an inhibitory role in H(2)O(2)-mediated Abeta toxicity. In competition to the cytotoxic potentiation caused by coincubation with Cu(2+), Zn(2+) rescued primary cortical and human embryonic kidney 293 cells that were exposed to Abeta1-42, correlating with the effect of Zn(2+) in suppressing Cu(2+)-dependent H(2)O(2) formation from Abeta1-42. Since plaques contain exceptionally high concentrations of Zn(2+), we examined the relationship between oxidation (8-OH guanosine) levels in AD-affected tissue and histological amyloid burden and found a significant negative correlation. These data suggest a protective role for Zn(2+) in AD, where plaques form as the result of a more robust Zn(2+) antioxidant response to the underlying oxidative attack.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cuajungco</LastName><ForeName>M P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Laboratory for Oxidation Biology, Genetics and Aging Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>L E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Nunomura</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Farrag</LastName><ForeName>Y W</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>A I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG09287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 AG-12686</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007477">Ions</NameOfSubstance></Chemical><Chemical><RegistryNumber>12133JR80S</RegistryNumber><NameOfSubstance UI="D006151">Guanosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002474" MajorTopicYN="N">Cell-Free System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006151" MajorTopicYN="N">Guanosine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007477" MajorTopicYN="N">Ions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10801774</ArticleId><ArticleId IdType="doi">10.1074/jbc.C000165200</ArticleId><ArticleId IdType="pii">S0021-9258(19)80004-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10801983</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.</ArticleTitle><Pagination><StartPage>6138</StartPage><EndPage>6143</EndPage><MedlinePgn>6138-43</MedlinePgn></Pagination><Abstract><AbstractText>gamma-Secretase is a membrane-associated protease that cleaves within the transmembrane region of amyloid precursor protein to generate the C termini of the two Abeta peptide isoforms, Abeta40 and Abeta42. Here we report the detergent solubilization and partial characterization of gamma-secretase. The activity of solubilized gamma-secretase was measured with a recombinant substrate, C100Flag, consisting largely of the C-terminal fragment of amyloid precursor protein downstream of the beta-secretase cleavage site. Cleavage of C100Flag by gamma-secretase was detected by electrochemiluminescence using antibodies that specifically recognize the Abeta40 or Abeta42 termini. Incubation of C100Flag with HeLa cell membranes or detergent-solubilized HeLa cell membranes generates both the Abeta40 and Abeta42 termini. Recovery of catalytically competent, soluble gamma-secretase critically depends on the choice of detergent; CHAPSO (3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate) but not Triton X-100 is suitable. Solubilized gamma-secretase activity is inhibited by pepstatin and more potently by a novel aspartyl protease transition-state analog inhibitor that blocks formation of Abeta40 and Abeta42 in mammalian cells. Upon gel exclusion chromatography, solubilized gamma-secretase activity coelutes with presenilin 1 (PS1) at an apparent relative molecular weight of approximately 2.0 x 10(6). Anti-PS1 antibody immunoprecipitates gamma-secretase activity from the solubilized gamma-secretase preparation. These data suggest that gamma-secretase activity is catalyzed by a PS1-containing macromolecular complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Y M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. yueming_li@merck.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>DiMuzio-Mower</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sardana</LastName><ForeName>M K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>X P</ForeName><Initials>XP</Initials></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>K C</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Shafer</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Gardell</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002793">Cholic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410009">L 685458</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010436">Pepstatins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>11076-29-2</RegistryNumber><NameOfSubstance UI="C014195">Streptomyces pepsin inhibitor</NameOfSubstance></Chemical><Chemical><RegistryNumber>82473-24-3</RegistryNumber><NameOfSubstance UI="C048531">chapso</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>QBP25342AG</RegistryNumber><NameOfSubstance UI="C028213">3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>V6Y2T27Q1U</RegistryNumber><NameOfSubstance UI="C031375">pepstatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2000 May 23;97(11):5690-2. doi: 10.1073/pnas.97.11.5690.</RefSource><PMID Version="1">10823929</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002793" MajorTopicYN="N">Cholic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010436" MajorTopicYN="N">Pepstatins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>8</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10801983</ArticleId><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="doi">10.1073/pnas.110126897</ArticleId><ArticleId IdType="pii">110126897</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett J T, Berger E P, Lansbury P T., Jr Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y M, Emmerling M R, Vigo-Pelfrey C, Kasunic T C, Kirkpatrick J B, Murdoch G H, Ball M J, Roher A E. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm J S, Schroeter E H, Schrijvers V, Wolfe M S, Ray W J, et al. Nature (London) 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, Xia W, Moore C L, Leatherwood D D, Ostaszewski B, Rahmati T, Donklor I O, Selkoe D J. Biochemistry. 1999;38:4720&#x2013;4727.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev E I, Liang Y, Rogaeva E A, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Nature (London) 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T D, Hardy J, Hutton M, Kukull W, et al. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada C M, Perez-Tur J, Hutton M, Buee L, Harigaya Y, Yager D, et al. Nature (London) 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D R, Thinakaran G, Eckman C B, Lee M K, Davenport F, Ratovitsky T, Prada C M, Kim G, Seekins S, Yager D, et al. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wijsman E M, Nemens E, Anderson L, Goddard K A B, Weber J L, Bird T D, Schellenberg G D. Science. 1995;269:970&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638621</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Nature (London) 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T, Selkoe D J. Nature (London) 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSolms S J, Giuliani E A, Guare J P, Vacca J P, Sanders W M, Graham S L, Wiggins J M, Darke P L, Sigal I S, Zugay J A, et al. J Med Chem. 1991;34:2852&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pubmed">1910089</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Leland J K, Yost D, Massey R J. Bio/Technology. 1994;12:193&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">7764436</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorkova O E, Patel K, Heroux J, Sahasrabudhe S. J Neurosci Methods. 1998;82:159&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida N, Hartmann T, Pantel J, Schr&#xf6;der J, Zerfass R, F&#xf6;rstl H, Sandbrink R, Masters C L, Beyreuther K. J Biol Chem. 1996;271:22908&#x2013;22914.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Barelli H, Lebeau A, Vizzavona J, Delaere P, Chevallier N, Drouot C, Marambaud P, Ancolio K, Buxbaum J D, Khorkova O, et al. Mol Med. 1997;3:695&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230230</ArticleId><ArticleId IdType="pubmed">9392006</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt D R, Lee M K, Slunt H H, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, et al. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Asami-Odaka A, Ishibashi Y, Kikuchi T, Kitada C, Suzuki N. Biochemistry. 1995;34:10272&#x2013;10278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7640283</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Gr&#xfc;nberg J, Pesold B, Diehlmann A, Citron M, Nixon R, Beyreuther K, Selkoe D J, Haass C. J Biol Chem. 1998;273:3205&#x2013;3211.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452432</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Diehl T S, Gordon G, Biere A L, Seubert P, Selkoe D J. Proc Natl Acad Sci USA. 1996;93:13170&#x2013;13175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24065</ArticleId><ArticleId IdType="pubmed">8917563</ArticleId></ArticleIdList></Reference><Reference><Citation>Tischer E, Cordell B. J Biol Chem. 1996;271:21914&#x2013;21919.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702994</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Chen F, Levesque G, Nishimura M, Zhang D M, Levesque L, Rogaeva E, Xu D, Liang Y, Duthie M, et al. J Biol Chem. 1998;273:16470&#x2013;16475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10802781</PMID><DateCompleted><Year>2000</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.</ArticleTitle><Pagination><StartPage>1760</StartPage><EndPage>1767</EndPage><MedlinePgn>1760-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">MRI-based measurements of hippocampal atrophy are a sensitive indicator of the early pathologic degeneration of the medial temporal lobe in AD. However, AD pathology appears first in the transentorhinal/entorhinal cortex, not the hippocampus. The authors tested the hypothesis that MRI-based measurements of the entorhinal cortex are more sensitive than measurements of hippocampal volume in discriminating among three clinical groups; controls, patients with a mild cognitive impairment (MCI), and patients with mild probable AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The authors studied 30 controls, 30 patients with MCI, and 30 patients with AD who were matched among clinical groups on age, gender, and education. All underwent a standardized MRI protocol from which the authors made measurements of hippocampal volume, entorhinal cortex volume, and the cumulative length of the medial border of the entorhinal cortex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pairwise intergroup differences (p &lt; 0.01) were found for all MRI measurements with the exception of the cumulative length of the entorhinal cortex, which did not differentiate controls from MCI patients. Whereas the hippocampal and entorhinal cortex volume measurements provided slightly better intergroup discrimination than the entorhinal distance measurement, overall differences in discriminating ability among the three MRI measurements were minor.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite the theoretical rationale for the superiority of entorhinal measurements in early AD, the authors found MRI measurements of the hippocampus and entorhinal cortex were approximately equivalent at intergroup discrimination. Measurements of the hippocampus may be preferable because MRI depiction of the boundaries of the entorhinal cortex can be obscured by anatomic ambiguity, image artifact, or both.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>C R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Kokmen</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Ivnik</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>B F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Tangalos</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08031</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2001 Mar 27;56(6):820-1. doi: 10.1212/wnl.56.6.820.</RefSource><PMID Version="1">11274335</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10802781</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.9.1760</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10805776</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure.</ArticleTitle><Pagination><StartPage>5129</StartPage><EndPage>5134</EndPage><MedlinePgn>5129-34</MedlinePgn></Pagination><Abstract><AbstractText>We have searched for a minimal interaction motif in tau protein that supports the aggregation into Alzheimer-like paired helical filaments. Digestion of the repeat domain with different proteases yields a GluC-induced fragment comprising 43 residues (termed PHF43), which represents the third repeat of tau plus some flanking residues. This fragment self assembles readily into thin filaments without a paired helical appearance, but these filaments are highly competent to nucleate bona fide PHFs from full-length tau. Probing the interactions of PHF43 with overlapping peptides derived from the full tau sequence yields a minimal hexapeptide interaction motif of (306)VQIVYK(311) at the beginning of the third internal repeat. This motif coincides with the highest predicted beta-structure potential in tau. CD and Fourier transform infrared spectroscopy shows that PHF43 acquires pronounced beta structure in conditions of self assembly. Point mutations in the hexapeptide region by proline-scanning mutagenesis prevent the aggregation. The data indicate that PHF assembly is initiated by a short fragment containing the minimal interaction motif forming a local beta structure embedded in a largely random-coil protein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Bergen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Unit for Structural Molecular Biology, Notkestrasse 85, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedhoff</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Heberle</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020449" MajorTopicYN="N">Repetitive Sequences, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10805776</ArticleId><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.10.5129</ArticleId><ArticleId IdType="pii">97/10/5129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koo E H, Lansbury P T, Jr, Kelly J W. Proc Natl Acad Sci USA. 1999;96:9989&#x2013;9990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33726</ArticleId><ArticleId IdType="pubmed">10468546</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P, Mandelkow E. In: Guidebook to the Cytoskeletal and Motor Proteins. Kreis T, Vale R, editors. Oxford: Oxford Univ. Press; 1998. pp. 230&#x2013;236.</Citation></Reference><Reference><Citation>Goedert M, Spillantini G, Cairns N J, Crowther R A. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik C, Novak M, Thogersen H, Edwards P, Runswick M, Jakes R, Walker J, Milstein C, Roth M, Klug A. Proc Natl Acad Sci USA. 1988;85:4506&#x2013;4510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, Drewes G, Biernat J, Mandelkow E M, Mandelkow E. J Cell Biol. 1992;118:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D W, Hwo S Y, Kirschner M W. J Mol Biol. 1977;116:227&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">146092</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweers O, Sch&#xf6;nbrunn-Hanebeck E, Marx A, Mandelkow E. J Biol Chem. 1994;269:24290&#x2013;24297.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929085</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M, Valpuesta J M, Medina M, Degarcini E M, Avila J. J Neurochem. 1996;67:1183&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Spillantini M G, Hasegawa M, Smith M J, Crowther R A. Nature (London) 1996;383:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P, Schneider A, Mandelkow E M, Mandelkow E. Biochemistry. 1998;37:10223&#x2013;10230.</Citation><ArticleIdList><ArticleId IdType="pubmed">9665729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow E M. FEBS Lett. 1996;399:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P, von Bergen M, Mandelkow E M, Davies P, Mandelkow E. Proc Natl Acad Sci USA. 1998;95:15712&#x2013;15717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28109</ArticleId><ArticleId IdType="pubmed">9861035</ArticleId></ArticleIdList></Reference><Reference><Citation>King M E, Ahuja V, Binder L I, Kuret J. Biochemistry. 1999;38:14851&#x2013;14859.</Citation><ArticleIdList><ArticleId IdType="pubmed">10555967</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther R A. Proc Natl Acad Sci USA. 1991;88:2288&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson D M, Binder L I. Am J Pathol. 1997;150:2181&#x2013;2195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858305</ArticleId><ArticleId IdType="pubmed">9176408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, Mandelkow E M, Mandelkow E. J Biol Chem. 1992;267:10737&#x2013;10742.</Citation><ArticleIdList><ArticleId IdType="pubmed">1375231</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure M A, Zhang E Y, Bubb M R, Purich D L. J Biol Chem. 1996;271:32702&#x2013;32706.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955102</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow E M, Schr&#xf6;ter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H E, Mercken M, Vandermeeren A, Goedert M, et al. EMBO J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Wischik C, Crowther R, Walker J, Klug A. Proc Natl Acad Sci USA. 1988;85:4051&#x2013;4055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280359</ArticleId><ArticleId IdType="pubmed">3131773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustke N, Trinczek B, Biernat J, Mandelkow E M, Mandelkow E. Biochemistry. 1994;33:9511&#x2013;9522.</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Udenfriend S, Stein S, Bohlen P, Dairman W, Leimgruber W, Weigele M. Science. 1972;178:871&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">5085985</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank R. J Biotechnol. 1995;41:259&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">7654352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zscherp C, Heberle J. J Phys Chem B. 1997;101:10542&#x2013;10547.</Citation></Reference><Reference><Citation>Heberle J. Rec Res Dev Appl Spectrosc. 1999;2:147&#x2013;159.</Citation></Reference><Reference><Citation>Schweers O, Mandelkow E M, Biernat J, Mandelkow E. Proc Natl Acad Sci USA. 1995;92:8463&#x2013;8467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41177</ArticleId><ArticleId IdType="pubmed">7667312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann R, Dawson N F, Wade J D, Otvos L., Jr J Pep Res. 1997;50:132&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">9273897</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian H, Szendrei G I, Mantsch H H, Otvos L., Jr Biochem Biophys Res Commun. 1993;191:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">8447825</ArticleId></ArticleIdList></Reference><Reference><Citation>Schladitz C, Vieira E P, Hermel H, Mohwald H. Biophys J. 1999;77:3305&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1300601</ArticleId><ArticleId IdType="pubmed">10585952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood S J, Wetzel R, Martin J D, Hurle M R. Biochemistry. 1995;34:724&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">7827029</ArticleId></ArticleIdList></Reference><Reference><Citation>Street A G, Mayo S L. Proc Natl Acad Sci USA. 1999;96:9074&#x2013;9076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17734</ArticleId><ArticleId IdType="pubmed">10430897</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M G, Murrell J R, Goedert M, Farlow M R, Klug A, Ghetti B. Neuron. 1998;21:955&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon C L, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al. Nature (London) 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark L N, Poorkaj P, Wszolek Z, Geschwind D H, Nasreddine Z S, Miller B, Li D, Payami H, Awert F, Markopoulou K, Andreadis A, et al. Am J Pathol. 1998;153:1359&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23724</ArticleId><ArticleId IdType="pubmed">9789048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Crowther R A, Jakes R, Goedert M. J Biol Chem. 1997;272:33118&#x2013;33124.</Citation><ArticleIdList><ArticleId IdType="pubmed">9407097</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow E M. Biochemistry. 1999;38:3549&#x2013;3558.</Citation><ArticleIdList><ArticleId IdType="pubmed">10090741</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M G, Crowther R A, Kamphorst W, Heutink P, van Swieten J C. Am J Pathol. 1998;153:1359&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853390</ArticleId><ArticleId IdType="pubmed">9811325</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird T D, Wijsman E, Nemens E, Garruto R M, Anderson L, Andreadis A, Wiederholt W C, Raskind M, Schellenberg G D. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Crowther R A. FEBS Lett. 1999;450:306&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">10359094</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacharaju P, Lewis J, Easson C, Yen S, Hackett J, Hutton M, Yen S H. FEBS Lett. 1999;447:195&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">10214944</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10805803</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets.</ArticleTitle><Pagination><StartPage>5468</StartPage><EndPage>5473</EndPage><MedlinePgn>5468-73</MedlinePgn></Pagination><Abstract><AbstractText>A definite diagnosis of prion diseases such as Creutzfeldt-Jakob disease (CJD) relies on the detection of pathological prion protein (PrP(Sc)). However, no test for PrP(Sc) in cerebrospinal fluid (CSF) has been available thus far. Based on a setup for confocal dual-color fluorescence correlation spectroscopy, a technique suitable for single molecule detection, we developed a highly sensitive detection method for PrP(Sc). Pathological prion protein aggregates were labeled by specific antibody probes tagged with fluorescent dyes, resulting in intensely fluorescent targets, which were measured by dual-color fluorescence intensity distribution analysis in a confocal scanning setup. In a diagnostic model system, PrP(Sc) aggregates were detected down to a concentration of 2 pM PrP(Sc), corresponding to an aggregate concentration of approximately 2 fM, which was more than one order of magnitude more sensitive than Western blot analysis. A PrP(Sc)-specific signal could also be detected in a number of CSF samples from patients with CJD but not in control samples, providing the basis for a rapid and specific test for CJD and other prion diseases. Furthermore, this method could be adapted to the sensitive detection of other disease-associated amyloid aggregates such as in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bieschke</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Max-Planck-Institute for Biophysical Chemistry, Am Fassberg, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giese</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schulz-Schaeffer</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zerr</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Poser</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Eigen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018620">PrPSc Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018620" MajorTopicYN="N">PrPSc Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012608" MajorTopicYN="N">Scrapie</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10805803</ArticleId><ArticleId IdType="pmc">PMC25852</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.10.5468</ArticleId><ArticleId IdType="pii">97/10/5468</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prusiner S B. Science. 1982;216:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">6801762</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmann C. FEBS Lett. 1996;389:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8682199</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S B. Arch Neurol. 1993;50:1129&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">8105771</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S B. Proc Natl Acad Sci USA. 1998;95:13363&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33918</ArticleId><ArticleId IdType="pubmed">9811807</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton D C, McKinley M P, Prusiner S B. Science. 1982;218:1309&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">6815801</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S B, Groth D F, Bolton D C, Kent S B, Hood L E. Cell. 1984;38:127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">6432339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan K-M, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick R J, Cohen F E, et al. Proc Natl Acad Sci USA. 1993;90:10962&#x2013;10966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47901</ArticleId><ArticleId IdType="pubmed">7902575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocisko D A, Come J H, Priola S A, Chesebro B, Raymond G J, Lansbury P T, Caughey B. Nature (London) 1994;370:471&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">7913989</ArticleId></ArticleIdList></Reference><Reference><Citation>Eigen M. Biophys Chem. 1996;63:A1&#x2013;A18.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981746</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D R, Quin K, Herms J W, Madlung A, Manson J, Strome R, Fraser P E, Kruck T, von Bohlen A, Schulz-Schaeffer W, et al. Nature (London) 1997;390:684&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">9414160</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretzschmar H A, Prusiner S B, Stowring L E, DeArmond S J. Am J Pathol. 1986;122:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888142</ArticleId><ArticleId IdType="pubmed">3079955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman N R, Loertscher R, Nalbantoglu J, Shaw I, Kascsak R J, Bolton D C, Bendheim P E. Cell. 1990;61:185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">1969332</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J, West J D, Thomson V, McBride P, Kaufman M H, Hope J. Development (Cambridge, UK) 1992;115:117&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">1353438</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B W, Dong A, Bhat K S, Ernst D, Hayes S F, Caughey W S. Biochemistry. 1991;30:7672&#x2013;7680.</Citation><ArticleIdList><ArticleId IdType="pubmed">1678278</ArticleId></ArticleIdList></Reference><Reference><Citation>Oesch B, Westaway D, W&#xe4;lchli M, McKinley M P, Kent S B H, Aebersold R, Barry R A, Tempst P, Teplow D B, Hood L E, et al. Cell. 1985;40:735&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">2859120</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S B, McKinley M P, Bowman K A, Bolton D C, Bendheim P E, Groth D F, Glenner G G. Cell. 1983;35:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">6418385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretzschmar H A, Ironside J W, DeArmond S J, Tateishi J. Arch Neurol. 1996;53:913&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">8815857</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, Gibbs C J, Rodgers-Johnson P, Asher D M, Sulima M P, Bacote A, Goldfarb L G, Gajdusek D C. Ann Neurol. 1994;35:513&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">8179297</ArticleId></ArticleIdList></Reference><Reference><Citation>Magde D, Elson E L, Webb W W. Phys Rev Lett. 1972;29:705&#x2013;708.</Citation></Reference><Reference><Citation>Elson E L, Magde D. Biopolymers. 1974;13:1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">4818131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenberg M, Rigler R. J Chem Phys. 1974;4:390&#x2013;401.</Citation></Reference><Reference><Citation>Rigler R, Mets &#xdc;, Widengren J, Kask P. Eur Biophys J. 1993;22:169&#x2013;175.</Citation></Reference><Reference><Citation>Eigen M, Rigler R. Proc Natl Acad Sci USA. 1994;91:5740&#x2013;5747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44073</ArticleId><ArticleId IdType="pubmed">7517036</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwille P, Bieschke J, Oehlenschl&#xe4;ger F. Biophys Chem. 1997;66:211&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">9362560</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwille P. Dissertation. Braunschweig, Germany: Technical University Braunschweig; 1996.</Citation></Reference><Reference><Citation>Schwille P, Meyer-Almes F-J, Rigler R. Biophys J. 1997;72:1878&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1184381</ArticleId><ArticleId IdType="pubmed">9083691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettling U, Koltermann A, Schwille P, Eigen M. Proc Natl Acad Sci USA. 1999;95:1416&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19026</ArticleId><ArticleId IdType="pubmed">9465029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieschke J, Schwille P. In: Fluorescence Microscopy and Fluorescent Probes. Slavik J, editor. Vol. 2. New York: Plenum; 1997. pp. 81&#x2013;86.</Citation></Reference><Reference><Citation>Koltermann K, Kettling U, Bieschke J, Winkler T, Eigen M. Proc Natl Acad Sci USA. 1998;95:1421&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19028</ArticleId><ArticleId IdType="pubmed">9465030</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler T, Kettling U, Koltermann A, Eigen M. Proc Natl Acad Sci USA. 1999;96:1375&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15470</ArticleId><ArticleId IdType="pubmed">9990031</ArticleId></ArticleIdList></Reference><Reference><Citation>Post K, Pitschke M, Sch&#xe4;fer O, Wille H, Appel T R, Kirsch D, Mehlhorn I, Serban H, Prusiner S B, Riesner D. Biol Chem. 1998;379:1307&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9865603</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitschke M, Prior R, Haupt M, Riesner D. Nat Med. 1998;4:832&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662376</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehlhorn I, Groth D, Stockel J, Moffat B, Reilly D, Yansura D, Willett W S, Baldwin M, Fletterick R, Cohen F E, et al. Biochemistry. 1996;35:5528&#x2013;5537.</Citation><ArticleIdList><ArticleId IdType="pubmed">8611544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kascsak R J, Rubenstein R, Merz P A, Tonna-DeMasi M, Fersko R, Carp R I, Wisniewski H M, Diringer H. J Virol. 1987;61:3688&#x2013;3693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC255980</ArticleId><ArticleId IdType="pubmed">2446004</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Groschup M H, Harmeyer S, Hunsmann G, Bodemer W. Mol Med. 1996;2:725&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230140</ArticleId><ArticleId IdType="pubmed">8972487</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Wkly Epidemiol Rec. 1998;73:361&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Muller J D, So P T C, YGratton E. Biophys J. 1999;76:A445&#x2013;A445.</Citation></Reference><Reference><Citation>Meyer R K, McKinley M P, Bowman K A, Braunfeld M B, Barry R A, Prusiner S B. Proc Natl Acad Sci USA. 1986;83:2310&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323286</ArticleId><ArticleId IdType="pubmed">3085093</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekes M, Baldauf E, Diringer H. J Gen Virol. 1996;77:1925&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pubmed">8760444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar H A, Weber T. Ann Neurol. 1998;43:32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450766</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10809936</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1351-5101</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.</ArticleTitle><Pagination><StartPage>159</StartPage><EndPage>169</EndPage><MedlinePgn>159-69</MedlinePgn></Pagination><Abstract><AbstractText>We evaluated the efficacy and safety of the centrally acting cholinesterase inhibitor, rivastigmine tartrate, for patients with mild to moderately severe Alzheimer's disease (AD) with or without concurrent vascular risk factors (VRF). Patients (45-90 years of age) were randomized to placebo (n = 235), low-dose rivastigmine (1-4 mg/day, n = 233), or high-dose rivastigmine (6-12 mg/day, n = 231) for 26 weeks. Efficacy measures included the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), the Clinician's Interview Based Impression of Change (CIBIC-Plus), the Progressive Deterioration Scale (PDS), the Global Deterioration Scale (GDS), and the Mini-Mental State Examination (MMSE). For efficacy and safety analysis, patients were categorized by baseline Modified Hachinski Ischemic Score (MHIS) for the determination of VRF (MHIS &gt; 0: presence of VRF; MHIS = 0: absence of VRF). As early as 12 weeks, the mean change from the baseline ADAS-Cog score was significantly different for those patients treated with high-dose rivastigmine compared with placebo controls in both MHIS categories. However, the treatment difference between high-dose rivastigmine and placebo at each time-point was larger for patients with MHIS &gt; 0. The proportion of responders was significantly greater in the high-dose rivastigmine group for each level of improvement. No differences were noted between treatment groups regarding safety evaluations. Rivastigmine is effective in both categories of patients, and those with VRF experience greater clinical benefit (cognition, activities of daily living, and disease severity).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Florida Institute of Neurosciences and Clinical Research, 530 S. Nokomis Avenue, Suite 14, Venice, FL 34284, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Messina</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Veach</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="Y">Phenylcarbamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10809936</ArticleId><ArticleId IdType="doi">10.1046/j.1468-1331.2000.00046.x</ArticleId><ArticleId IdType="pii">ene046</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10811821</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9525</ISSN><JournalIssue CitedMedium="Print"><Volume>149</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of cell biology</Title><ISOAbbreviation>J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice.</ArticleTitle><Pagination><StartPage>793</StartPage><EndPage>798</EndPage><MedlinePgn>793-8</MedlinePgn></Pagination><Abstract><AbstractText>Dysregulation of calcium signaling has been causally implicated in brain aging and Alzheimer's disease. Mutations in the presenilin genes (PS1, PS2), the leading cause of autosomal dominant familial Alzheimer's disease (FAD), cause highly specific alterations in intracellular calcium signaling pathways that may contribute to the neurodegenerative and pathological lesions of the disease. To elucidate the cellular mechanisms underlying these disturbances, we studied calcium signaling in fibroblasts isolated from mutant PS1 knockin mice. Mutant PS1 knockin cells exhibited a marked potentiation in the amplitude of calcium transients evoked by agonist stimulation. These cells also showed significant impairments in capacitative calcium entry (CCE, also known as store-operated calcium entry), an important cellular signaling pathway wherein depletion of intracellular calcium stores triggers influx of extracellular calcium into the cytosol. Notably, deficits in CCE were evident after agonist stimulation, but not if intracellular calcium stores were completely depleted with thapsigargin. Treatment with ionomycin and thapsigargin revealed that calcium levels within the ER were significantly increased in mutant PS1 knockin cells. Collectively, our findings suggest that the overfilling of calcium stores represents the fundamental cellular defect underlying the alterations in calcium signaling conferred by presenilin mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leissring</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neuropathogenesis, Department of Neurobiology and Behavior, Center for the Neurobiology of Learning and Memory and Institute for Brain Aging and Dementia, University of California Irvine 92697-4561, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Fanger</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Cahalan</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>F M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biol</MedlineTA><NlmUniqueID>0375356</NlmUniqueID><ISSNLinking>0021-9525</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010716">Phosphatidylinositols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>PX9AZU7QPK</RegistryNumber><NameOfSubstance UI="D001839">Bombesin</NameOfSubstance></Chemical><Chemical><RegistryNumber>S8TIM42R2W</RegistryNumber><NameOfSubstance UI="D001920">Bradykinin</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001839" MajorTopicYN="N">Bombesin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001920" MajorTopicYN="N">Bradykinin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010716" MajorTopicYN="N">Phosphatidylinositols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10811821</ArticleId><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="doi">10.1083/jcb.149.4.793</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Begley J.G., Duan W., Chan S., Duff K., Mattson M.P. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J. Neurochem. 1999;72:1030&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037474</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D.G., Sung J.C., Golde T.E., Felsenstein K.M., Wojczyk B.S., Tanzi R.E., Trojanowski J.Q., Lee V.M., Doms R.W. Expression and analysis of presenilin 1 in a human neuronal systemlocalization in cell bodies and dendrites. Proc. Natl. Acad. Sci. USA. 1996;93:9223&#x2013;9228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38623</ArticleId><ArticleId IdType="pubmed">8799182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs D.H., Chen L.S., Bende S.M., LaFerla F.M. Widespread neuronal expression of the presenilin-1 early-onset Alzheimer's disease gene in the murine brain. Am. J. Pathol. 1996;148:1797&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861636</ArticleId><ArticleId IdType="pubmed">8669467</ArticleId></ArticleIdList></Reference><Reference><Citation>Disterhoft J.F., Moyer J.R., Jr., Thompson L.T. The calcium rationale in aging and Alzheimer's disease. Evidence from an animal model of normal aging. Ann. NY Acad. Sci. 1994;747:382&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">7847686</ArticleId></ArticleIdList></Reference><Reference><Citation>Etcheberrigaray R., Hirashima N., Nee L., Prince J., Govoni S., Racchi M., Tanzi R.E., Alkon D.L. Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol. Dis. 1998;5:37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9702786</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.E., Zhang H., Toral-Barza L., Szolosi S., Tofel-Grehl B. Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease. Biochim. Biophys. Acta. 1996;1316:71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">8672553</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Furukawa K., Sopher B.L., Pham D.G., Xie J., Robinson N., Martin G.M., Mattson M.P. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport. 1996;8:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051814</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Christakos S., Robinson N., Mattson M.P. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1reduced oxidative stress and preserved mitochondrial function. Proc. Natl. Acad. Sci. USA. 1998;95:3227&#x2013;3232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19724</ArticleId><ArticleId IdType="pubmed">9501245</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Fu W., Sopher B.L., Miller M.W., Ware C.B., Martin G.M., Mattson M.P. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat. Med. 1999;5:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito E., Oka K., Etcheberrigaray R., Nelson T.J., McPhie D.L., Tofel-Grehl B., Gibson G.E., Alkon D.L. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 1994;91:534&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42983</ArticleId><ArticleId IdType="pubmed">8290560</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M.A., Parker I., LaFerla F.M. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1,4,5-trisphosphate-mediated calcium signals J. Biol. Chem 274 1999. 32535 32538a</Citation><ArticleIdList><ArticleId IdType="pubmed">10551803</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M.A., Paul B.A., Parker I., Cotman C.W., LaFerla F.M. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes J. Neurochem 72 1999. 1061 1068b</Citation><ArticleIdList><ArticleId IdType="pubmed">10037477</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis R.S. Store-operated calcium channels. Adv. Second Messenger Phosphoprotein Res. 1999;33:279&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguri G., Cecchi C., Latorraca S., Pieri A., Sorbi S., Degl'Innocenti D., Ramponi G. Alteration of acylphosphatase levels in familial Alzheimer's disease fibroblasts with presenilin gene mutations. Neurosci. Lett. 1996;210:153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">8805118</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P., Engle M.G., Rychlik B. Effects of elevated intracellular calcium levels on the cytoskeleton and tau in cultured human cortical neurons. Mol. Chem. Neuropathol. 1991;15:117&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">1663746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P., LaFerla F.M., Chan S.L., Leissring M.A., Shepel P.N., Geiger J.D. Calcium signaling in the ERits role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2000;23:222&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">10782128</ArticleId></ArticleIdList></Reference><Reference><Citation>Merritt J.E., Armstrong W.P., Benham C.D., Hallam T.J., Jacob R., Jaxa-Chamiec A., Leigh B.K., McCarthy S.A., Moores K.E., Rink T.J. SK&amp;F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem. J. 1990;271:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149585</ArticleId><ArticleId IdType="pubmed">2173565</ArticleId></ArticleIdList></Reference><Reference><Citation>Missiaen L., De Smedt H., Droogmans G., Casteels R. Ca2+ release induced by inositol 1,4,5-trisphosphate is a steady-state phenomenon controlled by luminal Ca2+ in permeabilized cells. Nature. 1992;357:599&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608471</ArticleId></ArticleIdList></Reference><Reference><Citation>Parekh A.B., Fleig A., Penner R. The store-operated calcium current I (CRAC)nonlinear activation by InsP3 and dissociation from calcium release. Cell. 1997;89:973&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">9200615</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent A., Linden D.J., Sisodia S.S., Borchelt D.R. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol. Dis. 1999;6:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078973</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth H.W., Selkoe D.J. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry. 1994;33:4550&#x2013;4561.</Citation><ArticleIdList><ArticleId IdType="pubmed">8161510</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399:A23&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan J.P., Swerdlow R.H., Miller S.W., Davis R.E., Parks J.K., Parker W.D., Tuttle J.B. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J. Neurosci. 1997;17:4612&#x2013;4622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573324</ArticleId><ArticleId IdType="pubmed">9169522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10811883</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of Notch.</ArticleTitle><Pagination><StartPage>5913</StartPage><EndPage>5918</EndPage><MedlinePgn>5913-8</MedlinePgn></Pagination><Abstract><AbstractText>Most of the genetically inherited Alzheimer's disease cases are caused by mutations in the presenilin genes, PS1 and PS2. PS mutations result in the enhanced production of the highly amyloidogenic 42/43 amino acid variant of amyloid beta-peptide (Abeta). We have introduced arbitrary mutations at position 286 of PS1, where a naturally occurring PS1 mutation has been described (L286V). Introduction of charged amino acids (L286E or L286R) resulted in an increase of Abeta42/43 production, which reached almost twice the level of the naturally occurring PS1 mutation. Although pathological Abeta production was increased, endoproteolysis of Notch and nuclear transport of its cytoplasmic domain was significantly inhibited. These results demonstrate that the biological function of PS proteins in the endoproteolysis of beta-amyloid precursor protein and Notch can be separated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kulic</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Adolf-Butenandt-Institute, Department of Biochemistry, Laboratory for Alzheimer's Disease Research, Ludwig Maximilians University, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Multhaup</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Teplow</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Baumeister</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Romig</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003062">Codon</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003062" MajorTopicYN="N">Codon</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>8</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10811883</ArticleId><ArticleId IdType="pmc">PMC18533</ArticleId><ArticleId IdType="doi">10.1073/pnas.100049897</ArticleId><ArticleId IdType="pii">100049897</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Nature (London) 1999;399:A23&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, De Strooper B. Science. 1999;286:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542139</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Nature (London) 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T, Selkoe D J. Nature (London) 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Leimer U, Lun K, Romig H, Walter J, Grunberg J, Brand M, Haass C. Biochemistry. 1999;38:13602&#x2013;13609.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521267</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Duff K, Capell A, Romig H, Grim M G, Lincoln S, Hardy J, Yu X, Picciano M, Fechteler K, et al. J Biol Chem. 1999;274:28669&#x2013;28673.</Citation><ArticleIdList><ArticleId IdType="pubmed">10497236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, Xia W, Moore C L, Leatherwood D D, Ostaszewski B, Rahmati T, Donkor I O, Selkoe D J. Biochemistry. 1999;38:4720&#x2013;4727.</Citation><ArticleIdList><ArticleId IdType="pubmed">10200159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M S, De Los Angeles J, Miller D D, Xia W, Selkoe D J. Biochemistry. 1999;38:11223&#x2013;11230.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471271</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt D R, Lee M K, Slunt H H, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, et al. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, Beyreuther K, Selkoe D J, Haass C. J Biol Chem. 1998;273:3205&#x2013;3211.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452432</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Regard J B, Bouton C M, Harris C L, Price D L, Borchelt D R, Sisodia S S. Neurobiol Dis. 1998;4:438&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666482</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Chen F, Levesque G, Nishimura M, Zhang D M, Levesque L, Rogaeva E, Xu D, Liang Y, Duthie M, et al. J Biol Chem. 1998;273:16470&#x2013;16475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632714</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeger M, Nordstedt C, Petanceska S, Kovacs D M, Gouras G K, Hahne S, Fraser P, Levesque L, Czernik A J, George-Hyslop P S, et al. Proc Natl Acad Sci USA. 1997;94:5090&#x2013;5094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24636</ArticleId><ArticleId IdType="pubmed">9144195</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Romig H, Pesold B, Philipp U, Baader M, Citron M, Loetscher H, Jacobsen H, Haass C. Biochemistry. 1999;38:14600&#x2013;14605.</Citation><ArticleIdList><ArticleId IdType="pubmed">10545183</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen H, Reinhardt D, Brockhaus M, Bur D, Kocyba C, Kurt H, Grim M G, Baumeister R, Loetscher H. J Biol Chem. 1999;274:35233&#x2013;35239.</Citation><ArticleIdList><ArticleId IdType="pubmed">10575009</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm J S, Schroeter E H, Schrijvers V, Wolfe M S, Ray W J, et al. Nature (London) 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan Y M, Jan Y N. Neuron. 1999;23:201&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray W J, Yao M, Mumm J, Schroeter E H, Saftig P, Wolfe M, Selkoe D J, Kopan R, Goate A M. J Biol Chem. 1999;274:36801&#x2013;36807.</Citation><ArticleIdList><ArticleId IdType="pubmed">10593990</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter E H, Kisslinger J A, Kopan R. Nature (London) 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Lukinova N, Fortini M E. Nature (London) 1999;398:525&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206647</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Greenwald I. Nature (London) 1999;398:522&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206646</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner B A. Proc Natl Acad Sci USA. 1999;96:6959&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Berechid B E, Thinakaran G, Wong P C, Sisodia S S, Nye J S. Curr Biol. 1999;9:1493&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607593</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson R T, Chen D F, Xia W, Selkoe D J, Tonegawa S. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P C, Zheng H, Chen H, Becher M W, Sirinathsinghji D J, Trumbauer M E, Chen H Y, Price D L, Van der Ploeg L H, Sisodia S S. Nature (London) 1997;387:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, et al. Proc Natl Acad Sci USA. 1999;96:11872&#x2013;11877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoviel D B, Hadjantonakis A K, Ikeda M, Zheng H, Hyslop P S, Bernstein A. Genes Dev. 1999;13:2801&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317124</ArticleId><ArticleId IdType="pubmed">10557208</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan D, Greenwald I. Nature (London) 1995;377:351&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566091</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan D, Doyle T G, Brousseau D, Lee M K, Thinakaran G, Slunt H H, Sisodia S S, Greenwald I. Proc Natl Acad Sci USA. 1996;93:14940&#x2013;14944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26241</ArticleId><ArticleId IdType="pubmed">8962160</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumeister R, Leimer U, Zweckbronner I, Jakubek C, Grunberg J, Haass C. Genes Funct. 1997;1:149&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">9680315</ArticleId></ArticleIdList></Reference><Reference><Citation>Westlund B, Parry D, Clover R, Basson M, Johnson C D. Proc Natl Acad Sci USA. 1999;96:2497&#x2013;2502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26813</ArticleId><ArticleId IdType="pubmed">10051671</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J A, Naruse S, Chen H, Eckman C, Younkin S, Price D L, Borchelt D R, Sisodia S S, Wong P C. Neuron. 1998;20:603&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539132</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S, Jiang P, Guan X M, Singh G, Trumbauer M E, Yu H, Chen H Y, Van de Ploeg L H, Zheng H. Neuron. 1998;20:611&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539133</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung A Y, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe D J. Nature (London) 1992;360:672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Schlossmacher M G, Hung A Y, Vigo-Pelfrey C, Mellon A, Ostaszewski B L, Lieberburg I, Koo E H, Schenk D, Teplow D B, et al. Nature (London) 1992;359:322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Grunberg J, Capell A, Pesold B, Schindzielorz A, Citron M, Mendla K, George-Hyslop P S, Multhaup G, Selkoe D J, Haass C. Proc Natl Acad Sci USA. 1997;94:5349&#x2013;5354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24681</ArticleId><ArticleId IdType="pubmed">9144240</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Romig H, Grim M G, Philipp U, Pesold B, Citron M, Baumeister R, Haass C. J Biol Chem. 1999;274:7615&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y, Haass C. J Biol Chem. 1997;272:16085&#x2013;16088.</Citation><ArticleIdList><ArticleId IdType="pubmed">9195901</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere C A, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe D J. Nat Med. 1995;1:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev E I, Liang Y, Rogaeva E A, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Nature (London) 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Neuron. 1997;18:687&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182794</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny M B, Citron M, Amarante P, Sherrington R, Xia W, Zhang J, Diehl T, Levesque G, Fraser P, Haass C, et al. Neurobiol Dis. 1997;3:325&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173929</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Capell A, Pesold B, Citron M, Kloetzel P M, Selkoe D J, Romig H, Mendla K, Haass C. J Biol Chem. 1998;273:32322&#x2013;32331.</Citation><ArticleIdList><ArticleId IdType="pubmed">9822712</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Eckman C B, Diehl T S, Corcoran C, Ostaszewski B L, Xia W, Levesque G, St. George Hyslop P, Younkin S G, Selkoe D J. Neurobiol Dis. 1998;5:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9746908</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, et al. Nat Med. 1997;3:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Steiner H, Romig H, Keck S, Baader M, Grim M G, Baumeister R, Haass C. Nat Cell Biol. 2000;2:205&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783238</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Harris C L, Ratovitski T, Davenport F, Slunt H H, Price D L, Borchelt D R, Sisodia S S. J Biol Chem. 1997;272:28415&#x2013;28422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353300</ArticleId></ArticleIdList></Reference><Reference><Citation>Klafki H W, Wiltfang J, Staufenbiel M. Anal Biochem. 1996;237:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660532</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T D, Hardy J, Hutton M, Kukull W, et al. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D R, Thinakaran G, Eckman C B, Lee M K, Davenport F, Ratovitsky T, Prada C M, Kim G, Seekins S, Yager D, et al. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs D M, Fausett H J, Page K J, Kim T W, Moir R D, Merriam D E, Hollister R D, Hallmark O G, Mancini R, Felsenstein K M, et al. Nat Med. 1996;2:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">8574969</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W G, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, George-Hyslop P S, Cordell B, Fraser P, De Strooper B. J Cell Biol. 1999;147:277&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Capell A, Grunberg J, Pesold B, Schindzielorz A, Prior R, Podlisny M B, Fraser P, Hyslop P S, Selkoe D J, Haass C. Mol Med. 1996;2:673&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230134</ArticleId><ArticleId IdType="pubmed">8972483</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky D M, Doms R W, Lee V M. J Cell Biol. 1998;141:1031&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132781</ArticleId><ArticleId IdType="pubmed">9585420</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez R G, Soriano S, Hayes J D, Ostaszewski B, Xia W, Selkoe D J, Chen X, Stokin G B, Koo E H. J Biol Chem. 1999;274:18851&#x2013;18856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10811879</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6037</StartPage><EndPage>6042</EndPage><MedlinePgn>6037-42</MedlinePgn></Pagination><Abstract><AbstractText>The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Small</LastName><ForeName>G W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024, USA. gsmall@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ercoli</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>D H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Komo</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bookheimer</LastName><ForeName>S Y</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Lavretsky</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Siddarth</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rasgon</LastName><ForeName>N L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Mazziotta</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Saxena</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Mega</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Roses</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Barrio</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG13308</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS026630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52453</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010123</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS031153</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013308</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH052453</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 AG011268</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2000 May 23;97(11):5696-8. doi: 10.1073/pnas.120178897.</RefSource><PMID Version="1">10811924</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10811879</ArticleId><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="doi">10.1073/pnas.090106797</ArticleId><ArticleId IdType="pii">090106797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ritchie K, Kildea D. Lancet. 1995;346:931&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">7564727</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans D A. Milbank Q. 1990;68:267&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">2233632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst R L, Hay J W. Am J Public Health. 1994;84:1261&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1615456</ArticleId><ArticleId IdType="pubmed">8059882</ArticleId></ArticleIdList></Reference><Reference><Citation>Small G W, Rabins P V, Barry P P, Buckholtz N S, DeKosky S T, Ferris S H, Finkel S I, Gwyther L P, Khachaturian Z S, Lebowitz B D, et al. J Am Med Assoc. 1997;278:1363&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343469</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J L, Morris J C. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Ikeda K, Akiyama H, Haga C, Usami M, Sahara N, Iritani S, Mori H. Acta Neuropathol. 1999;97:82&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930898</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach T G, Honer W G, Hughes L H. Acta Neuropathol. 1997;93:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039461</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R C, Smith G E, Waring S C, Ivnik R J, Tangalos E G, Kokmen E. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook T, Bartus R T, Ferris S H, Whitehouse P, Cohen G D, Gershon S. Dev Neuropsychol. 1986;2:261&#x2013;276.</Citation></Reference><Reference><Citation>Rogers S L, Friedhoff L T. Dementia. 1996;7:293&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">8915035</ArticleId></ArticleIdList></Reference><Reference><Citation>Small G W, Mazziotta J C, Collins M T, Baxter L R, Phelps M E, Mandelkern M A, Kaplan A, La Rue A, Adamson C F, Chang L, et al. J Am Med Assoc. 1995;273:942&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884953</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A M, Strittmatter W J, Schmechel D, George-Hyslop P H S, Pericak-Vance M A, Joo S H, Rosi B L, Gusella J F, Crapper-MacLachlan D R, Alberts M J, et al. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E H, Saunders A M, Strittmatter W J, Schmechel D E, Gaskell P C, Small G W, Roses A D, Haines J L, Pericak-Vance M A. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E H, Saunders A M, Risch M J, Strittmatter K E, Schmechel W J, Gaskell D E, Small G W, Roses A D, Haines J L, Rimmler J B, et al. Nat Genet. 1994;7:180&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman B T, Gomez-Isla T, Briggs M, Chung H, Nichols S, Kohout F, Wallace R. Ann Neurol. 1996;40:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">8687193</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps M E, Mazziotta J C, Huang S C. J Cereb Blood Flow Metab. 1982;2:113&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">6210701</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps M E, Mazziotta J C. Science. 1985;228:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">2860723</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps M E, Huang S C, Hoffman E J, Selin C, Sokoloff L, Kuhl D E. Ann Neurol. 1979;6:371&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">117743</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S C, Phelps M E, Hoffman E J, Sideris K, Selin C J, Kuhl D E. Am J Physiol. 1980;238:E69&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">6965568</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman D H S, Small G W, Phelps M E. Clin Positron Imaging. 1999;2:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">14516535</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E M, Caselli R J, Yun L S, Chen K, Bandy D, Minoshima S, Thibodeau S N, Osborne D. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Crum R M, Anthony J C, Bassett S S, Folstein M F. J Am Med Assoc. 1993;269:2386&#x2013;2391.</Citation><ArticleIdList><ArticleId IdType="pubmed">8479064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D A. Wechsler Memory Scale-Revised. New York: Psychological Corp.; 1981.</Citation></Reference><Reference><Citation>Buschke H, Fuld P A. Neurology. 1974;24:1019&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">4473151</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton A L. The Revised Visual Retention Test. New York: Psychological Corp.; 1974.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E M. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E H, Jelic V, Basun H, Lannfelt L, Valind S, Winblad B, Nordberg A. Arch Neurol. 1997;54:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">9074396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Yasuda M, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Hashimoto M, Yamashita H, Sasaki M. Alzheimer Dis Assoc Disord. 1998;12:362&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">9876966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K P, Huang S C, Baxter L, Phelps M E. IEEE Trans Nucl Sci. 1994;41:2850&#x2013;2855.</Citation></Reference><Reference><Citation>Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. Three-Dimensional Proportional System: An Approach to Cerebral Imaging. New York: Thieme; 1988.</Citation></Reference><Reference><Citation>Rottenberg D A, Moeller J R, Strother S C, Dhawan V, Sergi M L. J Cereb Blood Flow Metab. 1991;11:A83&#x2013;A88.</Citation><ArticleIdList><ArticleId IdType="pubmed">1997493</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston K J, Ashburner J, Frith C D, Poline J, Heather J D, Frackowiak R S J. Hum Brain Mapping. 1995;2:165&#x2013;189.</Citation></Reference><Reference><Citation>Friston K J, Holmes A, Poline J B, Price C J, Frith C D. NeuroImage. 1996;4:223&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345513</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman D H, Munakata J A, Ennes H, Mandelkern M A, Hoh C K, Mayer E A. Gastroenterology. 1997;112:64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978344</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston K J, Holmes A P, Worsley K J, Poline J P, Frith C D, Frackowiak R S J. Hum Brain Mapping. 1995;2:189&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N C, Arndt S, Cizadlo T, O'Leary D S, Watkins G L, Ponto L L, Hichwa R D. J Cereb Blood Flow Metab. 1996;16:804&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke R, Kessler J, Szelies B, Herholz K, Wienhard K, Heiss W D. J Neural Transm. 1998;105:821&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869321</ArticleId></ArticleIdList></Reference><Reference><Citation>Keilp J G, Alexander G E, Stern Y, Prohovnik I. Brain Cognit. 1996;32:365&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">8975677</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance M A, Bass M P, Yamaoka L H, Gaskell P C, Scott W K, Terwedow H A, Menold M M, Conneally P M, Small G W, Vance, et al. J Am Med Assoc. 1997;278:1237&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">9333264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J C, Phelps M E. In: Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. Phelps M, Mazziotta J, Schelbert H, editors. New York: Raven; 1986. pp. 493&#x2013;579.</Citation></Reference><Reference><Citation>Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron J C, Chavoix C. Brain. 1999;122:1519&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady C L, Haxby J V, Horwitz B, Gillette J, Salerno J A, Gonzalez-Aviles A, Carson R E, Herscovitch P, Schapiro M B, Rapoport S I. Neurobiol Aging. 1993;14:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8450930</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C R, Peterson R C, Xu Y C, Waring S C, O'Brien P C, Tangalos E G, Smith G E, Ivnik R J, Kokmen E. Neurology. 1997;49:786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez V, Pietrini P, Alexander G E, Furey M L, Teichberg D, Rajapakse J C, Rapoport S I, Schapiro M B, Horwitz B. Neurology. 1998;50:1585&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633698</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E M, Uecker A, Caselli R J, Lewis S, Bandy D, de Leon M J, De Santi S, Convit A, Osborne D, Weaver A, Thibodeau S N. Ann Neurol. 1998;44:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708558</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D, Schneider L S, Davis K, Talwalker S, Smith F, Hoover T, Gracon S the Tacrine Study Group. Neurology. 1996;47:166&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710072</ArticleId></ArticleIdList></Reference><Reference><Citation>Small G W, Donohue J A, Brooks R L. Clin Ther. 1998;20:838&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">9737841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittelman M S, Ferris S H, Shulman E, Steinberg G, Levin B. J Am Med Assoc. 1996;276:1725&#x2013;1731.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10816583</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>34</Issue><PubDate><Year>2000</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage.</ArticleTitle><Pagination><StartPage>26277</StartPage><EndPage>26284</EndPage><MedlinePgn>26277-84</MedlinePgn></Pagination><Abstract><AbstractText>Presenilins (PSs) are polytopic membrane proteins that have been implicated as potential therapeutic targets in Alzheimer's disease because of their role in regulating the gamma-secretase cleavage that generates the amyloid beta protein (Abeta). It is not clear how PSs regulate gamma-secretase cleavage, but there is evidence that PSs could be either essential cofactors in the gamma-secretase cleavage, gamma-secretase themselves, or regulators of intracellular trafficking that indirectly influence gamma-secretase cleavage. Using presenilin 1 (PS1) mutants that inhibit Abeta production in conjunction with transmembrane domain mutants of the amyloid protein precursor that are cleaved by pharmacologically distinct gamma-secretases, we show that PS1 regulates multiple pharmacologically distinct gamma-secretase activities as well as inducible alpha-secretase activity. It is likely that PS1 acts indirectly to regulate these activities (as in a trafficking or chaperone role), because these data indicate that for PS1 to be gamma-secretase it must either have multiple active sites or exist in a variety of catalytically active forms that are altered to an equivalent extent by the mutations we have studied.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>M P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Mayo Clinic Jacksonville, Department of Pharmacology, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uljon</LastName><ForeName>S N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Fauq</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lookingbill</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Findlay</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>T E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>McLendon</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>T E</ForeName><Initials>TE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-16065</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>30</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10816583</ArticleId><ArticleId IdType="doi">10.1074/jbc.M002812200</ArticleId><ArticleId IdType="pii">S0021-9258(19)61595-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10818128</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The plasmin system is induced by and degrades amyloid-beta aggregates.</ArticleTitle><Pagination><StartPage>3937</StartPage><EndPage>3946</EndPage><MedlinePgn>3937-46</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid-beta (Abeta) appears critical to Alzheimer's disease. To clarify possible mechanisms of Abeta action, we have quantified Abeta-induced gene expression in vitro by using Abeta-treated primary cortical neuronal cultures and in vivo by using mice transgenic for the Abeta precursor (AbetaP). Here, we report that aggregated, but not nonaggregated, Abeta increases the level of the mRNAs encoding tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Moreover, tPA and uPA were also upregulated in aged AbetaP overexpressing mice. Because others have reported that Abeta aggregates can substitute for fibrin aggregates in activating tPA post-translationally, the result of tPA induction by Abeta would be cleavage of plasminogen to the active protease plasmin. To gain insights into the possible actions of plasmin, we evaluated the hypotheses that tPA and plasmin may mediate Abeta in vitro toxicity or, alternatively, that plasmin activation may lead to Abeta degradation. In evaluating these conflicting hypotheses, we found that purified plasmin degrades Abeta with physiologically relevant efficiency, i.e., approximately 1/10th the rate of plasmin on fibrin. Mass spectral analyses show that plasmin cleaves Abeta at multiple sites. Electron microscopy confirms indirect assays suggesting that plasmin degrades Abeta fibrils. Moreover, exogenously added plasmin blocks Abeta neurotoxicity. In summation, we interpret these results as consistent with the possibility that the plasmin pathway is induced by aggregated Abeta, which can lead to Abeta degradation and inhibition of Abeta actions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Physiology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky 40536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kihiko</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>J N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kawarabayashi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Scheff</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McGillis</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Rydel</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Estus</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS-35607</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019715">Tissue Inhibitor of Metalloproteinase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.68</RegistryNumber><NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.7</RegistryNumber><NameOfSubstance UI="D005341">Fibrinolysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.73</RegistryNumber><NameOfSubstance UI="D014568">Urokinase-Type Plasminogen Activator</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001711" MajorTopicYN="N">Biotransformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005341" MajorTopicYN="N">Fibrinolysin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019715" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-1</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010959" MajorTopicYN="N">Tissue Plasminogen Activator</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014568" MajorTopicYN="N">Urokinase-Type Plasminogen Activator</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10818128</ArticleId><ArticleId IdType="pmc">PMC6772619</ArticleId><ArticleId IdType="pii">20/11/3937</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.20-11-03937.2000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Ikeda K, Kondo H, Kato M, McGeer PL. Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease. Neurosci Lett. 1993;164:233&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">8152607</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts J, Herr I, Lansink M, Angel P, Kooistra T. Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucleic Acids Res. 1997;25:311&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146448</ArticleId><ArticleId IdType="pubmed">9016559</ArticleId></ArticleIdList></Reference><Reference><Citation>Basbaum CB, Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol. 1996;8:731&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939664</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson BJ, Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19:357&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697696</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res. 1993;35:567&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">8377226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA. 1992;89:7427&#x2013;7431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49723</ArticleId><ArticleId IdType="pubmed">1502154</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmeliet P, Bouche A, De Clercq C, Janssen S, Pollefeyt S, Wyns S, Mulligan RC, Collen D. Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci. 1995;748:367&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">9428515</ArticleId></ArticleIdList></Reference><Reference><Citation>Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal Biochem. 1987;162:156&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440339</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb S, Gottschall PE. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem. 1996;66:1641&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627321</ArticleId></ArticleIdList></Reference><Reference><Citation>Estus S. Optimization and validation of RT-PCR as a tool to analyze apoptotic gene expression. In: Poirier J, editor. NeuroMethods 29: apoptosis techniques and protocols. Humana; Totowa, NJ: 1997. pp. 67&#x2013;84.</Citation></Reference><Reference><Citation>Estus S, Tucker HM, van Rooyen C, Wright S, Brigham E, Wogulis M, Rydel R. Aggregated amyloid-&#x3b2; protein induces cortical neuronal apoptosis and concomitant &#x201c;apoptotic&#x201d; pattern of gene induction. J Neurosci. 1997;17:7736&#x2013;7745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793913</ArticleId><ArticleId IdType="pubmed">9315895</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkin J, Marcotte P, Yang HC. The plasminogen-plasmin system. Prog Cardiovasc Dis. 1991;34:135&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832499</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">8097803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA. 1998;95:3275&#x2013;3280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19732</ArticleId><ArticleId IdType="pubmed">9501253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997;49:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9222170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastrikina TF, Taran LD, Kudinov SA. Kinetic characteristics of fibrinogen and fibrin hydrolysis by plasmin 1 and 2 and miniplasmin. Thromb Res. 1986;41:681&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">2938303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YH, Park JH, Hong SH, Koh JY. Nonproteolytic neuropro-tection by human recombinant tissue plasminogen activator. Science. 1999;284:647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213688</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med. 1995;1:138&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner DA, Inouye H, Duffy LK, Sinclair A, Lind M, Selkoe DJ. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci USA. 1987;84:6953&#x2013;6957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299203</ArticleId><ArticleId IdType="pubmed">3477820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992;11:291&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">1423820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lijnen HR, Silence J, Lemmens G, Frederix L, Collen D. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost. 1998;79:1171&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657444</ArticleId></ArticleIdList></Reference><Reference><Citation>Littell RC, Milliken GA, Stroup WW, Wolfsinger RD. SAS system for mixed models. SAS; Cary, NC: 1996.</Citation></Reference><Reference><Citation>Mentlein R, Ludwig R, Martensen I. Proteolytic degradation of Alzheimer's disease amyloid beta-peptide by a metalloproteinase from microglia cells. J Neurochem. 1998;70:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9453567</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997;69:1904&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349534</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17:553&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike C, Walencewicz A, Glabe C, Cotman C. In vitro aging of &#x3b2;-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991;563:311&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">1786545</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 1998;21:479&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem. 1996;271:8443&#x2013;8451.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626544</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem. 1997;272:6641&#x2013;6646.</Citation><ArticleIdList><ArticleId IdType="pubmed">9045694</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis [review]. Int J Oncol. 1998;13:893&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">9772277</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher A, Wolfe D, Palutke M, KuKuruga D. Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci USA. 1986;83:2662&#x2013;2666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323359</ArticleId><ArticleId IdType="pubmed">3458224</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matric metalloproteinase-9 reduces infarct size. Stroke. 1998;29:1020&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596253</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genotypes, phenotype, and treatments. Science. 1997;275:630&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">9019820</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994;45:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">8145724</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WBJ, Snyder SW, Ladror US, Wade WS, Miller MF, Perun TJ, Holzman TF, Krafft GA. The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. J Protein Chem. 1996;15:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8924204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton R, Keohane ME, VanderBerg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis. 1994;5:167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8054448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci USA. 1995;92:4299&#x2013;4303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41931</ArticleId><ArticleId IdType="pubmed">7753801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature. 1996;384:123&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8906786</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci. 1997;17:543&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573220</ArticleId><ArticleId IdType="pubmed">8987777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker HM, Mottonen J, Goldsmith EJ, Gerard RD. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol. 1995;2:442&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">7664104</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry. 1999;38:11570&#x2013;11576.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471309</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayaragahaven J, Tucker M, Fehrentz JA, Isbell D, Hersh LB. Reaction of neprilysin (neutral endopeptidase) and thermolysin with cyclic peptides. Arch Biochem Biophys. 1995;322:405&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">7574714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4:228&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wnendt S, Wetzels I, Gunzler WA. Amyloid beta peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb Res. 1997;85:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058496</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10821838</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>35</Issue><PubDate><Year>2000</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells.</ArticleTitle><Pagination><StartPage>27110</StartPage><EndPage>27116</EndPage><MedlinePgn>27110-6</MedlinePgn></Pagination><Abstract><AbstractText>Cerebral amyloid angiopathy is commonly associated with normal aging and Alzheimer's disease and it is also the principal feature of hereditary cerebral hemorrhage with amyloidosis Dutch type, a familial condition associated to a point mutation G to C at codon 693 of the amyloid beta (Abeta) precursor protein gene resulting in a Glu to Gln substitution at position 22 of the Abeta (E22Q). The patients carrying the AbetaE22Q variant usually present with lobar cerebral hemorrhages before 50 years of age. A different mutation described in several members of three Italian kindred who presented with recurrent hemorrhagic strokes late in life, between 60 and 70 years of age, also associated with extensive cerebrovascular amyloid deposition has been found at the same position 22, this time resulting in a Glu to Lys substitution (E22K). We have compared the secondary structure, aggregation, and fibrillization properties of the two Abeta40 variants and the wild type peptide. Using flow cytometry analysis after staining with propidium iodide and annexin V, we also evaluated the cytotoxic effects of the peptides on human cerebral endothelial cells in culture. Under the conditions tested, the E22Q peptide exhibited the highest content of beta-sheet conformation and the fastest aggregation/fibrillization properties. The Dutch variant also induced apoptosis of cerebral endothelial cells at a concentration of 25 micrometer, whereas the wild type Abeta and the E22K mutant had no effect. The data suggest that different amino acids at position 22 confer distinct structural properties to the peptides that appear to influence the onset and aggressiveness of the disease rather than the phenotype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miravalle</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, New York University School of Medicine, New York, New York 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chiarle</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Giaccone</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bugiani</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Frangione</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ghiso</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08721</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS38777</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003062">Codon</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003062" MajorTopicYN="Y">Codon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10821838</ArticleId><ArticleId IdType="doi">10.1074/jbc.M003154200</ArticleId><ArticleId IdType="pii">S0021-9258(19)61486-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10822429</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>23</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.</ArticleTitle><Pagination><StartPage>1916</StartPage><EndPage>1921</EndPage><MedlinePgn>1916-21</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia is a frequent complication of idiopathic parkinsonism or PD, usually occurring later in the protracted course of the illness. The primary site of neuropathologic change in PD is the substantia nigra, but the neuropathologic and molecular basis of dementia in PD is less clear. Although Alzheimer's pathology has been a frequent finding, recent advances in immunostaining of alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The brains of 22 demented and 20 nondemented patients with a clinical and neuropathologic diagnosis of PD were evaluated with standard neuropathologic techniques. In addition, CLBs and dystrophic neurites were identified immunohistochemically with antibodies specific for alpha-synuclein and ubiquitin; plaques and tangles were identified by staining with thioflavine S. Associations between dementia status and pathologic markers were tested with logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CLBs positive for alpha-synuclein are highly sensitive (91%) and specific (90%) neuropathologic markers of dementia in PD and slightly more sensitive than ubiquitin-positive CLBs. They are better indicators of dementia than neurofibrillary tangles, amyloid plaques, or dystrophic neurites.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CLBs detected by alpha-synuclein antibodies in patients with PD are a more sensitive and specific correlate of dementia than the presence of Alzheimer's pathology, which was present in a minority of the cases in this series.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hurtig</LastName><ForeName>H I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, PA, USA. hihurtig@pahosp.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Galvin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ewbank</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>V M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Glosser</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>M B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Gollomp</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH55199</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG09215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10822429</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.10.1916</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10828533</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0306-4522</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>3</Issue><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>Neuroscience</Title><ISOAbbreviation>Neuroscience</ISOAbbreviation></Journal><ArticleTitle>The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.</ArticleTitle><Pagination><StartPage>505</StartPage><EndPage>519</EndPage><MedlinePgn>505-19</MedlinePgn></Pagination><Abstract><AbstractText>In order to investigate the sequence and pattern of neurodegeneration in Huntington's disease, the distribution and density of cannabinoid CB(1), dopamine D(1) and D(2), adenosine A(2a) and GABA(A) receptor changes were studied in the basal ganglia in early (grade 0), intermediate (grades 1, 2) and advanced (grade 3) neuropathological grades of Huntington's disease. The results showed a sequential pattern of receptor changes in the basal ganglia with increasing neuropathological grades of Huntington's disease. First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus. Second, intermediate neuropathological grades (grades 1, 2) showed a further marked decrease of CB(1) receptor binding in the caudate nucleus and putamen; this was associated with a loss of D(1) receptors in the caudate nucleus and putamen and a loss of both CB(1) and D(1) receptors in the substantia nigra. Finally, advanced grades of Huntington's disease showed an almost total loss of CB(1) receptors and the further depletion of D(1) receptors in the caudate nucleus, putamen and globus pallidus internus, and an increase in GABA(A) receptor binding in the globus pallidus internus. These findings suggest that there is a sequential but overlapping pattern of neurodegeneration of GABAergic striatal efferent projection neurons in increasing neuropathological grades of Huntington's disease. First, GABA/enkephalin striatopallidal neurons projecting to the globus pallidus externus are affected in the very early grades of the disease. Second, GABA/substance P striatonigral neurons projecting to the substantia nigra are involved at intermediate neuropathological grades. Finally, GABA/substance P striatopallidal neurons projecting to the globus pallidus internus are affected in the late grades of the disease. In addition, the finding that cannabinoid receptors are dramatically reduced in all regions of the basal ganglia in advance of other receptor changes in Huntington's disease suggests a possible role for cannabinoids in the progression of neurodegeneration in Huntington's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Anatomy with Radiology, University of Auckland, Private Bag 92019, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragunow</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Faull</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroscience</MedlineTA><NlmUniqueID>7605074</NlmUniqueID><ISSNLinking>0306-4522</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043705">Receptor, Adenosine A2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043882">Receptors, Cannabinoid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011955">Receptors, Drug</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018047">Receptors, Purinergic P1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043705" MajorTopicYN="N">Receptor, Adenosine A2A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043882" MajorTopicYN="N">Receptors, Cannabinoid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011955" MajorTopicYN="N">Receptors, Drug</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018047" MajorTopicYN="N">Receptors, Purinergic P1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10828533</ArticleId><ArticleId IdType="doi">10.1016/s0306-4522(00)00008-7</ArticleId><ArticleId IdType="pii">S0306-4522(00)00008-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10830966</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>405</Volume><Issue>6784</Issue><PubDate><Year>2000</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Neurotoxicity induces cleavage of p35 to p25 by calpain.</ArticleTitle><Pagination><StartPage>360</StartPage><EndPage>364</EndPage><MedlinePgn>360-4</MedlinePgn></Pagination><Abstract><AbstractText>Cyclin-dependent kinase 5 (cdk5) and its neuron-specific activator p35 are required for neurite outgrowth and cortical lamination. Proteolytic cleavage of p35 produces p25, which accumulates in the brains of patients with Alzheimer's disease. Conversion of p35 to p25 causes prolonged activation and mislocalization of cdk5. Consequently, the p25/cdk5 kinase hyperphosphorylates tau, disrupts the cytoskeleton and promotes the death (apoptosis) of primary neurons. Here we describe the mechanism of conversion of p35 to p25. In cultured primary cortical neurons, excitotoxins, hypoxic stress and calcium influx induce the production of p25. In fresh brain lysates, addition of calcium can stimulate cleavage of p35 to p25. Specific inhibitors of calpain, a calcium-dependent cysteine protease, effectively inhibit the calcium-induced cleavage of p35. In vitro, calpain directly cleaves p35 to release a fragment with relative molecular mass 25,000. The sequence of the calpain cleavage product corresponds precisely to that of p25. Application of the amyloid beta-peptide A beta(1-42) induces the conversion of p35 to p25 in primary cortical neurons. Furthermore, inhibition of cdk5 or calpain activity reduces cell death in A beta-treated cortical neurons. These observations indicate that cleavage of p35 to p25 by calpain may be involved in the pathogenesis of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Y T</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>L H</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089495">neuronal Cdk5 activator (p25-p35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>526U7A2651</RegistryNumber><NameOfSubstance UI="D004533">Egtazic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>56092-81-0</RegistryNumber><NameOfSubstance UI="D015759">Ionomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical><Chemical><RegistryNumber>K22DDW77C0</RegistryNumber><NameOfSubstance UI="C025603">1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004533" MajorTopicYN="N">Egtazic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015759" MajorTopicYN="N">Ionomycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId><ArticleId IdType="doi">10.1038/35012636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10841577</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>12</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice.</ArticleTitle><Pagination><StartPage>6826</StartPage><EndPage>6831</EndPage><MedlinePgn>6826-31</MedlinePgn></Pagination><Abstract><AbstractText>Neurotrophin nerve growth factor (NGF) has been suggested to be involved in age-related neurodegenerative diseases, but no transgenic model is currently available to study this concept. We have obtained transgenic mice expressing a neutralizing anti-NGF recombinant antibody, in which the levels of antibodies are three orders of magnitude higher in adult than in newborn mice [F.R., S. C. , A.C., E. Di Daniel, J. Franzot, S. Gonfloni, G. Rossi, N. B. &amp; A. C. (2000) J. Neurosci., 20, 2589-2601]. In this paper, we analyze the phenotype of aged anti-NGF transgenic mice and demonstrate that these mice acquire an age-dependent neurodegenerative pathology including amyloid plaques, insoluble and hyperphosphorylated tau, and neurofibrillary tangles in cortical and hippocampal neurons. Aged anti-NGF mice also display extensive neuronal loss throughout the cortex, cholinergic deficit in the basal forebrain, and behavioral deficits. The overall picture is strikingly reminiscent of human Alzheimer's disease. Aged anti-NGF mice represent, to our knowledge, the most comprehensive animal model for this severe neurodegenerative disease. Also, these results demonstrate that, in mice, a deficit in the signaling and/or transport of NGF leads to neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Capsoni</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience Program, International School for Advanced Studies, SISSA, Via Beirut 2/4, 34014 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ugolini</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Comparini</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ruberti</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Berardi</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Cattaneo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>9061-61-4</RegistryNumber><NameOfSubstance UI="D020932">Nerve Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053938" MajorTopicYN="N">DNA Fragmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020932" MajorTopicYN="N">Nerve Growth Factor</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010275" MajorTopicYN="N">Parasympathetic Nervous System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10841577</ArticleId><ArticleId IdType="pmc">PMC18754</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.12.6826</ArticleId><ArticleId IdType="pii">97/12/6826</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levi-Montalcini R. Ann NY Acad Sci. 1952;55:330&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">12977049</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauterborn J C, Isackson P J, Gall C M. J Comp Neurol. 1991;306:439&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">1865003</ArticleId></ArticleIdList></Reference><Reference><Citation>Saporito M S, Carswell S. J Neurosci. 1995;15:2280&#x2013;2286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578110</ArticleId><ArticleId IdType="pubmed">7891166</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsching S, Auburger G, Heumann R, Scott J, Thoenen H. EMBO J. 1985;4:1389&#x2013;1393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC554356</ArticleId><ArticleId IdType="pubmed">2411537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobley W C, Rutkowski J L, Tennekoon G I, Gemski J, Buchanan K, Johnston M V. Mol Brain Res. 1986;1:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">3742234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefti F. J Neurosci. 1986;6:2155&#x2013;2162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568758</ArticleId><ArticleId IdType="pubmed">3746405</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D E, Roberts J, Gage F H, Tuszynski M H. Proc Natl Acad Sci USA. 1999;96:10893&#x2013;10898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17979</ArticleId><ArticleId IdType="pubmed">10485922</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W, Wictorin K, Bj&#xf6;rklund A, Williams L R, Varon S, Gage F H. Nature (London) 1987;329:65&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">3627243</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W, Sirevaag A, Wiegand S J, Lindsay R, Bj&#xf6;rklund A. Proc Natl Acad Sci USA. 1994;91:8607&#x2013;8611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44655</ArticleId><ArticleId IdType="pubmed">8078930</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska A L, Koliatsos V E, Breckler S J, Price D L, Olton D S. J Neurosci. 1994;14:4815&#x2013;4824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577162</ArticleId><ArticleId IdType="pubmed">8046452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus R T, Dean R L, III, Beer B, Lippa A S. Science. 1982;217:408&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">7046051</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor B, Dragunow M. Brain Res Rev. 1998;27:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9639663</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowley C, Spencer S D, Nishimura M C, Chen K S, Pitts-Meek S, Armanini M P, Lanway H L, McMahon S B, Shelton D L, et al. Cell. 1994;76:1001&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">8137419</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo A, Neuberger M S. EMBO J. 1987;6:2753&#x2013;2758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553699</ArticleId><ArticleId IdType="pubmed">3119328</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccioli P, Ruberti F, Biocca S, Di Luzio A, Werge T M, Bradbury A, Cattaneo A. Proc Natl Acad Sci USA. 1991;88:5611&#x2013;5615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51927</ArticleId><ArticleId IdType="pubmed">1712102</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccioli P, Di Luzio A, Amann R, Schuligoi R, Azim Surani M, Donnerer J, Cattaneo A. Neuron. 1995;15:373&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">7544142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, Rossi G, Berardi N, Cattaneo A. J Neurosci. 2000;20:2589&#x2013;2601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772248</ArticleId><ArticleId IdType="pubmed">10729339</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo A, Rapposelli B, Calissano P. J Neurochem. 1988;50:1003&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">2450170</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D J. Neuron. 1991;6:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Prog Brain Res. 1998;117:287&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932415</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar M, Ruberti F, Cozzari C, Domenici L, Cattaneo A. Eur J Neurosci. 1998;10:3127&#x2013;3140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9786207</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin K, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic; 1997.</Citation></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Nature (London) 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel R P, Cruz-Orive L M. J Microsc. 1988;150:117&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">3411604</ArticleId></ArticleIdList></Reference><Reference><Citation>West M J. Neurobiol Aging. 1993;14:275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">8367009</ArticleId></ArticleIdList></Reference><Reference><Citation>Capsoni S, Ruberti F, Di Daniel E, Cattaneo A. J Neurosci Res. 2000;59:553&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B L, Pruchnicki A, Dickson D W, Davies P. Science. 1986;232:648&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">3083509</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow E M, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, et al. EMBO J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang E, Szendrei G I, Lee V H, Otvos L., Jr Biochem Biophys Res Commun. 1992;187:783&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">1382420</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Jakes R, Edwards P C, Milstein C, Wischik C M. Proc Natl Acad Sci USA. 1991;88:5837&#x2013;5841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51973</ArticleId><ArticleId IdType="pubmed">1712107</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik C M, Novak M, Thogersen H C, Edwards P C, Runswick M J, Jakes R, Walker J E, Milstein C, Roth M, Klug A. Proc Natl Acad Sci USA. 1988;85:4506&#x2013;4510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheuens J, Cras P, Perry G, Boons J, Ceuterick-de Groote C, L&#xfc;bke U, Mercken M, Tabaton M, Gambetti P L, Vandermeeren M, et al. Brain Res. 1991;558:43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">1718569</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M A, Rudnicka-Nawrot M, Richey P L, Praprotnik D, Mulvihill P, Miller C A, Sayre L M, Perry G. J Neurochem. 1995;64:2660&#x2013;2666.</Citation><ArticleIdList><ArticleId IdType="pubmed">7539057</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse P J, Price D L, Struble R G, Clark A W, Coyle J T, Delon M R. Science. 1982;215:1237&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Hasegawa M. Am J Pathol. 1999;154:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853453</ArticleId><ArticleId IdType="pubmed">9916910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rylett R J, Goddard S, Schmidt B M, Williams L R. J Neurosci. 1993;13:3956&#x2013;3963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576469</ArticleId><ArticleId IdType="pubmed">8366354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellweg R, Gericke C A, Jendroska K, Hartung H D, Cervos-Navarro J. Int J Dev Neurosci. 1998;16:787&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">10198825</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Acta Neuropathol (Berlin) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Sommer B. Rev Neurosci. 1999;10:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10356989</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Hasegawa M. Am J Pathol. 1999;154:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853453</ArticleId><ArticleId IdType="pubmed">9916910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V M-Y, Trojanowski J Q. Neuron. 1999;24:507&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595503</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel H. Adv Anat Pathol. 1998;5:164&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">9868522</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K S, Nishimura M C, Armanini M P, Crowley C, Spencer S D, Philipps H S. J Neurosci. 1997;17:7228&#x2013;7296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573440</ArticleId><ArticleId IdType="pubmed">9295375</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10841784</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-2960</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>23</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes.</ArticleTitle><Pagination><StartPage>7024</StartPage><EndPage>7031</EndPage><MedlinePgn>7024-31</MedlinePgn></Pagination><Abstract><AbstractText>Aggregation of the amyloid beta-peptide (Abeta) into insoluble fibrils is a key pathological event in Alzheimer's disease. Zn(II) induces the Abeta aggregation at acidic-to-neutral pH, while Cu(II) is an effective inducer only at mildly acidic pH. We have examined Zn(II) and Cu(II) binding modes of Abeta and their pH dependence by Raman spectroscopy. The Raman spectra clearly demonstrate that three histidine residues in the N-terminal hydrophilic region provide primary metal binding sites and the solubility of the metal-Abeta complex is correlated with the metal binding mode. Zn(II) binds to the N(tau) atom of the histidine imidazole ring and the peptide aggregates through intermolecular His(N(tau))-Zn(II)-His(N(tau)) bridges. The N(tau)-metal ligation also occurs in Cu(II)-induced Abeta aggregation at mildly acidic pH. At neutral pH, however, Cu(II) binds to N(pi), the other nitrogen of the histidine imidazole ring, and to deprotonated amide nitrogens of the peptide main chain. The chelation of Cu(II) by histidine and main-chain amide groups results in soluble Cu(II)-Abeta complexes. Under normal physiological conditions, Cu(II) is expected to protect Abeta against Zn(II)-induced aggregation by competing with Zn(II) for histidine residues of Abeta.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miura</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Tohoku University, Aobayama, Sendai 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kohata</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QD397987E</RegistryNumber><NameOfSubstance UI="D006639">Histidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006639" MajorTopicYN="N">Histidine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013059" MajorTopicYN="N">Spectrum Analysis, Raman</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10841784</ArticleId><ArticleId IdType="doi">10.1021/bi0002479</ArticleId><ArticleId IdType="pii">bi0002479</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10850703</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>405</Volume><Issue>6786</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Presenilin-1 mutations in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>532</EndPage><MedlinePgn>531-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schettini</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>T C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Hulette</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lippa</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gambetti</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tabaton</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Teller</LastName><ForeName>J K</ForeName><Initials>JK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2001 Jun 7;411(6838):654-6. doi: 10.1038/35079682.</RefSource><PMID Version="1">11395757</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10850703</ArticleId><ArticleId IdType="doi">10.1038/35014735</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10851363</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.</ArticleTitle><Pagination><StartPage>2061</StartPage><EndPage>2066</EndPage><MedlinePgn>2061-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the effects of estrogen therapy on cognition, mood, and cerebral blood flow in patients with AD.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some studies have suggested estrogen may be effective in the treatment of AD. However, most of these studies were not controlled adequately.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty female AD patients were recruited in a randomized, double-blind, placebo-controlled 12-week trial. Each member of the estrogen-treated group received conjugated estrogen (Premarin) 1.25 mg/day. The primary outcome measures were the Cognitive Ability Screening Instrument (CASI), Clinical Dementia Rating (CDR), and Clinician Interview-Based Impression of Change (CIBIC-plus). The secondary outcome measures were Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD), Hamilton Anxiety Rating Scale (HARS), Hamilton Depression Rating Scale (HDRS), and 99mTc hexamethylpropylene amine oxime SPECT of the brain.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No meaningful differences were found between the outcome measures (CASI, CDR, CIBIC-plus, BEHAVE-AD, HARS, HDRS, and cerebral blood flow) taken from the estrogen-treated group and those from the control group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A 1.25-mg/day dose of Premarin administered for 12 consecutive weeks does not produce a meaningful effect on cognitive performance, dementia severity, behavior, mood, and cerebral perfusion in female AD patients. Because estrogen therapy has been suspected of yielding adverse effects, and its therapeutic effectiveness is in doubt, additional evaluation of its role in AD treatment ought to be conducted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>P N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Neurological Institute, Department of Nuclear Medicine, Taipei Veterans General Hospital &amp; National Yang-Ming University School of Medicine, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>S Q</ForeName><Initials>SQ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>C Y</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>H T</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>H Y</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004966">Estrogens, Conjugated (USP)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2000 Jun 13;54(11):2035-7. doi: 10.1212/wnl.54.11.2035.</RefSource><PMID Version="1">10851358</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="Y">Estrogen Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004966" MajorTopicYN="N">Estrogens, Conjugated (USP)</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10851363</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.11.2061</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10852539</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model.</ArticleTitle><Pagination><StartPage>739</StartPage><EndPage>747</EndPage><MedlinePgn>739-47</MedlinePgn></Pagination><Abstract><AbstractText>The epsilon4 allele of apolipoprotein E (ApoE) is an important genetic risk factor for Alzheimer's disease (AD). Increasing evidence suggests that this association may be linked to the ability of ApoE to interact with the amyloid-beta (Abeta) peptide and influence its concentration and structure. To determine the effect of ApoE on Abeta and other AD pathology in vivo, we used APPsw transgenic mice and ApoE knockout (-/-) mice to generate APPsw animals that carried two (ApoE +/+), one (ApoE +/-), or no copies (ApoE -/-) of the normal mouse ApoE gene. At 12 months of age, Abeta deposition was present in the cortex and hippocampus and was also prominent within leptomeningeal and cortical blood vessels of all APPsw ApoE +/+ mice. Importantly, although Abeta deposition still occurred in APPsw ApoE -/- mice, no fibrillar Abeta deposits were detected in the brain parenchyma or cerebrovasculature. There was also no neuritic degeneration associated with Abeta deposition in the absence of ApoE. These data demonstrate that ApoE facilitates the formation of both neuritic and cerebrovascular plaques, which are pathological hallmarks of AD and cerebral amyloid angiopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Mackey</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tenkova</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sartorius</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>K H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Irizarry</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG00861</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10854289</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Impaired proteasome function in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>436</StartPage><EndPage>439</EndPage><MedlinePgn>436-9</MedlinePgn></Pagination><Abstract><AbstractText>Inhibition of proteasome activity is sufficient to induce neuron degeneration and death; however, altered proteasome activity in a neurodegenerative disorder has not been demonstrated. In the present study, we analyzed proteasome activity in short-postmortem-interval autopsied brains from 16 Alzheimer's disease (AD) and nine age- and sex-matched controls. A significant decrease in proteasome activity was observed in the hippocampus and parahippocampal gyrus (48%), superior and middle temporal gyri (38%), and inferior parietal lobule (28%) of AD patients compared with controls. In contrast, no significant decrease in proteasome activity was observed in either the occipital lobe or the cerebellum. The loss of proteasome activity was not associated with a decrease in proteasome expression, suggesting that the proteasome may become inhibited in AD by a posttranslational modification. Together, these data indicate a possible role for proteasome inhibition in the neurodegeneration associated with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>J N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging and Alzheimer's Disease Research Center Department of Neurology, University of Kentucky, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanni</LastName><ForeName>K B</ForeName><Initials>KB</Initials></Author><Author ValidYN="Y"><LastName>Markesbery</LastName><ForeName>W R</ForeName><Initials>WR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1PO1-AG05119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P50-AG05144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009097">Multienzyme Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009097" MajorTopicYN="N">Multienzyme Complexes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020534" MajorTopicYN="N">Parahippocampal Gyrus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10854289</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0750436.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10856299</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>35</Issue><PubDate><Year>2000</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Mutation of conserved aspartates affects maturation of both aspartate mutant and endogenous presenilin 1 and presenilin 2 complexes.</ArticleTitle><Pagination><StartPage>27348</StartPage><EndPage>27353</EndPage><MedlinePgn>27348-53</MedlinePgn></Pagination><Abstract><AbstractText>Presenilin (PS1 and PS2) holoproteins are transiently incorporated into low molecular weight (MW) complexes. During subsequent incorporation into a higher MW complex, they undergo endoproteolysis to generate stable N- and C-terminal fragments. Mutation of either of two conserved aspartate residues in transmembrane domains inhibits both presenilin-endoproteolysis and the proteolytic processing of beta-amyloid precursor protein and Notch. We show that although PS1/PS2 endoproteolysis is not required for inclusion into the higher MW N- and C-terminal fragment-containing complex, aspartate mutant holoprotein presenilins are not incorporated into the high MW complexes. Aspartate mutant presenilin holoproteins also preclude entry of endogenous wild type PS1/PS2 into the high MW complexes but do not affect the incorporation of wild type holoproteins into lower MW holoprotein complexes. These data suggest that the loss of function effects of the aspartate mutants result in altered PS complex maturation and argue that the functional presenilin moieties are contained in the high molecular weight complexes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Research in Neurodegenerative Diseases, Departments of Medical Biophysics and Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kawarai</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Arawaka</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Supala</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Y Q</ForeName><Initials>YQ</Initials></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Milman</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>George-Hyslop</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10856299</ArticleId><ArticleId IdType="doi">10.1074/jbc.M002982200</ArticleId><ArticleId IdType="pii">S0021-9258(19)61517-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10861023</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>13</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>7609</StartPage><EndPage>7614</EndPage><MedlinePgn>7609-14</MedlinePgn></Pagination><Abstract><AbstractText>Strategies for treating Alzheimer's disease (AD) include therapies designed to decrease senile plaque (SP) formation and/or promote clearance of SPs, but clinical trials of these treatments are limited by the lack of effective methods to monitor changes in plaque burden in the brains of living AD patients. However, because SPs are extracellular deposits of amyloid-beta peptides (Abeta), it may be possible to eventually develop radioligands that cross the blood-brain barrier (BBB) and label SPs so they can be visualized by current imaging methods. As a first step toward the generation of such a radioligand, we developed a probe, [(trans,trans)-1-bromo-2, 5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB)], and we report here that BSB has the following properties essential for a probe that can detect SPs in vivo. First, BSB sensitively labels SPs in AD brain sections. Second, BSB permeates living cells in culture and binds specifically to intracellular Abeta aggregates. Third, after intracerebral injection in living transgenic mouse models of AD amyloidosis, BSB labels SPs composed of human Abeta with high sensitivity and specificity. Fourth, BSB crosses the BBB and labels numerous AD-like SPs throughout the brain of the transgenic mice after i.v. injection. Thus, we conclude that BSB is an appropriate starting point for future efforts to generate an antemortem diagnostic for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>H F</ForeName><Initials>HF</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>V M</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015335">Molecular Probes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015335" MajorTopicYN="Y">Molecular Probes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="Y">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2000</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10861023</ArticleId><ArticleId IdType="pmc">PMC16593</ArticleId><ArticleId IdType="doi">10.1073/pnas.97.13.7609</ArticleId><ArticleId IdType="pii">97/13/7609</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D J. Nature (London) 1999;399:A23&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X D, Golde T E, Younkin S G. Science. 1993;259:514&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">8424174</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung T T, Cai X D, Odaka A, Otvos L J, Eckman C, Golde T E, Younkin S G. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D R, Thinakaran G, Eckman C B, Lee M K, Davenport F, Ratovitsky T, Prada C M, Kim G, Seekins S, Yager D, et al. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada C M, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, et al. Nature (London) 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T D, Hardy J, Hutton M, Kukull W, et al. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F. Nature (London) 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon M N, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, et al. Nat Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Nature (London) 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett B D, Babu-Khan S, Kahn S, Mendiaz E A, Denis P, Teplow D B, Ross S, Amarante P, Loeloff R, et al. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W E, Debnath M L, Pettegrew J W. Neurobiol Aging. 1994;15:691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">7891823</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W E, Debnath M L, Pettegrew J W. Neurobiol Aging. 1995;16:541&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">8544903</ArticleId></ArticleIdList></Reference><Reference><Citation>Dezutter N A, Dom R J, de Groot T J, Bormans G M, Verbruggen A M. Eur J Nucleic Med. 1999;26:1392&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">10552079</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W E, Hamilton R L, Styren S D, Styren G, Debnath M L, Mathis C A, Mahmood A, Hsiao K K. Soc Neurosci Abstr. 1997;23:1638.</Citation></Reference><Reference><Citation>The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the NIA Working Group. Neurobiol Aging. 1998;19:109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558143</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky D M, Doms R W, Lee V M-Y. J Cell Biol. 1998;141:1031&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132781</ArticleId><ArticleId IdType="pubmed">9585420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner D A, Abraham C, Selkoe D J. Proc Natl Acad Sci USA. 1986;83:503&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC322888</ArticleId><ArticleId IdType="pubmed">3455785</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry M C, Soriano F, McNamara M, Page K J, Schenk D, Games D, Hyman B T. J Neurosci. 1997;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauer M F, Soreghan B, Burdick D, Kosmoski J, Glabe C G. Proc Natl Acad Sci USA. 1992;89:7437&#x2013;7441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49725</ArticleId><ArticleId IdType="pubmed">1502155</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H. Protein Sci. 1993;2:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang A J, Knauer M, Burdick D A, Glabe C. J Biol Chem. 1995;270:14786&#x2013;14792.</Citation><ArticleIdList><ArticleId IdType="pubmed">7782344</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, Kosmoski J, Knauer M F, Glabe C G. Brain Res. 1997;746:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9037507</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Ihara Y. Biochemistry. 1998;37:15247&#x2013;15253.</Citation><ArticleIdList><ArticleId IdType="pubmed">9799484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson D W, Trojanowski J Q, Lee V M-Y. Exp Neurol. 1999;158:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10863026</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>287</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>190</EndPage><MedlinePgn>187-90</MedlinePgn></Pagination><Abstract><AbstractText>A new sandwich ELISA is described which shows specificity for tau phosphorylated at threonine 231 and preferentially reacts with Alzheimer's disease (AD) brain extracts relative to other dementias. This assay was used to analyze 58 antemortem cerebrospinal fluid samples. Twenty-three of 27 AD samples (85% sensitivity) yielded signals greater than the cutoff, while only one of 31 non-AD samples (97% specificity) were greater. This indicates that detection of phosphotau in cerebrospinal fluid with this sandwich ELISA could prove useful in the diagnosis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohnken</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Geriatrics Corp., Vernon Hills, IL, USA. kohnken@moleculargeriatrics.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buerger</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zinkowski</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kerkman</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>DeBernardis</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>1114-81-4</RegistryNumber><NameOfSubstance UI="D010769">Phosphothreonine</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010769" MajorTopicYN="N">Phosphothreonine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10863026</ArticleId><ArticleId IdType="doi">10.1016/s0304-3940(00)01178-2</ArticleId><ArticleId IdType="pii">S0304394000011782</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10864326</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>405</Volume><Issue>6787</Issue><PubDate><Year>2000</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>694</EndPage><MedlinePgn>689-94</MedlinePgn></Pagination><Abstract><AbstractText>Cleavage of amyloid precursor protein (APP) by the beta- and gamma-secretases generates the amino and carboxy termini, respectively, of the A beta amyloidogenic peptides A beta40 and A beta42--the major constituents of the amyloid plaques in the brain parenchyma of Alzheimer's disease patients. There is evidence that the polytopic membrane-spanning proteins, presenilin 1 and 2 (PS1 and PS2), are important determinants of gamma-secretase activity: mutations in PS1 and PS2 that are associated with early-onset familial Alzheimer's disease increase the production of A beta42 (refs 4-6), the more amyloidogenic peptide; gamma-secretase activity is reduced in neuronal cultures derived from PS1-deficient mouse embryos; and directed mutagenesis of two conserved aspartates in transmembrane segments of PS1 inactivates the ability of gamma-secretase to catalyse processing of APP within its transmembrane domain. It is unknown, however, whether PS1 (which has little or no homology to any known aspartyl protease) is itself a transmembrane aspartyl protease or a gamma-secretase cofactor, or helps to colocalize gamma-secretase and APP. Here we report photoaffinity labelling of PS1 (and PS2) by potent gamma-secretase inhibitors that were designed to function as transition state analogue inhibitors directed to the active site of an aspartyl protease. This observation indicates that PS1 (and PS2) may contain the active site of gamma-secretase. Interestingly, the intact, single-chain form of wild-type PS1 is not labelled by an active-site-directed photoaffinity probe, suggesting that intact wild-type PS1 may be an aspartyl protease zymogen.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Y M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. yueming_li@merck.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>DiMuzio-Mower</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lellis</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nadin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Neduvelil</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Register</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Sardana</LastName><ForeName>M K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Shearman</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>A L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>X P</ForeName><Initials>XP</Initials></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>K C</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Shafer</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Gardell</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019920">Photoaffinity Labels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>6SO6U10H04</RegistryNumber><NameOfSubstance UI="D001710">Biotin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001710" MajorTopicYN="N">Biotin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019920" MajorTopicYN="N">Photoaffinity Labels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010777" MajorTopicYN="N">Photochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId><ArticleId IdType="doi">10.1038/35015085</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10867200</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>160</EndPage><MedlinePgn>153-60</MedlinePgn></Pagination><Abstract><AbstractText>Vascular disease and Alzheimer's disease are both common disorders, in particular among elderly subjects. Therefore, it can be expected that the joint occurrence of these two disorders is not a rare phenomenon. In recent years, evidence is increasing that the two may be more closely linked than just by chance. Epidemiological studies have suggested that risk factors for vascular disease and stroke are associated with cognitive impairment and Alzheimer's disease, and that the presence of cerebrovascular disease intensifies the presence and severity of the clinical symptoms of Alzheimer's disease. In this paper, current knowledge on the relation between vascular risk factors and risk indicators and Alzheimer's disease will be reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>M M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands. breteler@epib.fgg.eur.nl</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>98</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10867200</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(99)00110-4</ArticleId><ArticleId IdType="pii">S0197-4580(99)00110-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10867217</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>The role of cerebral ischemia in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>330</EndPage><MedlinePgn>321-30</MedlinePgn></Pagination><Abstract><AbstractText>The Alzheimer type of dementia and stroke are known to increase at comparable rates with age. Recent advances suggest that vascular risk factors linked to cerebrovascular disease and stroke in the elderly significantly increase the risk of developing Alzheimer's disease (AD). These include atherosclerosis, atrial fibrillation, coronary artery disease, hypertension, and diabetes mellitus. Moreover, review of various autopsy series shows that 60-90% of AD cases exhibit variable cerebrovascular pathology. Although some vascular lesions such as cerebral amyloid angiopathy, endothelial degeneration, and periventricular white matter lesions are evident in most cases of AD, a third will exhibit cerebral infarction. Despite the interpretation of pathological evidence, longitudinal clinical studies suggest that the co-existence of stroke and AD occurs more than by chance alone. Strokes known to occur in patients with Alzheimer syndrome and most frequently in the oldest old substantially worsen cognitive decline and outcome, implicating some interaction between the disorders. Nevertheless, the nature of a true relationship between the two disorders seems little explored. What predisposes to strokes in underlying cognitive decline or AD? Is it possible that cerebral ischemia is a causal factor for AD? I examined several vascular factors and the vascular pathophysiology implicated in stroke and AD, and propose that cerebral ischemia or oligemia may promote Alzheimer type of changes in the aging brain. Irrespective of the ultimate pathogenetic mechanism, these approaches implicate that management of peripheral vascular disease is important in the treatment or prevention of Alzheimer's disease or mixed dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalaria</LastName><ForeName>R N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Wolfson Research Centre, Institute for Health of the Elderly, Newcastle General Hospital, Westgate Road, NE4 6BE, Newcastle upon Tyne, United Kingdom. r.n.kalaria@ncl.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>90</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10867217</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(00)00125-1</ArticleId><ArticleId IdType="pii">S0197-4580(00)00125-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10867777</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort.</ArticleTitle><Pagination><StartPage>808</StartPage><EndPage>813</EndPage><MedlinePgn>808-13</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To relate performance on tests of cognitive ability to the subsequent development of probable Alzheimer disease (pAD) and to identify the pattern of earliest changes in cognitive functioning associated with a diagnosis of pAD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">From May 1975 to November 1979, a screening neuropsychological battery was administered to Framingham Study participants. They were followed up prospectively for 22 years and examined at least every 2 years for the development of pAD.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A community-based center for epidemiological research.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Subjects were 1076 participants of the Framingham Study aged 65 to 94 years who were free of dementia and stroke at baseline (initial) neuropsychological testing.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Presence or absence of pAD during a 22-year surveillance period was related to test performance at initial neuropsychological testing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lower scores for measures of new learning, recall, retention, and abstract reasoning obtained during a dementia-free period were associated with the development of pAD. Lower scores for measures of abstract reasoning and retention predicted pAD after a dementia-free period of 10 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The "preclinical phase" of detectable lowering of cognitive functioning precedes the appearance of pAD by many years. Measures of retention of information and abstract reasoning are among the strongest predictors of pAD when the interval between initial assessment and the development of pAD is long. Arch Neurol. 2000.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, Statistical Consulting Unit, 111 Cummington St, Boston University College of Arts and Sciences, Boston, MA 02215, USA. mfelias@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>5R01 AG08122-09</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R37 AG0355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC 38038</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2000 Jun;57(6):783-4. doi: 10.1001/archneur.57.6.783.</RefSource><PMID Version="1">10867772</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004493" MajorTopicYN="N">Education</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="N">Thinking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10867777</ArticleId><ArticleId IdType="doi">10.1001/archneur.57.6.808</ArticleId><ArticleId IdType="pii">noc90027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10867781</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample.</ArticleTitle><Pagination><StartPage>839</StartPage><EndPage>844</EndPage><MedlinePgn>839-44</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine the ability of the total score and individual items from the Mini-Mental State Examination in predicting the development of Alzheimer disease (AD) across a 3- and 6-year period in a population-based sample, and to describe the longitudinal changes in these measures across the same follow-up periods.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective follow-up of a community-based cohort, with 3 times of testing across a 6-year period. At each time of measurement, participants were clinically examined by physicians to identify demented and nondemented participants according to Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, criteria.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The study population consisted of all participants who were nondemented at the first follow-up and participated in the second follow-up examination. Among those, 459 remained nondemented and 73 developed AD during the second follow-up period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline differences in the total Mini-Mental State Examination score and the delayed memory item were seen 6 years before eventual dementia diagnosis (P&lt;.01). Analysis of the longitudinal changes showed no differences in the rate of decline for the incident AD or nondemented group between time 1 and time 2 (P&gt;.10). However, the incident AD group exhibited precipitous declines in 8 of the 10 subscales between time 2 and time 3, the point at which they were clinically diagnosed (P&lt;.01). Logistic regression analyses showed that only the delayed memory item was a significant predictor of who would develop AD, independent of age, sex, and years of education, at both of the first 2 times of measurement (P&lt;.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The diagnosis of AD is preceded by a long preclinical phase in which deficits in memory performance are most common. These deficits remain relatively stable up until the time that a dementia diagnosis can be rendered. Arch Neurol. 2000.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Small</LastName><ForeName>B J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Gerontology, Mailbox SOC 107, University of South Florida, 4202 E Fowler Ave, Tampa, FL 33620, USA. bsmall@luna.cas</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Viitanen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>B&#xe4;ckman</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10867781</ArticleId><ArticleId IdType="doi">10.1001/archneur.57.6.839</ArticleId><ArticleId IdType="pii">noc90093</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10869235</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9297</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.</ArticleTitle><Pagination><StartPage>383</StartPage><EndPage>394</EndPage><MedlinePgn>383-94</MedlinePgn></Pagination><Abstract><AbstractText>There has been great interest in the prospects of using single-nucleotide polymorphisms (SNPs) in the search for complex disease genes, and several initiatives devoted to the identification and mapping of SNPs throughout the human genome are currently underway. However, actual data investigating the use of SNPs for identification of complex disease genes are scarce. To begin to look at issues surrounding the use of SNPs in complex disease studies, we have initiated a collaborative SNP mapping study around APOE, the well-established susceptibility gene for late-onset Alzheimer disease (AD). Sixty SNPs in a 1.5-Mb region surrounding APOE were genotyped in samples of unrelated cases of AD, in controls, and in families with AD. Standard tests were conducted to look for association of SNP alleles with AD, in cases and controls. We also used family-based association analyses, including recently developed methods to look for haplotype association. Evidence of association (P&lt;/=.05) was identified for 7 of 13 SNPs, including the APOE-4 polymorphism, spanning 40 kb on either side of APOE. As expected, very strong evidence for association with AD was seen for the APOE-4 polymorphism, as well as for two other SNPs that lie &lt;16 kb from APOE. Haplotype analysis using family data increased significance over that seen in single-locus tests for some of the markers, and, for these data, improved localization of the gene. Our results demonstrate that associations can be detected at SNPs near a complex disease gene. We found that a high density of markers will be necessary in order to have a good chance of including SNPs with detectable levels of allelic association with the disease mutation, and statistical analysis based on haplotypes can provide additional information with respect to tests of significance and fine localization of complex disease genes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>E R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, NC, 27710, USA. emartin@chg.mc. duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Rogala</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Finch</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Livak</LastName><ForeName>K J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Slotterbeck</LastName><ForeName>B D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Slifer</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>L L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Conneally</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Schmechel</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Purvis</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Roses</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5 R01 NS31153-07</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS031153</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 P01 NS26630-11A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 P50 AG05128-16</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 NS026630</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2000</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2000</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2000</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2001</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10869235</ArticleId><ArticleId IdType="pmc">PMC1287185</ArticleId><ArticleId IdType="doi">10.1086/303003</ArticleId><ArticleId IdType="pii">S0002-9297(07)62649-4</ArticleId></ArticleIdList><ReferenceList><Title>Electronic-Database Information</Title><Reference><Citation>GenBank, http://www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html (for cosmid sequences)</Citation></Reference><Reference><Citation>GDA: Software for the Analysis of Discrete Genetic Data, http://alleyn.eeb.uconn.edu/gda</Citation></Reference><Reference><Citation>LocusLink, http://www.ncbi.nlm.nih.gov/LocusLink (for TOM40 [accession number 10452])</Citation></Reference><Reference><Citation>Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim (for AD [MIM 104300] and APOE [MIM 107741])</Citation></Reference></ReferenceList><ReferenceList><Reference><Citation>Ahting U, Thun C, Hegerl R, Typke D, Nargang FE, Neupert W, Nussberger S (1999) The TOM core complex: the general protein import pore of the outer membrane of mitochondria. J Cell Biol 147:959&#x2013;968</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169338</ArticleId><ArticleId IdType="pubmed">10579717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashworth LK, Batzer MA, Brandriff B, Branscomb E, De Jong P, Garcia E, Garnes JA, et al (1995) An integrated metric physical map of human chromosome 19. Nat Genet 11:422&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">7493023</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Haines JL, Rodes L, Terwedow H, Go RCP, Harrell LE, Perry RT, et al (1997) ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 48:139&#x2013;147</Citation><ArticleIdList><ArticleId IdType="pubmed">9008509</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton D (1999) A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission. Am J Hum Genet 65:1170&#x2013;1177</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288250</ArticleId><ArticleId IdType="pubmed">10486336</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Brooks LD, Chakravarti A (1998) A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 8:1229&#x2013;1231</Citation><ArticleIdList><ArticleId IdType="pubmed">9872978</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, et al (1994) Protective effect of apolipoprotein e type 2 allele for late onset Alzheimer disease. Nat Genet 7:180&#x2013;184</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas EM, Zhang WJ, Lalonde JP, Tay GK, Gaudieri S, Ashworth LK, Van Bockxmeer FM, et al (1998) Sequencing of 42kb of the APO E-C2 gene cluster reveals a new gene: PEREC1. DNA Seq 9:89&#x2013;101</Citation><ArticleIdList><ArticleId IdType="pubmed">10520737</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdes LU, Gerdes C, Hansen PS, Klausen IC, F&#xe6;rgeman O, Dyerberg J (1996) The apolipoprotein E polymorphism in Greenland Inuit in its global perspective. Hum Genet 98:546&#x2013;550</Citation><ArticleIdList><ArticleId IdType="pubmed">8882873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon CS, Rubinsztein DC (1995) Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans. Atherosclerosis 112:85&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pubmed">7772071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser ER, Boehnke M (1998) Genetic linkage analysis of complex genetic traits by using affected sibling pairs. Biometrics 54:1238&#x2013;1246</Citation><ArticleIdList><ArticleId IdType="pubmed">9883536</ArticleId></ArticleIdList></Reference><Reference><Citation>Heid CA, Stevens J, Livak KJ, Williams R (1996) Real time quantitative PCR. Genome Res 6:986&#x2013;994</Citation><ArticleIdList><ArticleId IdType="pubmed">8908518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai E, Riley J, Purvis I, Roses A (1998) A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics 54:31&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pubmed">9806827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathrop GM, Lalouel JM, Julier C, Ott J (1984) Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci USA 81:3443&#x2013;3446</Citation><ArticleIdList><ArticleId IdType="pmc">PMC345524</ArticleId><ArticleId IdType="pubmed">6587361</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall E (1999) Genomics: drug firms to create public database of genetic mutations. Science 284:406&#x2013;407</Citation><ArticleIdList><ArticleId IdType="pubmed">10232976</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin ER, Gilbert JR, Lai EH, Riley J, Slotterbeck BD, Rogala AR, Sipe CA, et al (2000) Analysis of association at SNPs in the APOE region. Genomics 63:7&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">10662539</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin ER, Kaplan NL, Weir BS (1997) Tests for linkage and association in nuclear families. Am J Hum Genet 61:439&#x2013;448</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1715892</ArticleId><ArticleId IdType="pubmed">9311750</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin ER, Monks SA, Warren LL, Kaplan NL (1999) A weighted sibship disequilibrium test for linkage and association in discordant sibships. Am J Hum Genet Suppl 65:A434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1287073</ArticleId><ArticleId IdType="pubmed">10825280</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray JC, Buetow KH, Weber JL, Ludwigsen S, Scherpbier-Heddma TS, Manion F, Quillen J, et al (1994) A comprehensive human linkage map with centimorgan density: Cooperative Human Linkage Center (CHLC). Science 265:2049&#x2013;2054</Citation><ArticleIdList><ArticleId IdType="pubmed">8091227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, et al (1997) Complete genomic screen in late-onset familial Alzheimer disease: evidence for a new locus on chromosome 12. JAMA 278:1237&#x2013;1241</Citation><ArticleIdList><ArticleId IdType="pubmed">9333264</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bebout JL, Gaskell PC, Yamaoka LH, Hung WY, Alberts MJ, Walker AP, et al (1991) Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am J Hum Genet 48:1034&#x2013;1050</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683100</ArticleId><ArticleId IdType="pubmed">2035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimmler J, McDowell JG, Slotterback BD, Haynes CS, Menold MM, Rogala A, Speer MC, et al (1998) Development of a data coordinating center (DCC): data quality control for complex disease studies. Am J Hum Genet Suppl 63:A240</Citation></Reference><Reference><Citation>Risch N, Merikangas K (1996) The future of genetic studies of complex human disorders. Science 273:1516&#x2013;1517</Citation><ArticleIdList><ArticleId IdType="pubmed">8801636</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Schmader KE, Breitner JC, Benson MD, Brown WT, Goldfarb L, Goldgaber D, et al (1993) Apolipoprotein E &#x3b5;4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342:710&#x2013;711</Citation><ArticleIdList><ArticleId IdType="pubmed">8103823</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, et al (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649&#x2013;9653</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Pericak-Vance MA, Salvesen GS, English J, Roses AD (1993a) Apolipoprotein E: high avidity binding to a bA amyloid and increased frequency of type 4 isoform in familial Alzheimer's disease. Proc Natl Acad Sci USA 90:1977&#x2013;1981</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance MA, Schmechel D, et al (1993b) Binding of human apolipoprotein E to synthetic amyloid b peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098&#x2013;8102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwilliger JD, Shannon WE, Lathrop GM, Nolan JP, Goldin LR, Chase GA, Weeks DE (1997) True and false positive peaks in genomewide scans: applications of length-biased sampling to linkage mapping. Am J Hum Genet 61:430&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1715919</ArticleId><ArticleId IdType="pubmed">9311749</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance JM, Martin ER, Lai E, Riley J, Slotterbeck BD, Sipe CA, Barker JM, et al (1998) Genotyping and association studies of single nucleotide polymorphisms (SNPs) in a 4 megabase region surrounding the Alzheimer's disease (AD) risk factor, APOE. Am J Hum Genet Suppl 63:A312</Citation></Reference><Reference><Citation>Zaykin D, Zhivotovsky L, Weir BS (1995) Exact tests for association between alleles at arbitrary numbers of loci. Genetica 96:169&#x2013;178</Citation><ArticleIdList><ArticleId IdType="pubmed">7607454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10869421</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>97</Volume><Issue>14</Issue><PubDate><Year>2000</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.</ArticleTitle><Pagination><StartPage>8093</StartPage><EndPage>8097</EndPage><MedlinePgn>8093-7</MedlinePgn></Pagination><Abstract><AbstractText>Huntington's disease (HD) is a fatal inherited neurodegenerative disorder characterized by personality changes, motor impairment, and subcortical dementia. HD is one of a number of diseases caused by expression of an expanded polyglutamine repeat. We have developed several lines of mice that are transgenic for exon 1 of the HD gene containing an expanded CAG sequence. These mice exhibit a defined neurological phenotype along with neuronal changes that are pathognomonic for the disease. We have previously observed the appearance of neuronal intranuclear inclusions, but did not find evidence for neurodegeneration. In this study, we report that all lines of these mice develop a late onset neurodegeneration within the anterior cingulate cortex, dorsal striatum, and of the Purkinje neurons of the cerebellum. Dying neurons characteristically exhibit neuronal intranuclear inclusions, condensation of both the cytoplasm and nucleus, and ruffling of the plasma membrane while maintaining ultrastructural preservation of cellular organelles. These cells do not develop blebbing of the nucleus or cytoplasm, apoptotic bodies, or fragmentation of DNA. Neuronal death occurs over a period of weeks not hours. We also find degenerating cells of similar appearance within these same regions in brains of patients who had died with HD. We therefore suggest that the mechanism of neuronal cell death in both HD and a transgenic mouse model of HD is neither by apoptosis nor by necrosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turmaine</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, University College London, Gower Street, London WC1E 6BT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raza</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mahal</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mangiarini</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>G P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>S W</ForeName><Initials>SW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506812">Htt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="Y">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="Y">Trinucleotide Repeat Expansion</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2001</Year><Month>1</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10869421</ArticleId><ArticleId IdType="pmc">PMC16675</ArticleId><ArticleId IdType="doi">10.1073/pnas.110078997</ArticleId><ArticleId IdType="pii">110078997</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vonsattel J-P G, Meyers R H, Stevens T J, Ferrante R J, Bird E D, Richardson E P. J Neuropathol Exp Neurol. 1985;44:559&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">2932539</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel J P G, DiFiglia M. J Neuropathol Exp Neurol. 1998;57:369&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596408</ArticleId></ArticleIdList></Reference><Reference><Citation>Robitaille Y, Lopes-Cendes I, Becher M, Rouleau G, Clark A W. Brain Pathol. 1997;7:877&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098401</ArticleId><ArticleId IdType="pubmed">9217975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C A, Becher M W, Coloner V, Engelender S, Wood J D, Sharp A H. Brain Pathol. 1997;7:1003&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098431</ArticleId><ArticleId IdType="pubmed">9217980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangiarini L, Sathasivam K, Seller M, Cozens B A, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies S W, et al. Cell. 1996;87:493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">8898202</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies S W, Turmaine M, Cozens B A, DiFiglia M, Sharp A H, Ross C A, Scherzinger E, Wanker E E, Mangiarini L, Bates G P. Cell. 1997;90:537&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267033</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies S W, Turmaine M, Cozens B A, Raza A S, Mahal A, Mangiarini L, Bates G P. Philos Trans R Soc London B. 1999;354:971&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692612</ArticleId><ArticleId IdType="pubmed">10434295</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates G P, Davies S W, Lehrach H, Wanker E E. Cell. 1997;90:549&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267034</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates G P, Lehrach H, Wanker E E. Proc Natl Acad Sci USA. 1999;96:4604&#x2013;4609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16379</ArticleId><ArticleId IdType="pubmed">10200309</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz M F. Trends Biochem Sci. 1999;24:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10098399</ArticleId></ArticleIdList></Reference><Reference><Citation>DiFiglia M, Sapp E, Chase K O, Davies S W, Bates G P, Vonsattel J P, Aronin N. Science. 1997;277:1990&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302293</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher M W, Kotzuk J A, Sharp A H, Davies S W, Bates G P, Price D L, Ross C A. Neurobiol Dis. 1998;4:387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">9666478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourfinkel-An I, Cancel G, Duyckaerts C, Faucheaux B, Hauw J-J, Trottier Y, Brice A, Agid Y, Hirsch E C. NeuroReport. 1998;9:1823&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pubmed">9665608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Kakita A, Yamada M, Koide R, Igarashi S, Takano H, Ikeuchi T, Wakabayashi K, Egawa S, Tsuji S, et al. Acta Neuropathol. 1998;96:547&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845282</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi S, Koide R, Shimohata T, Yamada M, Hayashi Y, Takano H, Date H, Oyake M, Sato T, Sato A, et al. Nat Genet. 1998;18:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462738</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Miwa S, Kobayshi Y, Merry D E, Yamamoto M, Tanaka F, Doyu F, Hashizume Y, Fischbeck K H, Sobue G. Ann Neurol. 1998;44:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708548</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner P J, Koshy B T, Cummings C J, Klement I A, Helin K, Servadio A, Zoghbi H Y, Orr H T. Nature (London) 1997;389:971&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353120</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson H L, Perez M K, Trottier Y, Trojanowski J Q, Subramony S H, Das S S, Vig P, Mandel J L, Fischbeck K H, Pitmann R N. Neuron. 1997;19:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">9292723</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmberg M, Duyckaerts C, D&#xfc;rr A, Cancel G, Gourfinkel-An I, Damier P, Faucheux B, Trottier Y, Hirsch E C, Agid Y, et al. Hum Mol Genet. 1998;7:913&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">9536097</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt T, Landwehrmeyer G B, Schmitt I, Trottier Y, Auberger G, Laccone F, Klockgether T, V&#xf6;lpel M, Epplen J T, Sch&#xf6;ls L, et al. Brain Pathol. 1998;8:669&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098309</ArticleId><ArticleId IdType="pubmed">9804376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J F R, Wyllie A H, Currie A R. Br J Cancer. 1972;26:239&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2008650</ArticleId><ArticleId IdType="pubmed">4561027</ArticleId></ArticleIdList></Reference><Reference><Citation>Portera-Cailliau C, Hedreen J C, Price D L, Koliatsos V E. J Neurosci. 1995;15:3775&#x2013;3787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578226</ArticleId><ArticleId IdType="pubmed">7751945</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragunow M, Faull R L M, Lawlor P, Beihartz E J, Singleton K, Walker E B, Mee E. Clin Neurosci Neuropathol. 1995;6:1053&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">7632894</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannon Thomas L, Gates D J, Richfield E K, O'Bien T F, Schweitzer J B, Steindler D A. Exp Neurol. 1995;133:265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">7649231</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke P G H. Anat Embryol. 1990;181:195&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">2186664</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucassen P J, Chung W C J, Kamphorst W, Swaab D F. J Neuropathol Exp Neurol. 1997;56:887&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson G R, Salecker I, Dong X, Yao X, Arnheim N, Faber P W, MacDonald M E, Zipursky S L. Cell. 1998;21:633&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768849</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P H, Williams M, Charles C, Garrett L, Pike-Buchanan L, Whetsell W O, Jr, Miller G, Tagle D. Nat Genet. 1998;20:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771716</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou F, Finkbinder S, Devys D, Greenberg M E. Cell. 1998;95:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778247</ArticleId></ArticleIdList></Reference><Reference><Citation>Klement I A, Skinner P J, Kayfor M D, Yi H, Hersch S M, Clark H B, Zoghbi H Y, Orr H T. Cell. 1998;95:41&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayberg H S, Starkstein S E, Peyser C E, Brandt J, Dannals R F, Folstein S E. Neurology. 1992;42:1791&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pubmed">1387463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotrel A, Paskevitch P A, Kiely D K, Bird E D, Williams R S, Myers R H. Neurology. 1991;41:1117&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">1829794</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M, Gentleman S, Lennox G, Ward L, Gray T, Randall K, Morell K, Lowe J. J Neuropathol Appl Neurobiol. 1995;21:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">7770116</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10878808</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>7</Issue><PubDate><Year>2000</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.</ArticleTitle><Pagination><StartPage>428</StartPage><EndPage>434</EndPage><MedlinePgn>428-34</MedlinePgn></Pagination><Abstract><AbstractText>The beta-amyloid precursor protein (beta-APP), which is involved in the pathogenesis of Alzheimer's disease, and the Notch receptor, which is responsible for critical signalling events during development, both undergo unusual proteolysis within their transmembrane domains by unknown gamma-secretases. Here we show that an affinity reagent designed to interact with the active site of gamma-secretase binds directly and specifically to heterodimeric forms of presenilins, polytopic proteins that are mutated in hereditary Alzheimer's and are known mediators of gamma-secretase cleavage of both beta-APP and Notch. These results provide evidence that heterodimeric presenilins contain the active site of gamma-secretase, and validate presenilins as principal targets for the design of drugs to treat and prevent Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esler</LastName><ForeName>W P</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimberly</LastName><ForeName>W T</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Diehl</LastName><ForeName>T S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Rahmati</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG12749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS37537</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000345">Affinity Labels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2002 May;4(5):E110-1; author reply E111-2. doi: 10.1038/ncb0502-e110b.</RefSource><PMID Version="1">11988746</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000345" MajorTopicYN="N">Affinity Labels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008861" MajorTopicYN="N">Microsomes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10878808</ArticleId><ArticleId IdType="doi">10.1038/35017062</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>